

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cost measurement in value-based healthcare – science or fiction? A systematic review.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-066568
Article Type:	Original research
Date Submitted by the Author:	12-Jul-2022
Complete List of Authors:	Leusder, Maura; Erasmus University Rotterdam, Erasmus School of Health Policy and Management Porte, Petra; Erasmus University Rotterdam, Erasmus School of Health Policy and Management Ahaus, Kees; Erasmus University Rotterdam Institute of Health Policy and Management, Department Health Services Management & Organisation van Elten, Hilco; Erasmus Universiteit Rotterdam, Erasmus School of Health Policy & Management
Keywords:	Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title: Cost measurement in value-based health care – science or fiction? A systematic**
4 **review.**
5

6 **Running head: Cost measurement in value-based health care**
7

8
9 **Authors:** Maura Leusder, Petra Porte, Kees Ahaus & Hilco van Elten
10

11 Maura Leusder, MSc.

12 Department Health Services Management & Organisation, Erasmus University Rotterdam
13 The Netherlands
14
15

16 Petra J. Porte, PhD.

17 Department Health Services Management & Organisation, Erasmus University Rotterdam
18 The Netherlands
19
20

21 C.T.B. (Kees) Ahaus, Prof. Dr. Ir.

22 Department Health Services Management & Organisation, Erasmus University Rotterdam
23 The Netherlands
24
25

26 Hilco J. van Elten, PhD.

27 Department Health Services Management & Organisation, Erasmus University Rotterdam
28 The Netherlands
29

30 **Corresponding author;** Maura Leusder, MSc.
31

32 leusder@eshpm.eur.nl.

33 +31 06 38002149

34 J6-41, Bayle Building (J) Burgemeester Oudlaan 50, 3062 PA Rotterdam

35 Postbus 1738, 3000 DR Rotterdam
36
37
38
39

40 Word count: 4090

41 Tables and figures: 5
42
43
44
45
46
47
48

49 **Keywords:** Costs, value-based healthcare, cost accounting, process improvements, time-driven
50 activity-based costing, activity-based costing, decision-making
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective Value-based health care (VBHC) considers accurate cost information to be relevant to the pursuit of value, but little is known about how costs of care should be measured. The aim of this review is to identify how costs are measured in VBHC, and which cost measurement methods can facilitate VBHC or value-based decision making.

Design We systematically screen PubMed/MEDLINE, Embase, EBSCOhost and Web of Science with two reviewers following PRISMA guidelines, including studies up to 1/1/2022.

Eligibility criteria We require studies to measure costs of an intervention, treatment, or care path and to label the study as 'value-based'. An inductive qualitative approach was used to categorize studies following management accounting to identify if or how cost information facilitated VBHC by aiding decision making.

Results We find 1,930 studies, 215 of which measured costs in a VBHC setting. Half of all studies measure hospital costs (110, 51.2%) while the remainder use reimbursements. Sophisticated costing methods that allocate both direct and indirect costs to care paths can provide valuable managerial information by facilitating care path adjustments (40), benchmarking (39), the identification of cost drivers (47), and measurement of total costs or cost savings (26) We find three best practices important to success in costing: process mapping (34), expert input (16), and observations (24).

Conclusions Cost information can facilitate VBHC. While time-driven activity-based costing (TDABC) is prized as the best method, its ability to inform decision-making depends on its implementation. Costing short or partial care paths and surgical episodes produces accurate cost information but limited decision-making information. Practitioners are advised to prioritize costing full cycles of care and to consider both direct and indirect costs through TDABC.

Strengths and limitations

- Using two independent reviewers this systematic review analyzes and all value-based healthcare studies that have measured costs to date to provide a comprehensive comparison of cost measurement methods.
- By revealing four mechanisms through which cost measurement facilitates value-based healthcare, this research operationalizes the potential benefits of cost measurement to practitioners.
- By comparing the methods used by studies to collect cost information, this study finds three best practices for practitioners and researchers.
- Due to limiting the search to studies labeled as ‘value-based’ in the title or abstract, this review omits studies that measure costs in healthcare but do not explicitly pursue value-based healthcare.
- Included studies may have achieved value-based healthcare without reporting this in the paper, and therefore may be underrepresented in research question 2.

INTRODUCTION

To make value-based decisions in health care, hospital practitioners and health care providers require patient-level information on the costs and outcomes achieved in hospitals and health care organizations [1]. This enables care providers to steer towards better patient-reported outcome measures, patient-reported experience measures, and clinical outcomes at equal or lower cost [2]. With detailed cost and outcome information, care paths can be optimized continuously [3]. Value-based health care (VBHC) is therefore also considered one solution to the financial pressures our global health care system places on managers and administrators [1,4,5] based on its promise to streamline care by focusing on desirable outcomes. This is of relevance to hospital administrators and managers facing complex decisions under considerable financial pressures. Additionally, hospitals benefit from cost information by gaining insight into the sources of costs to guide cost-containment strategies. Cost information may therefore facilitate process and quality improvement initiatives pursued by management [6–10]. Furthermore, insight into patient-level or treatment-level costs enables hospitals to negotiate appropriate prices with insurance firms, especially as we move towards new payment models and away from fee-for-service payments [11,12]. Lastly, such treatment-level cost information is suggested to enable competition among hospitals based on outcomes and prices due to market forces [13].

Considerable research has addressed the outcome side of Porter's value equation and The Triple Aim [14]. Many studies measured patient-level outcomes from both the patient perspective (e.g., patient-reported outcome measures, patient-reported experience measures) and clinical outcome perspective [15,16]. Less is known about the cost side of this equation. Often, the term 'cost' is conflated with the price paid by insurance firms or patients to the hospital [17,18]. However, prices do not reflect the full costs incurred by hospitals [6,19–21]. Prices paid by

1
2
3 insurance firms are negotiated sums that include profit margins by both the insurer and the hospital
4 [22]. They are also impacted by political factors, such as hospital-payor mix [23], which refers to
5
6 [22]. They are also impacted by political factors, such as hospital-payor mix [23], which refers to
7
8 the range of private vs. public insurance firms that make up the hospital's income stream. Lastly,
9
10 fee-for-service payments fail to account for patient-level differences in care required.
11
12 Reimbursements are therefore a poor indicator of costs.
13
14

15
16 Some authors argue for the implementation of time-driven activity-based costing
17 (TDABC) as the 'golden standard' of cost measurement in healthcare organizations [3,5,15].
18
19 TDABC is a method of matching direct and indirect costs to activities in a fine-grained way, based
20
21 on the amount of time an activity takes. A care path is made up of many activities, each generating
22
23 costs. The costs of a care path can be calculated by first identifying all relevant costs to each
24
25 activity, and then adding up those costs across the activities [22]. One step of this method called
26
27 'process mapping' presents care paths visually in a flowchart.
28
29
30
31

32
33 Though initial research is growing and promising, we have relatively little empirical
34
35 evidence supporting TDABC as the best costing method to enable VBHC, as studies rarely
36
37 compare methods of cost measurement or simply use whichever system the investigated hospital
38
39 or care provider uses. Costing methods vastly differ by how they allocate indirect costs to products
40
41 or services [24]; moreover, indirect costs cannot causally be attributed to patients and need to be
42
43 properly allocated. One example of indirect costs are salaries of administrative personnel, e.g.,
44
45 front office staff who welcomes patients, coordinates schedules, or manages equipment such as a
46
47 Da Vinci surgical robot system by Intuitive Surgical (Sunnyvale, CA, USA). While some methods
48
49 ignore this (e.g., direct costing), other methods average indirect costs across days or months, or
50
51 systematically allocate them to patients. These methods exist on a continuum from imprecise to
52
53 fine-grained, with TDABC leaning towards fine-grained. This insight is particularly relevant to
54
55
56
57
58
59
60

1
2
3 health care, where indirect costs are high. The most fine-grained method is activity-based costing
4 (ABC), which allocates indirect costs based on actual units of resources used per activity. In
5
6
7
8 comparison, TDABC allocates indirect costs based on a per-minute cost, making it considerably
9
10
11
12 easier to implement than ABC. Costing methods that do not consider the indirect costs of a care
13
14
15 path underestimate the true costs of the care delivered.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Prior systematic reviews found that TDABC was able to facilitate VBHC, citing mostly
cost savings as a result and without comparing it to alternative methods [3,4,15]. Therefore, we do
not know how this compares to other cost measurement methods currently being used. While
TDABC may be able to facilitate VBHC [5,15], it is unclear how these benefits compare to other
costing methods currently used in practice. Therefore, the cost side of the value equation remains
unclear. To address this challenge, we pose two questions:

RQ1: Which costing methods are currently being used by practitioners to facilitate VBHC?

RQ2: What are the consequences of applying one specific costing method in VBHC?

Such consequences may include whether the method enables cost reduction at equal or
better outcomes or provides sufficient information to further improve a care path.

This comprehensive review draws on accounting literature [24] to categorize costing
methods in empirical VBHC literature published over the last two decades (January 1, 2003 to
January 1, 2022). Compiling the evidence in this way reveals four ways in which cost information
facilitates VBHC and three best practices.

MATERIALS AND METHODS

Literature search strategy

To identify eligible studies, we systematically searched four major databases: Embase, Medline,
Web of Science, and CINAHL EBSCOhost. Our search string (**online supplementary appendix**)

1
2
3 was developed by assessing previously identified relevant papers; it is designed to catch all studies
4 that address VBHC and measure costs of an intervention, care path, or treatment by including the
5
6 following specific terms:
7

8
9
10 *cost*, microcost*, macrocost* AND [meaning in combination with] value-based, value
11 based, OR valuebased
12

13 Prior search string testing showed that restricting the search to the phrase “value-based healthcare”
14 excluded too many relevant studies because authors use “value-based perspective,” “value-based
15 equation,” or similar variations when referring to VBHC. Conversely, the term “value” alone was
16 too broad and yielded more than 40,000 mostly non-specific results. By using wildcard terms
17 indicated by stars we include all variations on the term ‘cost’.
18
19
20
21
22
23
24
25
26

27 **Study eligibility criteria, record selection, and data collection**

28
29 We limited inclusions to studies that were peer-reviewed empirical research and measured or
30 estimated costs in a VBHC context. All inclusion criteria and variables extracted are detailed in
31 the **online supplementary appendix**. The following variables were collected, inspired by Porter
32 [2] and the cost measurement methods defined in accounting literature:
33
34
35
36
37

- 38 • Cost types included (direct vs. indirect).
- 39 • Cost perspective (provider, payer, patient).
- 40 • Portion of the care path costed (full, partial).
- 41 • Cost measurement method used (as labelled by the authors of the study).
- 42 • Cost measurement method applied, e.g. direct costing, absorption costing, step-down
43 allocation, other recognized methods [24].
- 44 • Consequences of the costing information generated.

45
46
47
48
49
50
51
52 **Patient and public involvement:** This study did not involve patients or the public in designing,
53 executing, or reporting of the research.
54
55
56
57

RESULTS

Record selection

Our four-person (ML, PP, HvE, KA) research group identified 3,275 relevant papers, of which 1,930 remained after deduplication. We conducted a trial screening of 30 papers to test and specify the screening criteria. The screening process comprised two rounds as shown in **Figure 1**. In Round 1, ML and PP screened the titles and abstracts independently. If there was uncertainty about the eligibility of the paper, it was included for the full-text screen following Bramer [25]. We admitted 674 studies based on titles and abstracts with a Cohen's kappa inter-rater reliability score of 0.78, indicating substantial agreement [26].

In Round 2, both ML and PP screened the full text of all 674 studies independently. 215 out of 674 studies were included for RQ1, with a Cohen's kappa of 0.76 between both ML and PP. HvE was included in the discussion as needed. Lastly, we assessed whether the paper discussed if or how the costing information facilitated VBHC (RQ2), yielding 49 cases in which the costing method facilitated VBHC. This review was not registered.

Figure 1 here

Figure 1. PRISMA flowchart depicting screening, exclusion, and inclusion process with 2 reviewers.

Descriptive characteristics

An overview of the included studies is provided in **Table 1**. Our earliest study is from 2005, with a spike in studies for 2017. Just under half (n=98, 45.6%) of studies were published in the last two years. An overwhelming majority is from the US (n= 178, 82.8%). Europe is the second most common continent with 22 (10.6%) studies being European, 9 (4.2%) of which are Dutch.

The three largest medical specialty groups represented are surgical (n=99; 46.0%), oncology (n=37; 17.2%) and paediatrics (n=19; 8.8%). The complete list of 215 inclusions is summarized in the **online supplementary appendix**. Extracted data is available in the **supplementary file**.

Characteristic	n	%	Characteristic	n	%
Year published			Topic		
2005-2009	3	1.4%	Cardiology	5	2.3%
2010-2013	6	2.8%	Dermatology	1	0.5%
2014	6	2.8%	Emergency & acute care	11	5.1%
2015	7	3.3%	Endocrinology	3	1.4%
2016	9	4.2%	Surgical, <i>of which</i>	99	46.0%
2017	17	7.9%	Appendicitis, 2		
2018	28	13.0%	Abdominal, 6		
2019	41	19.1%	Bariatric, 2		
2020	43	20.0%	Cardiac/Thoracic, 12		
2021	51	23.7%	Colon/Rectal, 2		
2022 as per 1/1/2022	4	1.9%	Endocrine, 2		
Geography			Ear/Nose/Throat, 2		
Americas		84.3%	Gallbladder, 2		
Brazil	3		Liver, 2		
Canada	1		Neurosurgical, 5		
US <i>of which</i>	178		Orthopaedic arthroplasty, 25		
Boston, 8			Orthopaedic fracture, 12		
California, 18			Orthopaedic rotator cuff repair, 2		
New York, 23			Orthopaedic other, 3		
Texas, 12			Plastic surgery, 2		
Pennsylvania, 9			Spine, 13		
Other states, 108			other surgical, 5		
Asia		2.3%	Geriatrics	1	0.5%
China	1		Gynaecology & obstetrics	8	3.7%
Iran	1		Infectious disease	1	0.5%
Kuwait	1		Internal medicine	12	5.6%
Lebanon	1		Multiple	3	1.4%
Singapore	1		Nephrology	1	0.5%
Europe		10.6%	Neurology	2	0.9%
Andalusia	1		Oncology	37	17.2%
Germany	1		Ophthalmology	3	1.4%
Italy	3		Orthopaedic	1	0.5%
Norway	1		Pain medicine	3	1.4%
Serbia	1		Paediatrics <i>of which</i>	19	8.8%
Spain	2		Appendicitis, 3		
Netherlands	9		Emergency & acute care, 2		
UK	4		Neonatal, 3		
Oceania		1.9%	Oncology, 1		
Australia	4		Surgical, 5		
Transcontinental		0.9%	Surgical, plastic surgery, 2		
Russia	1		Other paediatric, 3		
Turkey	1		Toxicology	1	0.5%
			Urology	4	1.9%

Table 1. Characteristics of value-based health care studies measuring costs (n=215).

Which cost measurement methods are currently being used to facilitate VBHC?

To answer RQ1, we look at how costs were measured. A summary of our findings is presented in **Table 2**. The literature contains many overlapping and contradicting terms, as costs can refer to insurer costs, reimbursements, hospital costs, or patient costs. About half (n=110, 51.2%) take the provider perspective, meaning costs were calculated for the hospital or care facility. Many studies use charges or payments because hospital cost data are unavailable, considering charges to be a relative proxy. Some studies use terms such as ‘costs,’ ‘charges,’ ‘prices,’ ‘payments,’ and ‘reimbursements’ interchangeably, making it difficult to differentiate [17,18,27–30]. For example, Jain et al, [17] stated, “The terms reimbursement, cost, and payment have been used interchangeably throughout the text to represent actual amounts paid by insurers.” Similarly, Robles et al, [30] explained, “Total hospital charges were utilized in this standardized costing analysis. Hospital charge data provides a relative measure of the ‘cost’ of episodes of care, as actual cost data are generally not ascertainable in the healthcare setting.” When calculating costs with TDABC, Ahluwalia et al, [31] called these costs ‘prices.’ To address this confusion, some recent studies refer to provider costs as the ‘true cost’ of care [6,7,9,19]. A portion of studies comparing several cost types [19,20] also differentiate ‘traditional hospital accounting’ costs vs. ‘true costs’ calculated with TDABC [6,9,20,32,33].

Characteristic	Studies		Perspectives	
	n	%	n	%
Cost perspective				
Provider	110	51.2%	111	51.6%
Insurer	103	47.9%	106	49.3%
Patient	2	0.9%	5	2.3%
N*	215		222	
		All studies (n=215)	Provider only	Payer only
Cost types included				
Direct	28	13.0%	24	2
Direct and indirect	177	81.9%	84	93
Unspecified	10	4.6%	2	8
Costs measurement implementation				
No, costs measured for purpose of study	34	15.7%	33	
Yes, costing method is implemented	39	17.6%	39	
Unspecified or not applicable	142	66.2%	38	102
Costs coverage				
Full care path	47	21.8%	30	16
Full care path (full surgical episode)	17	7.4%	13	4
Partial care path (full surgical episode)	22	8.3%	19	3
Partial care path	86	42.1%	37	49
Unspecified	43	19.9%	11	31

Note: N differs between studies and perspectives because seven studies measured two cost types.

Table 2. Characteristics of costing methods in value-based health care

We categorized studies based on the cost types they include. Both direct and indirect costs were considered by 177 (81.9%) studies, while 28 (13.0%) papers only included direct costs.

Next, we looked at whether costs were calculated for a complete care path. We found 64 (29.8%) studies measure costs for a full care path, of which 16 (7.4%) are full surgical episodes but labelled so without considering all pre- or post-surgical costs. The remaining 86 (42.1%) measures costs for a partial care path.

Table 3 categorizes studies based on their costing method used. For those papers measuring costs within the care provider, we found two clear categories in line with management

1
2
3 accounting literature[24]. The first is direct costing (n=23), where direct costs of care are summed
4
5 up and indirect costs are not considered. This implies that if costs cannot causally be attributed to
6
7 the treatment of a specific patient, they are not considered and hence neglected when making
8
9 managerial decisions [24].
10
11

12
13 Studies considering direct and indirect costs use absorption costing, whereby indirect costs
14
15 are allocated to patients [31]. These include but are not limited to TDABC (n=31) and ABC (n=7),
16
17 in which costs are allocated per individual care activity (e.g., a consultation or treatment step). The
18
19 remaining absorption costing papers (n=47) also consider direct and indirect costs, but how
20
21 indirect costs are attributed to activities are not reported. Authors of absorption costing studies
22
23 state that cost information was calculated based on diagnosis-related group costs, micro costing,
24
25 bottom-up clinical costing, or hospital accounting system not further classified. A full list of all
26
27 terms used is presented in the **online supplementary appendix**.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Perspective	Method	n
<i>Provider</i>	Direct costs only	
	Direct costing	23
	Absorption costing	
	ABC	7
	TDABC	31
	Other	47
	Not specified	3
<i>Insurer</i>	Charges & reimbursements	
	Charges, reimbursements, claims	81
	Charges adjusted with cost-to-charge ratio	25
<i>Patient</i>	Out-of-pocket costs to patient	5

Note: Total number of studies here is 222; seven studies measure two cost types. Studies are classified based on actual costs included and methods described, not necessarily the labels used by authors.

Table 3. Overview of cost measurement methods used in value-based health care

How do these costing methods facilitate VBHC?

To answer RQ2, we extracted all consequences described by papers related to the costing method.

Not all studies included to address RQ1 describe facilitating VBHC, or the consequences of the cost information generated. Here, we were looking for how the costing information facilitated VBHC, similar to Etges et al, [3]. These reported consequences were grouped inductively, revealing four categories:

1. Identification of cost drivers, in terms of cost items (e.g., staff costs, material costs) or activities (e.g., surgery, initial consult; n=48).
2. Comparison of costs across patients' groups, care providers, or procedures (n=39).
3. Measured cost difference, or cost saving, at equal or better care (n=26).
4. Suggested or measured care path improvements (n=40).

These studies are presented in **Table 4**. The studies reporting these facilitators used ABC (n=6), TDABC (n=29), other absorption costing methods (n=12), or direct costing (n=3).

Study Characteristics					Best practices				Value-Based consequences of costing information				
	Medical Specialty	Costing method	period	Centre	Study type	PM	EI	DO	CG	Compare costs across	ICD	MPS	Care path adjustment
[34]	Internal medicine	TDABC	partial	single	retro	yes	yes		items, activities		yes		suggested
[33]	Surgical, orthopaedic, rotator cuff repair	TDABC	full (FSE)	single	retro	yes		yes	items, activities	surgeons, two alternative treatments	yes	yes, ± \$727 about the mean per patient	suggested
[4]	Cardiology, surgical	TDABC	full (FSE)	multi	retro	yes	yes	yes	items, activities	hospitals, procedures	yes	yes, estimate 51.0% of procedure cost	yes
[10]	Oncology	TDABC	full	single	retro	yes	yes	yes	items, activities	treatment care paths	yes	\$2,302 (25.0%) difference across treatments	suggested
[35]	Surgical, orthopaedic	TDABC	full (FSE)	single	retro	yes			items, activities	patients	yes		suggested
[36]	Surgical, orthopaedic	TDABC	full (FSE)	single	retro	yes			items, activities	patients	yes		suggested
[19]	Surgical, orthopaedic	TDABC	full (FSE)	single	retro	yes		yes	items, activities	costing methods (TA and TDABC)	yes		suggested
[20]	Surgical, orthopaedic	TDABC	full (FSE)	single	retro	yes		yes	items, activities	five treatments, cost vs. reimbursement	yes		
[37]	Paediatric, surgical, plastic surgery	TDABC	full (FSE)	multi	pro	yes		yes	items, activities	treatment care paths	yes	up to \$8900, but long-term outcomes yet unknown	suggested
[38]	Emergency & acute care	TDABC	full (multiple)	multi	retro	yes	yes	yes	items, activities	eight care paths for acute ureteral stones (patient journeys)	yes	yes, \$6614 difference across care paths	suggested
[39]	Surgical, orthopaedic	TDABC	full (FSE)	single	retro	yes		yes	items, activities	surgeons	yes		suggested
[40]	Oncology	TDABC	partial	single	pro	yes	yes	yes	items, activities	treatments and individual care paths	yes	yes, cost difference of up to 3.33 times, depending on case mix	suggested
[41]	Oncology (incl. surgery)	TDABC	full	single	retro	yes		yes	items, activities		yes		suggested
[42]	Oncology	TDABC	partial (FSE)	single	retro	yes			items	pre and post implementation	yes	yes, mean cost savings of €309 per patient	yes
[43]	Cardiology	AC (other)	partial	multi	retro				items	patient journeys	yes		suggested
[44]	Emergency & acute care	AC (other)	partial	single	retro	yes			items	surgeons	yes		
[45]	Surgical, bariatric	AC (other)	full (FSE)	single	retro				items	treatment	yes		
[46]	Gynaecology & obstetrics	AC (other)	full	single	retro	yes			items, activities	procedures	yes	yes, \$967 per patient	suggested
[47]	Emergency & acute care	AC (other)	partial	single	retro				items, activities		yes		
[48]	Surgical, colorectal	AC (other)	partial (FSE)	single	retro				items	intervention	yes	yes, reduced variable cost, similar total cost	yes
[21]	Surgical, orthopaedics, fracture	ABC	partial (FSE)	single	retro				items	patients, patient groups, demographics	yes		
[49]	Surgical, orthopaedic, arthroplasty	ABC	full (FSE)	single	both		yes	yes	items, activities	treatment care paths	yes	estimate €2,054,000 annually	yes
[50]	Surgical, spine	ABC	Full	single	retro	yes			items, activities	patients, patient groups	yes		suggested
[6]	Paediatric, surgical	TDABC	full (FSE)	single	both	yes		yes	items, activities	costing methods (TA and TDABC)	yes	20.0% and without care path alteration	suggested
[51]	Oncology	TDABC	full (FSE)	single	retro	yes	yes	yes	items, activities	treatment care paths	yes	yes, estimate for each 10.0% decrease in case duration, total costs could decrease by about 8.0%.	suggested
[31]	Surgical, orthopaedic	TDABC	full (FSE)	single	pro	yes	yes	yes	items, activities	treatment care paths	yes	£2,018 per patient	suggested
[52]	Paediatric, neonatal	TDABC	partial	single	retro	yes	yes	yes	items, activities	Pre and post intervention	yes	yes, 36.0% or \$92,000 per tracheostomy care cycle	yes
[53]	Surgical, cardiac/thoracic	AC (other)	partial	multi	retro	yes			items	patients, implant devices	yes		suggested

[54]	Oncology, surgical	AC (other)	partial	single	retro				items		yes	yes, multiple		
[55]	Multiple	TDABC	full	multi, pilot	retro	yes	yes	yes	items, activities	before and after intervention (IPUs)	yes	yes, quarterly costs declined	suggested	
[56]	Oncology	TDABC	partial (PSE)	single	pro	yes		yes	items, activities	treatment care paths (parallel vs. induction design in OR)	yes	yes, estimate OR time reduction of 55 min, or \$,2818 missed revenue	suggested	
[57]	Surgical, orthopaedics fracture	TDABC	partial (FSE)	single	both	yes			items		yes		suggested	
[58]	Surgical, foot debridement	TDABC	partial (FSE)	single	retro			yes	items	before and after intervention	yes		yes	
[59]	Ophthalmology	TDABC	full	single	retro	yes	yes	yes	items, activities		yes		suggested	
[60]	Gynaecology & obstetrics, surgical	AC (other)	partial (FSE)	single	retro				items		yes		suggested	
[61]	Gynaecology & obstetrics, surgical	AC (other)	partial (FSE)	single	retro				items		yes			
[62]	Multiple	Direct costing	partial	single	retro				items		yes			
[63]	Surgical, orthopaedic	Direct costing	full (FSE)	multi	retro				items	intervention		yes, £255 per patient	yes	
[5]	Surgical, carpal tunnel release	TDABC	partial (FSE)	multi	retro	yes		yes	items, activities	multiple treatment care paths	yes	yes, 70.9% (\$27,103) and 31.6% (\$178)	yes	
[64]	Surgical, appendicitis	AC (other)	partial (FSE)	single	pro		yes	yes	items	pre and post intervention (dashboard)	yes	yes, decreased by \$496 per operation	yes	
[65]	Surgical, orthopaedic	Direct costing	partial (FSE)	single	retro	yes			items	intervention	yes			
[8]	Urology	TDABC	partial	single	pro	yes		yes	items, activities		yes	yes, estimate two hours per cycle	suggested	
[66]	Paediatrics, appendicitis	TDABC	full (FSE)	single	pro	yes	yes	yes	items, activities	treatment care paths (pre and post intervention)	yes	11.0% cost reduction, and 51.0% hospitalization time reduction	yes, several	
[67]	Urology	AC (other)	partial	multi	retro		yes		items					
[7]	Oncology, surgical, 11 surgeries	TDABC	Partial (FSEs)	single	retro	yes			items, activities	potential staffing ratios	yes	estimate 13.0-28.0% per surgery type	modelled and suggested	
[9]	Oncology	TDABC	full	single	retro	yes	yes	yes	items, activities	treatments (high-dose vs. low-dose brachytherapy)	yes	\$2,668 difference across treatments	yes	
[68]	Urology	TDABC	partial (FSE)	single	retro	yes	yes		items, activities	five treatment care paths	yes	yes, 400.0% increase from least to most expensive pathways	suggested	
[32]	Surgical, neurosurgery	ABC	partial (FSE)	single	retro	yes			items, activities	patients	yes	yes, 25.0%	yes, several	
[69]	Surgical, neurosurgery	ABC	partial (FSE)	single	retro	yes			items, activities	patients	yes		suggested	
[70]	Paediatric plastic surgery	ABC	partial, 1 year	single	retro				items	patients	yes		suggested	
						Count	34	16	24		39	47	26	40

Note: ABC: Activity-Based costing; TDABC: Time-Driven activity-based costing; FSE: Full surgical episode; AC (other): Absorption costing, other; PSE: Partial surgical episode; Retro: Retrospective; Pro: Prospective; PM: Process mapping; EI: Expert input; DO: Direct Observation; CG: Cost grouping, cost items only or activities; ICD: Identify cost drivers; MPS: Measured provider cost savings (at equal or better care). Costing methods are classified based on actual reported costs and methods applied, not necessarily the labels used by authors.

Table 4. Costing method applications, method used, and consequences, sorted by year.

Activity-based costing

All six studies applying ABC explained that they did so because this was the provider's existing costing method. Three of these studies measured costs for a full surgical episode [21,32,69] as part of a longer care path, two measured costs for a full care path [49,50], and one measured costs of a partial care path [70]. While these studies all applied ABC, their ability to facilitate VBHC differs. Jacobs et al [50] measured costs for a complete care path for patients with adult spinal deformity, a complex care path spanning about one year. The authors compared costs across patient groups and patients, found major cost drivers, and suggested where to concentrate cost containment. Similarly, McLaughlin et al [32,69] both measured costs, identified cost drivers and evaluated targeted cost containment initiatives. In their paper [32], the cost containment initiatives were informed by the costing information—activities with the highest costs were targeted for reduction—and a 25.0% total cost reduction was achieved. While McLaughlin et al [69] identified comorbidities and demographics strongly related to the total costs in patients undergoing neurosurgery, Wise et al [21] found the opposite for geriatric hip fracture patients. This study identified cost drivers, and costs were compared across patient groups. McLaughlin et al [71] were able to measure and record costs savings of 25.0%, and Vanni et al [49] successfully predicted about €2,054,000 annual cost savings associated with an alternative enhanced recovery pathway.

Time-driven activity-based costing

The largest portion of papers included for RQ2 used TDABC. These studies were able to identify significant cost drivers linked to activities in a care path, and some suggest where to target improvement initiatives [4,6–8,10,33,40,59]. A large selection of TDABC studies was able to suggest (n=19) [6,8,10,19,33–38,40,41,51,55–59,68] or measure (n=6) [5,9,31,42,52,66] care path improvements as shown in **table 4**.

1
2
3 The length and specificity of the care paths costs varies greatly. Some studies were narrow in scope
4 and breadth, calculating costs for sub-sections of a single care path or surgical procedure
5 [6,8,38,39,56]. Isaacson et al [8] calculated costs for cleaning a single reusable piece of equipment,
6 while others costed single surgical days [6], compared alternative surgeons [39] or anaesthesia
7 solutions within a care path [56]. In this group, McClintock et al [38] took the broadest perspective
8 by mapping individual patient journeys.
9
10
11
12
13
14
15

16
17
18 The largest group of TDABC studies measured costs across care paths, within a single
19 provider, and for a single diagnosis (n=10) [9,10,31,33,37,40–42,51,66]. Typically, these studies
20 compared costs between a new intervention and usual care [9,10,31,51,52,66], or alternative care
21 paths [33,37,40,42] in order to measure cost savings.
22
23
24
25
26

27
28 Some studies were broader in scope, costing multiple care paths or treatments within one
29 specialty [5,7,20,68], an entire department [34,59], or multiple practice units [55] or providers [4].
30 Some compared ‘true costs’ calculated with TDABC across care providers within specialties or
31 care paths [4,37], while others argued TDABC costs are too subjective to be compared across
32 hospitals [10,38]. While most identified studies compared costs across care paths, some also
33 compared costs across patient groups [19,35,36] or even individual patient journeys [38,40].
34
35
36
37
38
39
40
41

42 Technology played a large role in studies aiming to reduce costs. One study was able to
43 suggest how to use technology more efficiently [6], and some show how technology can reduce
44 costs [37,40,51] by integrating technological investments in the TDABC cost calculated.
45 Conversely, studies using unspecified absorption methods did not include investments in
46 technology such as a Da Vinci robot mentioned above [60,61]. This is surprising because
47 absorption costing methods require indirect costs to be allocated.
48
49
50
51
52
53
54
55
56
57

Analyses enabled by activity-based and time-driven activity-based costing

Several ABC and TDABC studies compared costs calculated with traditional accounting costs [6,19,20] or reimbursements [20,21], finding that prices do not equal costs. Some conducted quantitative analyses using the cost information generated with ABC or TDABC. These include regression analyses to identify correlations [7,33,35,36,40], compare patient groups [20,35,36], and compare costs and outcomes across a matched patient sample [40].

Two recent studies conducted patient-level value-analysis (PLVA)[33,40], comparing patient-reported outcomes with patient-level TDABC costs. Wise et al [33] did so for rotator cuff repair surgeries over the span of one year, while McCreary et al [57] analyzed ankle fractures. Both studies found costs to be unrelated to patient-reported outcome measures.

Other absorption costing methods and direct costing

Other absorption costing methods used by studies were labelled as micro costing (n=5), bottom-up clinical costing [47], or were described but not labelled (n=6). Most were able to find cost drivers (n=12, for details see **table 4**) and some could compare costs within providers. Notably, Robinson et al,[64] used the cost information to build and evaluate a dashboard that provides real-time feedback to surgeons during operations and monthly, decreasing costs significantly. Some studies omitted cost categories, e.g., equipment [61]. Direct costing enabled cost driver identification [62,63,65], and in some instances granular cost measurement.

Best practices

After finding these four facilitators, we compared studies to find common practices. This is of particular importance because costing methods are not labelled consistently. For example, many studies refer to ABC as 'bottom-up costing.' To look beyond labels, we compared the exact methods used to measure costs. We found that studies able to facilitate VBHC used process

1
2
3 mapping (n=34), expert input (n=17), and/or direct observations (n=24) when measuring costs.
4
5 These practices overlap with TDABC best practices but are not exclusive to TDABC, as shown in
6

7
8 **Table 4.**
9

10
11 Studies that made specific care path improvement suggestions used process mapping, and
12 especially those with a multidisciplinary team reported great benefits [4,9,10,19]. This enables
13 experts (doctors, care professionals, administrators) with the required knowledge and experience
14 to reflect critically on the process [4,9,10,19] which resulted in actionable suggestions. In
15 comparison, studies that did not use process mapping could suggest minimizing high-cost items
16 (e.g., total operating time, nursing costs) but could not couple these suggestions to activities, or
17 chronological points in the care path. Only commenting on cost items, instead of chronological
18 time points, limits the ability of cost information to inform management on where to focus process
19 improvement initiatives.
20
21
22
23
24
25
26
27
28
29
30
31

32 Expert input while creating process maps or measuring costs was often cited by authors as
33 being valuable, especially for estimating preparation time or other behind-the-scenes activities that
34 do not involve the patient but are critical to delivering care. Some studies unable to use expert
35 input cited this as a limitation of their work. Rare cases also evaluated the impact of costing
36 information, for example by involving experts in evaluating a dashboard [64].
37
38
39
40
41
42
43

44 Lastly, direct observations were used by some studies, particularly those calculating
45 process times down to the minute or those measuring costs for individual patient journeys.
46
47
48

49 **DISCUSSION**
50
51
52
53
54
55
56
57
58
59
60

1
2
3 This review focused on VBHC studies measuring or estimating costs, and on identifying which
4 costing methods can facilitate VBHC. By assessing the consequences of the costing methods used,
5
6 we were able to identify the characteristics of costing methods that facilitate VBHC.
7
8
9

10 Previous research found that TDABC can facilitate VBHC through cost containment and
11 process improvements [3,15]. We build on these by comparing value-based consequences across
12 costing methods. While the field is young and alternatives seem scarce, we have found
13 considerable evidence that TDABC and ABC can indeed facilitate VBHC. As previously
14 mentioned, TDABC is considerably easier to implement than ABC, which leads us to recommend
15 it over ABC. We found no well-documented alternatives to TDABC or ABC in our review. Not
16 all TDABC studies were able to achieve the facilitating factors we describe here. We emphasize
17 the need for future studies to follow TDABC guidelines properly and to document the methods
18 used explicitly. Several included studies in this review simply stated that TDABC was applied,
19 outsourced, used with incomplete costs, or used without listing exact cost rates.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Care path start and endpoints are well-documented by authors, but remain inconsistent. To
35 view costs in relation to outcomes as suggested by Porter [2], total costs from start to finish of a
36 trajectory must be considered [72]. Many studies chose the start and endpoints to their cost
37 measurement windows ad hoc and labelled this a full care path. Consequently, this results in
38 inconsistencies across studies, limiting comparisons. A selection of more recent studies measured
39 costs for a true full care path from beginning to end. Future research should do the same, and
40 explicitly define start and endpoints. This would allow for consistent comparison across providers.
41 Like ICHOM standard outcome sets produced by the International Consortium for Health
42 Outcomes Measurement, costs could be catalogued and compared for full care paths. In a recent
43 expert consensus study, experts reached consensus on the need for focusing on full care paths [72].
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Furthermore, we see a trade-off in the specificity and length of the care path costed. Studies
4 measuring costs for parts of a care path (e.g., a surgery) can provide detailed costs for that portion
5 of the care path, but not total costs of care per patient because the remainder of that patient's care
6 path is not included. Some surgical studies measured costs for partial care paths, and often
7 concluded that operating theatre time should be minimized due to high surgeon and operating
8 theatre costs.
9
10
11
12
13
14
15
16
17

18 This is a conclusion with limited impact for the value agenda [13] because it does not
19 provide cost information for an entire care path, or advice for how to circumvent the surgery. Yet,
20 studies measuring costs for complete care paths presented less detailed costing methods (due to
21 the sheer length of the care path) but were able to compute total costs of care per patient. This
22 enabled cost benchmarking across providers, as well as cost comparisons of new vs. standard care,
23 or treatment alternatives. This allowed providers to steer towards outcomes at lowest costs to
24 maximize value. Future research should focus on measuring costs for full care paths, and on
25 comparing costs to outcomes as demonstrated by some of the more recently published studies
26 included in our review [33,40,57].
27
28
29
30
31
32
33
34
35
36
37
38

39 Our review highlights the need to involve medical professionals in this process, both when
40 implementing costing methods as well as when evaluating the results. Future cost measurement
41 studies, and hospitals looking to implement TDABC, should do so with multidisciplinary teams.
42 Studies that have involved medical professionals in the process of cost measurement and usage
43 were able to improve care paths via improvement initiatives and/or dashboards. This suggests that
44 generating and using costing information can be viewed as a process. Future qualitative research
45 should follow this process to better understand the mechanisms through which this happens, and
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the impact of staff involvement on cost containment success. Previous research suggests that staff
4 involvement is critical as it builds trust in the model [73].
5
6

7 8 **Limitations and future research** 9

10
11 We acknowledge several limitations related to the scope, breadth, and quality of the included
12 studies. Firstly, our search strategy does not capture studies that measure costs but do not label the
13 study as VBHC-oriented. Not all TDABC studies make value-based claims or contributions and
14 may therefore be underrepresented in our review. Additionally, not all studies explicitly discuss
15 the impact or consequence of the costing method applied, which may impact our findings. Future
16 qualitative research should implement TDABC and evaluate whether the facilitating factors found
17 in this review are achieved. Secondly, sophisticated methods such as TDABC are currently used
18 in predictable and/or short care paths such as orthopaedic surgeries. Further research testing the
19 feasibility and practicality of TDABC in different settings, such as emergency on-call care, or long
20 care paths such as fertility treatments, is warranted. Our findings may have limited generalizability
21 across medical specialties as indicated in **Table 1**. Finally, we rely on the reporting of authors
22 which differs in style and quality across disciplines and journals. We partially circumvented this
23 limitation by looking beyond the cost measurement labels used by authors, and extracting the costs
24 included and methods used. However, we cannot exclude the potential for error, or lack of explicit
25 reporting, in the studies reviewed.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Conclusion** 47

48
49 This systematic review reveals that cost information at the treatment or patient level, for complete
50 care paths, enables value-based decision making through several mechanisms. Such cost
51 information directs quality and process improvement initiatives, next to informing reimbursement
52
53
54
55
56
57

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

amounts. Practitioners and academics should apply process mapping, expert input and observations when implementing absorption costing systems such as ABC or TDABC. Hospital cost measurement is strongly advised.

For peer review only

1
2
3 **Patient and public involvement:** This study did not involve patients or the public in designing,
4 executing, or reporting of the research.
5

6 **Acknowledgement:** We thank W.M. Bramer, biomedical information specialist from the
7 Erasmus MC. We also thank our fellow members of the value-based healthcare consortium
8 involving the Amsterdam UMC, Erasmus MC, Radboudumc, and Erasmus University
9 Rotterdam, led by J.G.M. Jelsma and M.C. de Bruijne.
10

11
12 **Funding:** This work was supported by Dutch ministry of health, welfare, and sport through grant
13 number 330843.
14

15 **Data sharing:** The supplementary appendix and data file are available from the Erasmus Data
16 Repository (DOI: 10.25397/eur.20279883). This DOI is reserved but not yet published. The
17 appendix and raw data file were submitted with the manuscript.
18

19
20 **Competing interests:** The third author, KA, was a speaker at the 2022 TDABC conference and
21 was reimbursed for his stay in Lisbon by the TDABC consortium.
22

23 **Contributors** ML: study design, screening of titles and abstracts for inclusion, data analysis and
24 interpretation, writing. PP: screening of titles and abstracts for inclusion, assisted in writing. KA:
25 study design, assisted in interpretation of results, assisted in writing. HvE: study design,
26 screening of titles and abstracts for inclusion, data analysis and interpretation, assisted in writing.
27
28

29 **ORCID ID**

30
31 Maura Leusder 0000-0001-7134-1003
32 Petra Porte 0000-0003-0228-1013
33 Kees Ahaus 0000-0001-9973-3746
34 Hilco van Elten 0000-0003-3909-5521
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Kaplan, Porter. How to solve the cost crisis in health care. *Harv Bus Rev* 2011;**89**:46–52, 54, 56-61 passim. <https://www.ncbi.nlm.nih.gov/pubmed/21939127>
- 2 Porter ME. What Is Value in Health Care? *N Engl J Med* 2010;**363**:2477–81. doi:10.1056/NEJMp1011024
- 3 Etges APB da S, Ruschel KB, Polanczyk CA, *et al* Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review. *Value Health* 2020;**23**:812–23. doi:10.1016/j.jval.2020.02.004
- 4 Etges, Cruz LN, Schlatter R, *et al* Time-driven activity-based costing as a strategy to increase efficiency: An analyses of interventional coronary procedures. *Int J Health Plann Manage* Published Online First: 9 September 2021. doi:10.1002/hpm.3320
- 5 Martin JA, Mayhew CR, Morris AJ, *et al* Using Time-Driven Activity-Based Costing as a Key Component of the Value Platform: A Pilot Analysis of Colonoscopy, Aortic Valve Replacement and Carpal Tunnel Release Procedures. *J Clin Med Res* 2018;**10**:314–20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=inleurlib_fft&cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=29511420
- 6 Bodar YJL, Srinivasan AK, Shah AS, *et al* Time-Driven activity-based costing identifies opportunities for process efficiency and cost optimization for robot-assisted laparoscopic pyeloplasty. *J Pediatr Urol* 2020;**16**:460.e1-460.e10. doi:10.1016/j.jpuro.2020.05.146
- 7 French KE, Guzman AB, Rubio AC, *et al* Value based care and bundled payments: Anesthesia care costs for outpatient oncology surgery using time-driven activity-based costing. *Healthc (Amst)* 2016;**4**:173–80. doi:10.1016/j.hjdsi.2015.08.007
- 8 Isaacson D, Ahmad T, Metzler I, *et al* Defining the Costs of Reusable Flexible Ureteroscope Reprocessing Using Time-Driven Activity-Based Costing. *J Endourol* 2017;**31**:1026–31. doi:10.1089/end.2017.0463
- 9 Ilg AM, Laviana AA, Kamrava M, *et al* Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer. *Brachytherapy* 2016;**15**:760–7. <https://www.ncbi.nlm.nih.gov/pubmed/27720202>
- 10 Dziemianowicz M, Burmeister J, Dominello M. Examining the Financial Impact of Altered Fractionation in Breast Cancer: An Analysis Using Time-Driven Activity-Based Costing. *Pract Radiat Oncol* 2021;**11**:245–51. doi:10.1016/j.prro.2021.01.003
- 11 Cattel D, Eijkenaar F. Value-Based Provider Payment Initiatives Combining Global Payments With Explicit Quality Incentives: A Systematic Review. *Med Care Res Rev* 2020;**77**:511–37. doi:10.1177/1077558719856775

- 12 Counte MA, Howard SW, Chang L, *et al* Global Advances in Value-Based Payment and Their Implications for Global Health Management Education, Development, and Practice. *Front Public Health* 2018;**6**:379. doi:10.3389/fpubh.2018.00379
- 13 Porter ME, Teisberg EO. Redefining competition in health care. *Harv Bus Rev* 2004;**82**:64–76, 136. <https://www.ncbi.nlm.nih.gov/pubmed/15202288>
- 14 Rathert C, Mittler JN, Lee YSH. Patient-provider therapeutic connections to improve health care: Conceptual development and systematic review of patient measures. *Health Care Manage Rev* Published Online First: 14 February 2022. doi:10.1097/HMR.0000000000000339
- 15 Zanotto BS, Etges APB da S, Marcolino MAZ, *et al* Value-Based Healthcare Initiatives in Practice: A Systematic Review. *J Healthc Manag* 2021;**66**:340. doi:10.1097/JHM-D-20-00283
- 16 Gibbons C, Porter I, Gonçalves-Bradley DC, *et al* Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice. *Cochrane Database Syst Rev* 2021;**10**:CD011589. doi:10.1002/14651858.CD011589.pub2
- 17 Jain N, Brock JL, Phillips FM, *et al* Chronic preoperative opioid use is a risk factor for increased complications, resource use, and costs after cervical fusion. *Spine J* 2018;**18**:1989–98. doi:10.1016/j.spinee.2018.03.015
- 18 Rice-Townsend S, Barnes JN, Hall M, *et al* Variation in practice and resource utilization associated with the diagnosis and management of appendicitis at freestanding children's hospitals: Implications for value-based comparative analysis. *Ann Surg* 2014;**259**:1228–34. doi:10.1097/SLA.0000000000000246
- 19 Fang, Shaker J, Drew JM, *et al* The Cost of Hip and Knee Revision Arthroplasty by Diagnosis-Related Groups: Comparing Time-Driven Activity-Based Costing and Traditional Accounting. *J Arthroplasty* 2021;**36**:2674-2679.e2673. doi:10.1016/j.arth.2021.03.041
- 20 Fang, Shaker J, Hart P-A, *et al* Variation in the profit margin for different types of total joint arthroplasty. *J Bone Joint Surg Am* 2021;**Publish Ahead of Print**. doi:10.2106/JBJS.21.00223
- 21 Wise, Blaschke BL, Parikh HR, *et al* Variation of the Inpatient Cost of Care in the Treatment of Isolated Geriatric Intertrochanteric Hip Fractures. *Geriatr Orthop Surg Rehabil* 2020;**11**. doi:10.1177/2151459320976533
- 22 Keel G, Savage C, Rafiq M, *et al* Time-driven activity-based costing in health care: A systematic review of the literature. *Health Policy* 2017;**121**:755–63. doi:10.1016/j.healthpol.2017.04.013
- 23 Hoenigl M, Lo M, Coyne CJ, *et al* 4th Generation HIV screening in the emergency department: net profit or loss for hospitals? *AIDS Care* 2021;:1–5. doi:10.1080/09540121.2021.1995838

- 1
2
3 24 Zimmerman JL. *Accounting For Decision Making and Control Seventh Edition*. McGraw-Hill 2011. <http://digilib.umpalopo.ac.id:8080/jspui/handle/123456789/151>
- 4
5
6 25 Bramer WM, Milic J, Mast F. Reviewing retrieved references for inclusion in systematic reviews using endnote. *J Med Libr Assoc* 2017;**105**:84–7. doi:10.5195/jmla.2017.111
- 7
8
9 26 Pérez J, Díaz J, Garcia-Martin J, *et al* Systematic literature reviews in software engineering—enhancement of the study selection process using Cohen’s Kappa statistic. *Journal of Systems and Software* 2020;**168**:110657. doi:10.1016/j.jss.2020.110657
- 10
11
12
13 27 Burnett RA Iii, Yang J, Courtney PM, *et al* Costs of unicompartmental compared with total knee arthroplasty : a matched cohort study over ten years. *Bone Joint J* 2021;**103-B**:23–31. doi:10.1302/0301-620X.103B6.BJJ-2020-2259.R1
- 14
15
16
17 28 Sun LL, Cao DY, Yang JX, *et al* Value-based medicine analysis on loop electrosurgical excision procedure and CO2 laser vaporization for the treatment of cervical intraepithelial neoplasia 2. *J Obstet Gynaecol Res* 2012;**38**:1064–70. doi:10.1111/j.1447-0756.2011.01832.x
- 18
19
20
21
22
23 29 Cronin KJ, Mair SD, Hawk GS, *et al* Increased Health Care Costs and Opioid Use in Patients with Anxiety and Depression Undergoing Rotator Cuff Repair. *Arthroscopy - Journal of Arthroscopic and Related Surgery* 2020;**36**:2655–60. doi:10.1016/j.arthro.2020.05.038
- 24
25
26
27 30 Robles AJ, Kornblith LZ, Hendrickson CM, *et al* Health care utilization and the cost of posttraumatic acute respiratory distress syndrome care. *J Trauma Acute Care Surg* 2018;**85**:148–54. doi:10.1097/TA.0000000000001926
- 28
29
30
31
32 31 Ahluwalia R, Cook J, Raheman F, *et al* Improving the efficiency of ankle fracture care through home care and day-surgery units: Delivering safe surgery on a value-based healthcare model. *Surgeon* Published Online First: November 2020. doi:10.1016/j.surge.2020.08.004
- 33
34
35
36 32 McLaughlin N, Upadhyaya P, Buxey F, *et al* Value-based neurosurgery: measuring and reducing the cost of microvascular decompression surgery. *J Neurosurg* 2014;**121**:700–8. doi:10.3171/2014.5.JNS131996
- 37
38
39
40 33 Wise KL, Parikh HR, Okelana B, *et al* Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care. *J Shoulder Elbow Surg* 2022;**31**:72–80. doi:10.1016/j.jse.2021.07.004
- 41
42
43
44 34 Alibrahim A, Abdulsalam Y, Al Mutawa S, *et al* Towards value-based healthcare: Establishing baseline pharmacy care costs for diabetes management. *Int J Health Plann Manage* 2022;**37**:790–803. doi:10.1002/hpm.3370
- 45
46
47
48
49 35 Fang C, Hagar A, Gordon M, *et al* Differences in Hospital Costs among Octogenarians and Nonagenarians Following Primary Total Joint Arthroplasty. *Geriatrics* 2021;**6**:26. doi:10.3390/geriatrics6010026
- 50
51
52
53 36 Fang C, Pagani N, Gordon M, *et al* Episode-of-Care Costs for Revision Total Joint Arthroplasties by Decadal Age Groups. *Geriatrics* 2021;**6**:49. doi:10.3390/geriatrics6020049
- 54
55
56
57


- 1
2
3 37 Ganske IM, Sanchez K, Le E, *et al* Time-Driven, Activity-Based Costing of Presurgical Infant
4 Orthopedics: A Critical Component of Establishing Value of Latham Appliance and
5 Nasoalveolar Molding. *Plastic & Reconstructive Surgery* 2021;**147**:444–54.
6 doi:10.1097/PRS.00000000000007669
7
8
9 38 McClintock TR, Friedlander DF, Feng AY, *et al* Determining Variable Costs in the Acute
10 Urolithiasis Cycle of Care Through Time-Driven Activity-Based Costing. *Urology*
11 2021;**157**:107–13. doi:10.1016/j.urology.2021.05.102
12
13 39 Sethi RK, Pumpian RP, Drolet CE, *et al* Utilizing Lean Methodology and Time-Driven
14 Activity-Based Costing Together: An Observational Pilot Study of Hip Replacement Surgery
15 Utilizing a New Method to Study Value-Based Health Care. *J Bone Joint Surg Am* Published
16 Online First: 14 October 2021. doi:10.2106/JBJS.21.00129
17
18 40 Thaker NG, Boyce-Fappiano D, Ning, *et al* Activity-Based Costing of Intensity-Modulated
19 Proton versus Photon Therapy for Oropharyngeal Cancer. *International Journal of Particle*
20 *Therapy* 2021;**8**:374–82. doi:10.14338/IJPT-20-00042.1
21
22 41 Kukreja JB, Seif MA, Mery MW, *et al* Utilizing time-driven activity-based costing to
23 determine open radical cystectomy and ileal conduit surgical episode cost drivers. *Urologic*
24 *Oncology: Seminars and Original Investigations* 2021;**39**:237.e1-237.e5.
25 doi:10.1016/j.urolonc.2020.11.030
26
27 42 Mattar D, Di Filippo A, Invento A, *et al* Economic implications of ACOSOG Z0011 trial
28 application into clinical practice at the European Institute of Oncology. *Eur J Surg Oncol*
29 2021;**47**:2499–505. doi:10.1016/j.ejso.2021.06.016
30
31 43 Bueno H, Bernal JL, Jimenez-Jimenez V, *et al* The Clinical outcomes, healthcare resource
32 utilization, and related costs (COHERENT) model. Application in heart failure patients. *Rev*
33 *Esp Cardiol* Published Online First: 20 October 2021. doi:10.1016/j.rec.2021.08.009
34
35 44 Casey M, Perera D, Enticott J, *et al* High utilisers of emergency departments: the profile and
36 journey of patients with mental health issues. *Int J Psychiatry Clin Pract* 2021;**25**:316–24.
37 doi:10.1080/13651501.2021.1904998
38
39 45 Cohen RV, Nishikawa AM, Ribeiro RA, *et al* Surgical Management of Obesity in Brazil:
40 Proposal for a Value-Based Healthcare Model and Preliminary Results. *Value in Health*
41 *Regional Issues* 2021;**26**:10–4. doi:10.1016/j.vhri.2020.11.005
42
43 46 Negrini R, da Silva Ferreira RD, Guimaraes DZ. Value-based care in obstetrics: comparison
44 between vaginal birth and caesarean section. *BMC Pregnancy Childbirth* 2021;**21**:333.
45 doi:10.1186/s12884-021-03798-2
46
47 47 Fernando-Canavan L, Gust A, Hsueh A, *et al* Measuring the economic impact of hospital-
48 acquired complications on an acute health service. *Aust Health Rev* 2021;**45**:135–42.
49 doi:10.1071/AH20126
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 48 Khanijow AN, Wood LN, Xie R, *et al* The impact of an enhanced recovery program (ERP)
4 on the costs of colorectal surgery. *Am J Surg* 2021;**222**:186–92.
5 doi:10.1016/j.amjsurg.2020.11.034
6
7
8 49 Vanni F, Foglia E, Pennestrì F, *et al* Introducing enhanced recovery after surgery in a high-
9 volume orthopaedic hospital: a health technology assessment. *BMC Health Serv Res*
10 2020;**20**:773. doi:10.1186/s12913-020-05634-3
11
12 50 Jacobs K, Dewilde T, Vandoren C, *et al* Variability in hospital costs of Adult Spinal
13 Deformity care. *Spine* 2020;**45**:1221–8. doi:10.1097/BRS.0000000000003497
14
15 51 Ning MS, Venkatesan AM, Stafford RJ, *et al* Developing an intraoperative 3T MRI-guided
16 brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and
17 value-based analysis. *Brachytherapy* 2020;**19**:427–37. doi:10.1016/j.brachy.2019.09.010
18
19 52 Caloway C, Yamasaki A, Callans KM, *et al* Quantifying the benefits from a care coordination
20 program for tracheostomy placement in neonates. *Int J Pediatr Otorhinolaryngol* 2020;**134**.
21 doi:10.1016/j.ijporl.2020.110025
22
23 53 Burnhope E, Waring M, Guilder A, *et al* A systematic approach towards implementing value-
24 based health care in heart failure: Understandings from retrospective analysis methods in
25 South London. *Health Serv Manage Res* Published Online First: 2020.
26 doi:10.1177/0951484820971442
27
28 54 Lenfant L, Sawczyn G, Kim S, *et al* Single-institution Cost Comparison: Single-port Versus
29 Multiport Robotic Prostatectomy. *European Urology Focus* Published Online First: 2020.
30 doi:10.1016/j.euf.2020.06.010
31
32 55 Hernandez A, Kaplan RS, Witkowski ML, *et al* Navy Medicine Introduces Value-Based
33 Health Care. *Health Aff* 2019;**38**:1393–400. doi:10.1377/hlthaff.2019.00280
34
35 56 Basto J, Chahal R, Riedel B. Time-driven activity-based costing to model the utility of parallel
36 induction redesign in high-turnover operating lists. *Healthc Pap* 2019;**7**.
37 doi:10.1016/j.hjdsi.2019.01.003
38
39 57 McCreary DL, Dugarte AJ, Vang S, *et al* Patient-Level Value Analysis: An Innovative
40 Approach to Optimize Care Delivery. *J Orthop Trauma* 2019;**33**:S49–52.
41 doi:10.1097/BOT.0000000000001624
42
43 58 Ahluwalia R, Vainieri E, Tam J, *et al* Surgical Diabetic Foot Debridement: Improving
44 Training and Practice Utilizing the Traffic Light Principle. *Int J Low Extrem Wounds*
45 2019;**18**:279–86. doi:10.1177/1534734619853657
46
47 59 Kurt P, Saban M, Cankaya F, *et al* Time-Driven Activity-Based Costing in the Ophthalmology
48 Department of State Hospital: a Case Study. *Fresenius Environ Bull* 2019;**28**:2754–70.
49
50 60 Danilyants N, MacKoul P, van der Does L, *et al* A value-based evaluation of minimally
51 invasive hysterectomy approaches. *Gynecol Surg* 2019;**16**:5. doi:10.1186/s10397-019-1057-
52 9
53
54
55
56
57
58
59
60

- 1
2
3 61 Danilyants N, MacKoul P, Baxi R, *et al* Value-based assessment of hysterectomy approaches. *J Obstet Gynaecol Res* 2019;**45**:389–98. doi:10.1111/jog.13853
4
5
6
7 62 Chatfield SC, Volpicelli FM, Adler NM, *et al* Bending the cost curve: Time series analysis of
8 a value transformation programme at an academic medical centre. *BMJ Qual Saf*
9 2019;**28**:449–58. doi:10.1136/bmjqs-2018-009068
10
11 63 Featherall J, Brigati DP, Arney AN, *et al* Effects of a Total Knee Arthroplasty Care Pathway
12 on Cost, Quality, and Patient Experience: Toward Measuring the Triple Aim. *J Arthroplasty*
13 2019;**34**:2561–8. doi:10.1016/j.arth.2019.06.011
14
15 64 Robinson JR, Carter NH, Gibson C, *et al* Improving the value of care for appendectomy
16 through an individual surgeon-specific approach. *J Pediatr Surg* 2018;**53**:1181–
17 6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994354/pdf/nihms949182.pdf>
18
19 65 Karns MR, Jones DL, Todd DC, *et al* Patient- and Procedure-Specific Variables Driving Total
20 Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction. *Orthop J Sports Med*
21 2018;**6**:2325967118788543. doi:10.1177/2325967118788543
22
23 66 Yu YR, Abbas PI, Smith CM, *et al* Time-driven activity-based costing: A dynamic value
24 assessment model in pediatric appendicitis. *J Pediatr Surg* 2017;**52**:1045–9.
25 doi:10.1016/j.jpedsurg.2017.03.032
26
27 67 Parra E, Arenas MD, Alonso M, *et al* Assessing value-based health care delivery for
28 haemodialysis. *J Eval Clin Pract* 2017;**23**:477–85. doi:10.1111/jep.12483
29
30 68 Kaplan AL, Agarwal N, Setlur NP, *et al* Measuring the cost of care in benign prostatic
31 hyperplasia using time-driven activity-based costing (TDABC). *Healthcare*. 2015;**3**:43–8.
32 doi:10.1016/j.hjdsi.2014.09.007
33
34 69 McLaughlin N, Martin NA, Upadhyaya P, *et al* Assessing the cost of contemporary pituitary
35 care. *Neurosurg Focus* 2014;**37**:E7. doi:10.3171/2014.8.FOCUS14445
36
37 70 Abbott MM, Meara JG. A microcosting approach for isolated, unilateral cleft lip care in the
38 first year of life. *Plast Reconstr Surg* 2011;**127**:333–9. doi:10.1097/PRS.0b013e3181f95af3
39
40 71 McLaughlin N, Burke MA, Setlur NP, *et al* Time-driven activity-based costing: a driver for
41 provider engagement in costing activities and redesign initiatives. *Neurosurg Focus*
42 2014;**37**:E3. doi:10.3171/2014.8.FOCUS14381
43
44 72 Steinmann G, Delnoij D, van de Bovenkamp H, *et al* Expert consensus on moving towards a
45 value-based healthcare system in the Netherlands: a Delphi study. *BMJ Open*
46 2021;**11**:e043367. doi:10.1136/bmjopen-2020-043367
47
48 73 Hoozée S, Bruggeman W. Identifying operational improvements during the design process of
49 a time-driven ABC system: The role of collective worker participation and leadership style.
50 *Manag Acc Res* 2010;**21**:185–98. doi:10.1016/j.mar.2010.01.003
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



PRISMA flowchart depicting screening, exclusion, and inclusion process with 2 reviewers.

1428x873mm (96 x 96 DPI)

Inclusions RQ1 (215) extracted data to be shared with Erasmus Data Repository (FigShare)

Authors	Year Pub	Title paper (see full reference in manuscript)	Geography (country) of study	Geography, state of country, if N/A country	study design (if incl. in RQ2)	unit of analysis	disease/topic labels provided by study (overlapping tags, can be multiple)	Medical Specialty (non overlapping labels)	Medical Specialty sub category, where applicable	Care path studied	Costs included	Costs perspective (all)	Primary Cost perspective	Secondary Cost perspective if applicable	Costing method used as described in study	Primary Costing method classification	Secondary Costing method classification, if applicable	Implementation of costing method (N/A if reimbursements or charges, unspecified if not discussed in study)	if reimbursement: actual measurement used for estimation	RQ2 included - discuss consequences or impact of cost information in study
Gálvez, A. C. M. Sánchez, F. J. Moreno, C. A. Pérez Fernández, A. J. García, R. B. López, M. C. González, M. D. P.	2020	Value-based healthcare in ostomies	Andalusia	Andalusia		71 surgical ostomy patients	digestive, urology, surgical	Urology		partial care path (full surgical episode)	Direct and indirect	provider	provider		unspecified	Absorption costing - unspecified/generic		Paper only		no
McLaughlin, N. Upadhyaya, P. Busey, F. Martin, N. A.	2014	Value-based neurosurgery: Measuring and reducing the cost of microvascular decompression surgery	US	US: California	single center, retrospective	44 neurosurgical patients	neurosurgical, microvascular decompression, trigeminal neuralgia (TN) or hemifacial spasm (HFS)	Surgical	Neurosurgery	partial care path (full surgical episode)	Direct and indirect	provider	provider		ABC	Absorption costing - ABC		implemented		yes see second sheet
Hennink, S. D. Hofland, N. Gopic, J. P. Van Der Kaa, C. De Koning, K. Nielsen, M. Tone, C.	2016	Value-based healthcare in Lynch syndrome	The Netherlands	The Netherlands		64 Lynch Syndrome patients	oncology, lynch syndrome, colorectal cancer	Oncology		full care path	Direct and indirect	provider	provider		unspecified	Absorption costing - unspecified/generic		unspecified		no
French, K. E. Guzman, A. B. Rubio, A. C. Frenzel, J. C. Feeley, T. W.	2016	Value based care and bundled payments: Anesthesia care costs for outpatient oncology surgery using time-driven activity-based costing	US	US: Virginia	single center, retrospective, multiple care paths	5,357 outpatient anesthesia cases across 11 procedure groups	oncology	Oncology		partial care path (full surgical episode)	Direct and indirect	provider	provider		TDABC	Absorption costing - TDABC		implemented		yes see second sheet
Tan, R. Y. C. Met-Domestici, M. Zhou, K. Guzman, A. B. Lim, S. T. Soo, K. C. Feeley, T. W.	2016	Using quality improvement methods and time-driven activity-based costing to improve value-based cancer care delivery at a Cancer Genetics clinic	Singapore	Singapore	single center, retrospective, process mapping, observation	251 Patients with high-risk features suggestive of hereditary cancer	oncology, genetics, Cancer genetics	Oncology		partial care path	Direct	provider	provider		TDABC	Direct costing		unspecified		no
Daniylants, N. MacKoul, P. Baxi, R. van der Does, L. Q. Haworth, L. R.	2019	Value-based assessment of hysterectomy approaches	US	US: Maryland	single center, retrospective	2689 patients, female, 18 or over	gynecology, vaginal hysterectomy, robot, robot-assisted	gynecology & obstetrics		partial care path (full surgical episode)	Direct and indirect	provider	provider		Microcosting supplemented with charges	Absorption costing - unspecified/generic		Paper only		yes see second sheet
Hernandez, A. Kaplan, R. S. Wikowski, M. L. Forrest Faison, C. Porter, M. E.	2019	Navy medicine introduces value-based health care	US	US: Florida	single center, retrospective, multiple care paths, pilot project	22877 patients total	pregnancy, osteoarthritis, diabetes, lower back pain, multiple	gynecology & obstetrics		full care path	Direct and indirect	provider	provider		TDABC	Absorption costing - TDABC		implemented		yes see second sheet
Parra, E. Arenas, M. D. Alonso, M. Martínez, M. F. Gamen, A. Aguarón, J. Escobedo, M. T.	2017	Assessing value-based health care delivery for haemodialysis	Spain	Spain	multi center, retrospective	5 haemodialysis treatment centers, patients unspecified	haemodialysis, renal	Urology		partial care path	Direct and indirect	provider	provider		Microcosting	Absorption costing - unspecified/generic		Paper only		yes see second sheet
Brown, G. C. Brown, M. M. Brown, H. C. Kindermann, S. Sharna, S.	2007	A Value-Based Medicine Comparison of Interventions for Subfoveal Neovascular Macular Degeneration	US	US: Pennsylvania		233 patients with age-related macular degeneration	Ophthalmology, Neovascular, macular degeneration	ophthalmology		partial care path	Direct	payer	payer		none, reimbursements	Charges/Reimbursements-based		N/A	average medicare reimbursements	no
Medbery, R. L. Chadd, T. S. Sweeney, J. F. Knechtle, S. J. Kooby, D. A. Maribel, S. K. Lau, J.	2014	Laparoscopic vs open right hepatectomy: A value-based analysis	US	US: Georgia		105 patients total, elective laparoscopic liver resection surgery or open right hepatectomy	Surgical, Hepatectomy, Laparoscopic liver resections	Surgical	Liver	partial care path	Direct and indirect	provider	provider		unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic		implemented		no
Daniylants, N. MacKoul, P. van der Does, L. Haworth, L. Baxi, R.	2019	A value-based evaluation of minimally invasive hysterectomy approaches	US	US: Maryland	single center, retrospective	2689 patients, female, 18 or over	gynecology, vaginal hysterectomy, robot, robot-assisted	gynecology & obstetrics		partial care path (full surgical episode)	Direct and indirect	provider	provider		Microcosting	Absorption costing - unspecified/generic		Paper only		yes see second sheet
Gabriel, L. Casey, J. Gee, M. Palmer, C. Sinha, J. Moxham, J. Gardner, T. J. Van Deen, W. K.	2019	Value-based healthcare analysis of joint replacement surgery for patients with primary hip osteoarthritis	UK	UK: London		50 patients primary hip osteoarthritis	orthopedics, joint replacement, total hip osteoarthritis	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	provider	provider		Patient Level Information Costing System methodology (PLICS)	Absorption costing - unspecified/generic		implemented		no
Spiro, A. Burak Ozbay, A. Skop, M. Centeno, A. Duran, N. E. Lopez, D. N.	2017	The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: A pilot study	US	US: California		60 patients with inflammatory bowel disease	IBS, bowel, Inflammatory bowel disease	Internal Medicine		full care path	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements-based		N/A	Medicare reimbursements based on DRG/HCPCS codes	no

1	Isaacson, D. Ahmad, T. Mertzler, I. Tjou, D. T. Taguchi, K. Usawachintachit, M. Zaboniar, K. Zhanov, M. V. Zhukova, O. V.	2017	US	US, California	single center, direct observation, process mapping	10 Uteroscopes	Urology, Ureterorenoscopy	Urology	partial care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	
2	Yudina, Y. S. Avdonina, N. G. Emelyanov, I. V. Kurapchev, D. I. Zasosin, A. E.	2020	Russia	Russia		240 hypertensive patients	Blood pressure, hypertension, Blood pressure telemonitoring and remote counselling (BPTM)	Cardiology	partial care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	unspecified	no	
3	Annabathula, R. Dugan, A. Bhalla, V. Davis, G. A. Smyth, S. S. Gupta, V. A.	2020	US	US, Kentucky		634 patients, 18 or over, acute Pulmonary Embolism	Cardiology, pulmonary embolism	Cardiology	unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursemen t-based	N/A	total reimbursements no	
4	Goretti, G. Marinari, G. M. Vanni, E. Ferrari, C.	2020	Italy	Italy		2122 patients, morbidly obese, bariatric surgery	Obesity, surgical, bariatric surgery, Morbid Obesity	Surgical	Bariatric	unspecified	Direct and indirect	provider	provider	Absorption costing - unspecified/generic	Paper only	no	
5	Konda, S. R. Lott, A. Egol, K. A.	2020	US	US, New York		361 operative hip fracture patients	Geriatrics, trauma, hip fracture	Surgical	Orthopedic fracture	partial care path	Direct and indirect	provider	provider	unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	no
6	Emis, R. D. Parikh, A. B. Sanderson, M. Liu, M. Isola, L.	2019	US	US, New York		210 patients, 377 episodes of care	Oncology, Hematology, prostate cancer	Oncology	full care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursemen t-based	N/A	reimbursements no	
7	Denneny, J. C. Cyr, D. D. Witsell, D. L. Bretton, J. Schulz, K.	2019	US	US, Maryland		7499183 patients, 18-64, acute rhinosinitis	Rhinosinitis, Typical chronic rhinosinitis	Surgical	ENT	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursemen t-based	N/A	claims no
8	Peele, P. Keyser, D. Lovelace, J. Moss, D.	2018	US	US, Pennsylvania		262 child patients, under 21.	Pediatrics, complex conditions	Pediatrics	Pediatric other	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursemen t-based	N/A	reimbursements no
9	Brown, M. M. Brown, G. C. Brown, H. C. Pect, J.	2008	US	US, Pennsylvania		716 patients, classic or neovascular macular degeneration 158 patients undergoing implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization	Neovascular, macular degeneration, Subfoveal Neovascular Macular Degeneration	ophthalmology	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursemen t-based	N/A	reimbursements no	
10	Burnhope, E. Waring, M. Guilider, A. Malhotra, B. Cardoso, J. M. Razavi, R. Czuchra, J.	2020	UK	UK, London		A systematic approach towards implementing value-based health care in heart failure: Understandings from retrospective analysis methods in South London	Cardiology, heart failure	Surgical	Cardiac/Thoracic	partial care path	Direct and indirect	provider	provider	unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	yes see second sheet
11	Khullar, O. V. Jiang, R. Furze, S. D. Pickens, A. Sanchetti, M. S. Ward, K. Zalbasas, T.	2015	US	US, Georgia		942 patients esophagectomy 967 patients receiving primary percutaneous cutanary intervention between 2009 and 2011	Oncology, esophageal cancer	Oncology	full care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursemen t-based	N/A	Medicare costs, reimbursements no	
12	Eringer, J. E. Strauss, C. E. Garberich, R. R. Bradley, S. M. Rush, P. Chavez, J. J. Dobson, A. K.	2018	US	US, Minnesota		Value-based ST-segment-elevation myocardial infarction care using risk-guided triage and early discharge	Cardiology, heart failure, myocardial infarction	Surgical	Cardiac/Thoracic	full care path (surgical episode)	Direct	provider	provider	unspecified, Hospital accounting data not otherwise specified	Unspecified	implemented	no
13	Bodar, Y. J. L. Srinivasan, A. K. Shah, A. S. Kawal, T. Shukla, A. R.	2020	US	US, Pennsylvania	single center, retrospective, direct observation	25 robot assisted laparoscopic pyeloplasties	Pediatrics, urology, robotics, robot	Pediatrics	Pediatric surgical	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet
14	Verberne, W. R. Dijkers, J. Kelder, J. C. Geers, A. B. M. Jellema, W. T. Vincent, H. H. Van Dalen, J. T. M.	2018	The Netherlands	The Netherlands		366 patients aged ≥70 years with advanced chronic kidney disease	Nephrology, kidney, dialysis, chronic	Nephrology	full care path	Direct and indirect	provider	provider	unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	no	

Gregory, D. Scotti, D. J. de Lissovoy, G. Palacios, I. Dixon, S. Main, B. Lokani, W. Ravikumar, T. S. Sharma, C. Marini, C. Steele, G. D. Ritter, G. Barrera, R. Kuo, M. Ning, M. S. Venkatesan, A. M. Stafford, R. J. Bui, T. P. Carlson, R. Baillard, N. S. Judson, S. Sun, L. L. Cao, D. Y. Yang, J. X. Bian, M. L. Wei, L. H. Shen, K.	A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention	2013	US	US; various states	427 patients enrolled in trial, mean age 68, 80.6% male	Cardiology, heart failure	Surgical	Cardiac/Thoracic	partial care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursement-based proxy	N/A	none, charges, cost to charges	no
Yoshida, S. Sun, L. L. Cao, D. Y. Yang, J. X. Bian, M. L. Wei, L. H. Shen, K.	A validated value-based model to improve hospital-wide perioperative outcomes: Adaptability to combined medical/surgical inpatient cohorts	2010	US	US; New York	>100,000 hospital admissions	Surgical	Surgical	other	partial care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	Paper only		no
Fortmann, A. L. Walker, C. Barger, K. Robacker, M. Morrisey, R. Orwine, K. Lewandowski, J. Ramirez, M. M. Brennan, G. P.	Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis	2020	US	US; Texas	single center, retrospective, direct observation, process mapping	Oncology, Gynecology, gynecologic pelvic tumor	Oncology		full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet
Fortmann, A. L. Walker, C. Barger, K. Robacker, M. Morrisey, R. Orwine, K. Lewandowski, J. Ramirez, M. M. Brennan, G. P.	Value-based medicine analysis on loop electrocautery excision procedure and CO2 laser vaporization for the treatment of cervical intraepithelial neoplasia 2	2012	China	China	10 female patients 358 female patients, 18-65, colposcopic-histopathologically confirmed CIN2, intact uterus, no past history of cervical neoplasia, and had a	Obstetrics, Gynecology, cervical neoplasia	gynecology & obstetrics		partial care path	unspecified	provider	provider	unspecified	Unspecified	unspecified		no
Fortmann, A. L. Walker, C. Barger, K. Robacker, M. Morrisey, R. Orwine, K. Lewandowski, J. Ramirez, M. M. Brennan, G. P.	Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care	2020	US	US; California	236 treated patients, 239 usual care patients. All diagnosed with type 1 or 2 diabetes.	Diabetes	Internal Medicine		partial care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	implemented		no
Fortmann, A. L. Walker, C. Barger, K. Robacker, M. Morrisey, R. Orwine, K. Lewandowski, J. Ramirez, M. M. Brennan, G. P.	Using the value-based care paradigm to compare physical therapy access to care models in cervical spine radiculopathy: a case report	2020	US	US; Florida	case study; 39 yo female	Physiotherapy	Neurology		partial care path	Direct and indirect	payer, patient	payer	patient	Charges/Reimbursement-based patient OoO	N/A	cost to patient, reimbursement	no
Ryan, S. P. Plate, J. F. Black, C. S. Howell, C. B. Jiranek, W. A. Bolognesi, M. P. Plate, J. F. Ryan, S. P. Black, C. S. Howell, C. B. Jiranek, W. A. Bolognesi, M. P. Scotti, D. J. Abbott, M. M. Meara, J. G.	Value-Based Care Has Not Resulted in Biased Patient Selection: Analysis of a Single Center's Experience in the Care for Joint Replacement Bundle	2019	US	US; North Carolina	1248 total knee arthroplasty patients,	orthopedics, joint replacement, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	full care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	implemented		no
Ryan, S. P. Plate, J. F. Black, C. S. Howell, C. B. Jiranek, W. A. Bolognesi, M. P. Scotti, D. J. Abbott, M. M. Meara, J. G.	No Changes in Patient Selection and Value-Based Metrics for Total Hip Arthroplasty After Comprehensive Care for Joint Replacement Bundle Implementation at a Single Center	2019	US	US; North Carolina	751 total hip arthroplasty patients,	orthopedics, joint replacement, total hip arthroplasty	Surgical	Orthopedic, arthroplasty	full care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	implemented		no
Ryan, S. P. Plate, J. F. Black, C. S. Howell, C. B. Jiranek, W. A. Bolognesi, M. P. Scotti, D. J. Abbott, M. M. Meara, J. G.	A microcosting approach for isolated, unilateral cleft lip care in the first year of life	2011	US	US; Massachusetts	single center, retrospective	12 children, cleft lip repair	Pediatrics, cleft palate, plastic surgery	Pediatrics	Pediatric Plastic surgery	partial care path (full surgical episode)	Direct and indirect	provider	provider	Microcosting	Absorption costing - ABC	Paper only	yes see second sheet
Regan, D. K. Manoli, A. Hutzler, L. Konda, S. R. Egol, K. A.	Impact of Diabetes Mellitus on Surgical Quality Measures After Ankle Fracture Surgery: Implications for "Value-Based" Compensation and "Pay for Performance"	2015	US	US; New York	58,748 patients, 7501 with Diabetes Mellitus	Diabetes	Internal Medicine		unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursement-based	N/A	mean total hospital charges	no
Yu, Y. R. Abbas, P. I. Smith, C. M. Carberry, K. E. Ren, H. Patel, B. Steinbock, J. G. Rice-Townsend, S. Barnes, J. N. Hall, M. Baxter, J. L. Rangel, S. J.	Time-driven activity-based costing: A dynamic value assessment model in pediatric appendicitis	2017	US	US; Texas	single center, retrospective, direct observation, process mapping	207 patients total, 6 simple appendicitis	Pediatrics, appendicitis	Pediatrics	Pediatric appendicitis	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet
Ahluwalia, R. Cook, J. Raheman, F. Karupppiah, K. Colegate-Stone, T. Tavakolizadeh, A. Kasambasa, M. Basto, J. Chahal, R. Riedel, B.	Variation in practice and resource utilization associated with the diagnosis and management of appendicitis at freestanding children's hospitals: Implications for value-based comparative analysis	2014	US	US; Massachusetts	13,328 patients, 34 children's hospitals, 25 states in US, acute appendicitis, age 3-18	Pediatrics, appendicitis	Pediatrics	Pediatric appendicitis	unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursement-based	N/A	charges transformed with cost-to-charge ratio	no
Ahluwalia, R. Cook, J. Raheman, F. Karupppiah, K. Colegate-Stone, T. Tavakolizadeh, A. Kasambasa, M. Basto, J. Chahal, R. Riedel, B.	Improving the efficiency of ankle fracture care through home care and day-surgery units: Delivering safe surgery on a value-based healthcare model	2020	UK	UK; London	single center, prospective, process mapping	53 trauma patients	trauma, orthopedics, surgical, ankle fracture	Surgical	Orthopedic fracture	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet
Ahluwalia, R. Cook, J. Raheman, F. Karupppiah, K. Colegate-Stone, T. Tavakolizadeh, A. Kasambasa, M. Basto, J. Chahal, R. Riedel, B.	Time-driven activity-based costing to model the utility of parallel induction redesign in high-turnover operating lists	2019	Australia	Australia	single center, prospective, process mapping	19 all-day surgery lists, patients unspecified	melanoma, oncology	Oncology	partial care path (partial surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	

1	Kadakia, R. J., Ahearn, B.M., Tenenbaum, S., Bariteau, J.T.	Costs Associated With Geriatric Ankle Fractures, Operative Versus Nonoperative Management	2017	US	US, Georgia	19648 ankle fracture patients	trauma, orthopedics, geriatrics, ankle fracture	Surgical	Orthopedic fracture	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	medicare reimbursements	no		
2	Barkley, R. S., Sosabauer, M. J., Wang, J., Blau, S., Page, R. D.	Reducing Cancer Costs Through Symptom Management and Triage Pathways	2019	US	US, Florida	10417 ER Events, 1879 unique patients	Emergency care, Acute care, Oncology	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	medicare claims	no		
3	McLaughlin, N., Martin, N. A., Upadhyaya, P., Bari, A. A., Buxey, F., Wang, M. B., Hersh, E. H., Yeager, K. A., Neifert, S. N., Kim, J., Dangayach, N. S., Weiss, N.	Assessing the cost of contemporary pituitary care	2014	US	US, California	single center, retrospective	27 neurosurgical patients	Neurosurgical, pituitary adenoma	Surgical	Neurosurgery	partial care path (full surgical episode)	Direct and indirect	provider	provider	ABC	Absorption costing - ABC	implemented	yes see second sheet		
4	Meara, J. G., Hughes, C. D., Sanchez, K., Catalozzo, L., Clark, R., Kummer, A. W.	Optimal Outcomes Reporting (OOR): A New Value-Based Metric for Outcome Reporting Following Cleft Palate Repair	2020	US	US, Massachusetts	Retrospective, single-center cohort analysis	94 patients were identified who underwent primary cleft palate repair by the same surgeon	Cleft palate, Palatoplasty, plastic surgery	Surgical	Plastic surgery	full care path	Direct and indirect	provider	provider	Relative Value Units	Absorption costing - unspecified/generic	Paper only	no		
5	Jakovljevic, M., Zagic, A., Rankovic, A., Dugovic, A.	Radiation therapy remains the key cost driver of oncology inpatient treatment	2015	Serbia	Serbia	2544 complex oncology patients		Oncology	Oncology	partial care path	Direct	provider	provider	Microcosting direct costs only	Direct costing	unspecified	no			
6	Sudan, R. S., He, W., Sun, C. C., Zhao, H., Rauh-Haim, J. A., Fleming, N. D., Lenzini, L., Sawczyn, G., Kim, S., Aminsharif, A., Kaouk, J.	Total and out-of-pocket costs of different primary management strategies in ovarian cancer	2019	US	US, Texas	12761 patients	Gynecology, oncology, ovarian cancer	gynecology & obstetrics		unspecified	Direct and indirect	Payer, patient	payer	patient	none, reimbursements	Charges/Reimbursements-based	Charges/Reimbursement-based patient OoO	N/A	charges	no
7	Hemmila, M. R., Cain-Nielsen, A. H., Wahl, W. L., Vander Kolk, W. E., Jakubus, J. L., Mikhail, J. N., AlAbdur, A., Goktepe, M. E., Kilic, G. S., Borahay, M. A.	Regional collaborative quality improvement for trauma reduces complications and costs	2014	US	US, Texas	72084 episodes of acute trauma care	Acute care	emergency care & acute care		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	price-standardized payments, claims, DRG prices	no		
8	Naghavi, A. O., Gonzalez, R. J., Scott, J. G., Kim, Y., Aboodeh, Y. A., Strom, T. J., Puvanesarajah, V., Kirby, D. J., Jain, A., Werner, B. C., Hassanzadeh, H.	Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma	2017	US	US, Florida	22 soft-tissue sarcoma patients	Oncology, soft-tissue sarcoma	Oncology		full care path	unspecified	payer	payer	none, charges	Charges/Reimbursements-based	N/A	charges	no		
9	Siu, A., Patel, J., Prentice, H. A., Cappuzzo, J. M., Hashemi, H., Mukherjee, D.	Cost Variation of Anterior Cervical Fusions in Elderly Medicare Beneficiaries	2017	US	US, unspecified	21,853 patients	orthopedics, geriatrics, elective anterior cervical fusions	Surgical	Orthopedic fracture	unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no		
10	Kirsch, D. B., Yang, H., Maslow, A. L., Stolzenbach, M., McCall, A.	Association of Positive Airway Pressure Use With Acute Care Utilization and Costs	2019	US	US, North Carolina	1098 patients	Sleep medicine, sleep apnea, Obstructive Sleep Apnea	Internal Medicine		partial care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented	no			

1	Passias, P. G. Poorman, G. W. Bortz, C. A. Qureshi, R. Diebs, B. G. Paul, J. C. Lyon, S. D.	2018	US	US, New York	2408 patients	orthopedic, surgical	Surgical	Spine	partial care path	unspecified	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no
2	Monroe, G. R. Frederix, G. W. Savelberg, S. M. C. De Vries, T. I. Duran, K. J. Van Der Smagt, J. J. Lambert, B.	2016	The Netherlands	The Netherlands	17 patients	Genetics, Pediatrics, Intellectual disability	Pediatrics	Pediatric other	full care path	Direct	provider	provider	bottom-up clinical costing approach	Direct costing	implemented		no
3	Manriquez, E. Mandelbaum, A. Aguayo, E. Zakbour, M. Karlan, B. Benharash, P. Coban, T. G.	2020	US	US, Virginia	21853 patients	Geriatrics, oncology, ovarian cancer, anterior cervical discectomy and fusion, anterior cervical fusion, cervical spine, cervical spondylosis	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursement	no
4	Wise, K. Blaschke, B. L. Parikh, H. R. Gorman, T. Casnovsky, I. McMillan, L. J. Einhorn, L.	2020	US	US, Minnesota	single center, retrospective 287 patients	orthopedics, geriatrics, hip fracture, surgical	Surgical	Orthopedic fracture	partial care path (full surgical episode)	Direct and indirect	provider	provider	ABC	Absorption costing - ABC	implemented		yes see second sheet
5	Rocque, G. B. Williams, C. P. Jackson, B. E. Ingram, S. A. Halliava, K. I. Pisu, M. Kawachi, K. M.	2018	US	US, Alabama	988 patients	Geriatrics, oncology, De Novo Metastatic Breast Cancer	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursement	no
6	Schwartz, D. A. Shah, A. A. Zogg, C. K. Nicholas, L. H. Velopoulos, C. G. Efron, D. T. Schubert, E. D.	2015	US	US, Massachusetts	191032 patient records	Surgical, acute care, acute cholecystitis, laparoscopic cholecystectomy	Surgical	Gallbladder	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
7	Brixner, D. Rubin, D. T. Mease, P. Mittal, M. Liu, H. Davis, M. Cassiani, A.	2019	US	US, various states	1134 patients	Multiple	multiple		unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
8	Aguayo, E. Sanaiba, Y. Seo, Y. J. Mardock, A. Bailey, K. Dobaria, V. Kishore, S. Cronin, K. J.	2018	US	US, California	13943 patients	Cardiology, surgical, thrombocytopenia, Heparin-induced thrombocytopenia	Surgical	Cardiac/Thoracic	unspecified	Direct and indirect	payer	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
9	Mair, S. D. Hawk, G. S. Thompson, K. L. Hettrich, C. M. Jacobs, C. A.	2020	US	US, Kentucky	170329 patients	orthopedic, surgical, depression, Rotator Cuff Repair	Surgical	Orthopedic rotator cuff repair	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
10	Alli, V. V. Zhang, J. Telem, D. A.	2018	US	US, Texas	14290 patients	Surgical, hernia, Incisional hernia	Surgical	Abdominal	full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
11	Robles, A. J. Komblioth, L. Z. Hendrickson, C. M. Howard, B. M. Conroy, A. S. Moazed, F. Lafont, C. E.	2018	US	US, California	1552 patients	Acute care, trauma care	emergency care & acute care		unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
12	van Dijk, J. T. J. M. van Essen, T. A. Dijkman, M. D. Mostert, C. Q. B. Polinder, S. Peul, W. C. de Raaij-Maclean, C. W.	2019	The Netherlands	The Netherlands	108 patients	Acute care, brain injury, acute subdural hematoma, trauma care	emergency care & acute care		partial care path	Direct and indirect	provider	provider	Absorption costing - reference pricing	unspecified/generic	Paper only		no
13	Thakore, R. V. Greenberg, S. E. Shi, H. Fox, A. M. Francois, E. L. Prabek, M. A. Kosman, K. Smith, B. D.	2015	US	US, Tennessee	78 patients	orthopedic, surgical	Surgical	Orthopedic	unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
14	Jiang, J. Shih, Y. C. Giordano, S. H. Huo, J. Jaggi, R. Monosh, A. G.	2017	US	US, Texas	105 211 female patients	Oncology, breast cancer	Oncology		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no

1	Lentz, T. A. Rhon, D. I. George, S. Z.	Predicting Opioid Use, Increased Health Care Utilization and High Costs for Musculoskeletal Pain: What Factors Mediate Pain Intensity and Disability?	2020	US	US, Washington	283 patients	Pain, Musculoskeletal Pain	Pain medicine	partial care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	unspecified	no	
2	Kaul, S. Korgenski, E. K. Ying, J. Ng, C. F. Smits-Scoemann, R. R. Nelson, R. E. Arias-Solis, S. Silva-Velazco, J.	A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia	2016	US	US, Utah	single center, retrospective 505 patients	Oncology, leukemia, acute lymphoblastic leukemia	Pediatrics	Pediatric Oncology	partial care path	Direct and indirect	provider	provider	ABC	Absorption costing - ABC	implemented	no
3	Dietz, D. W. Stocchi, L. Costello, M. Gorgan, E. Kalady, M. F. Kessler, J. Cunizares, M. F. Feldman, L. Miller, P. E. Waters, P. M. Bae, D. S.	Considering Value in Rectal Cancer Surgery: An Analysis of Costs and Outcomes Based on the Open, Laparoscopic, and Robotic Approach for Proctectomy	2017	US	US, Ohio	488 patients	Oncology, rectal cancer	Oncology	partial care path (surgical episode)	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	unspecified	no	
4	Vuong, B. Dehal, A. Uppal, A. Stern, S. L. Mejia, J. Weerasinghe, R. Sanaia, Y. Mantha, A. Zaician, B. Juo, Y. Y. Shemin, R. J. Benharash, P.	Complications and Cost of Syndactyly Reconstruction in the United States: Analysis of the Pediatric Health Information System	2017	US	US, Massachusetts	38 hospitals, 2047 procedures	Pediatrics, orthopedic, surgical, Syndactyly Reconstruction	Pediatrics	Pediatric surgical	partial care path	Direct and indirect	provider (proxy)	payer	none, charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio no
5	Chatfield, S. C. Volpicelli, F. M. Adler, N. M. Kim, K. L. Jones, S. A. Francois, F. Chawla, S. S. Whitson, A. J. Schiffman, C. J. Matsen, F. A. Hsu, J. E.	What Are the Most Significant Cost and Value Drivers for Pancreatic Resection in an Integrated Healthcare System?	2018	US	US, California	796 patients	Surgical, Pancreas, Pancreatic Resection	Surgical	Endocrine	partial care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	unspecified	no
6	Charfield, S. C. Volpicelli, F. M. Adler, N. M. Kim, K. L. Jones, S. A. Francois, F. Chawla, S. S. Whitson, A. J. Schiffman, C. J. Matsen, F. A. Hsu, J. E.	Trends in Readmission and Costs After Transcatheter Implantation Versus Surgical Aortic Valve Replacement in Patients With Renal Dysfunction	2020	US	US, LA	350,609 isolated aortic valve replacements	Cardiology, Renal, Aortic Repair, Thoracic Endovascular Aortic Repair	Surgical	Cardiac/Thoracic	partial care path	Direct and indirect	provider (proxy)	payer	none, charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio no
7	Chatfield, S. C. Volpicelli, F. M. Adler, N. M. Kim, K. L. Jones, S. A. Francois, F. Chawla, S. S. Whitson, A. J. Schiffman, C. J. Matsen, F. A. Hsu, J. E.	Bending the cost curve: time series analysis of a value transformation programme at an academic medical centre	2019	US	US, New York	single center, retrospective 74 projects, 160434 patients	Multiple	multiple	partial care path	Direct	provider	provider	ABC	Direct costing	implemented	yes see second sheet	
8	Klink, A. J. Chmielowski, B. Feinberg, B. Ahsan, S. Nero, D. Liu, F. X.	Drivers of lower inpatient hospital costs and greater improvements in health-related quality of life for patients undergoing total shoulder and ream-and-run arthroplasty	2020	US	US, Washington	433 patients	orthopedics, athroplasty, total shoulder and ream-and-run arthroplasty	Surgical	Orthopedic, arthroplasty	unspecified	Direct and indirect	provider	provider	unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	no
9	Klink, A. J. Chmielowski, B. Feinberg, B. Ahsan, S. Nero, D. Liu, F. X.	Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States	2019	US	US, various states	1599 patients	Oncology, melanoma	Oncology	unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	claims no	
10	Chotali, S. Sivaganesan, A. Parker, S. L. Sielatycki, J. A. McGirt, M. J. Devlin, C. J.	Drivers of Variability in 90-Day Cost for Elective Anterior Cervical Discectomy and Fusion for Cervical Degenerative Disease	2018	US	US, Tennessee	445 patients	Spine, cervical degenerative disease	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements no
11	Sanaia, Y. Kaviampour, B. Downey, P. Morchi, R. Shemin, R. J. Benharash, P.	National Study of Index and Readmission Mortality and Costs for Thoracic Endovascular Aortic Repair in Patients With Renal Disease	2020	US	US, California	121046 patients	Cardiology, Surgical, Aortic repair, Renal Disease	Surgical	Cardiac/Thoracic	unspecified	Direct and indirect	provider (proxy)	payer	none, charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio no
12	Jain, N. Brock, J. L. Phillips, F. M. Weaver, T. Khan, S. N.	Chronic preoperative opioid use is a risk factor for increased complications, resource use, and costs after cervical fusion	2018	US	US, various states	29101 patients	Spine, cervical degenerative disease	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges no
13	Featherall, J. Brigati, D. P. Atney, A. N. Faour, M. Bokar, D. V. Murray, T. G. Mullins, R. M. Ackerman, R. S. Hirschi, M. Alford, B. Evans, T. Kiluk, J. V. Patel, S. Y.	Effects of a Total Knee Arthroplasty Care Pathway on Cost, Quality, and Patient Experience: Toward Measuring the Triple Aim	2019	US	US, Ohio	6760 surgeries	orthopedics, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	full care path (surgical episode)	Direct	provider	provider	Relative Value Unit costing	Direct costing	implemented	yes see second sheet
14	Featherall, J. Brigati, D. P. Atney, A. N. Faour, M. Bokar, D. V. Murray, T. G. Mullins, R. M. Ackerman, R. S. Hirschi, M. Alford, B. Evans, T. Kiluk, J. V. Patel, S. Y.	Enhanced REVENUE After Surgery? A Cost-Standardized Enhanced Recovery Pathway for Mastectomy Decreases Length of Stay	2019	US	US, unspecified	103 patients	Oncology, mastectomy	Oncology	unspecified	Direct and indirect	payer	payer	none, charges	Charges/Reimbursements-based	N/A	charges no	

Williams, S. B. Shan, Y. Jazzar, U. Mehra, H. B. Baillargeon, J. G. Huo, J. Somasundara, A. J. Schilling, P. L. He, J. Chen, S. Placzek, H. Bini, S. A.	2018	US	US; various states	3200 patients	Oncology, urology, surgical, bladder cancer	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges	no	
Lott, A. Haglin, J. Saleh, H. Hall, J. Egol, K. A. Konda, S. R.	2018	US	US; various states	366380 patients	Surgical	Surgical	Orthopedic, arthroplasty	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges	no	
Ackerman, S. J. Knight, T. Wahl, P. M. Cartwright, C. P.	2019	US	US; various states	1486 patients	Acute care, geriatrics, Emergency care	emergency care & acute care		partial care path	Direct	provider	provider	unspecified; Hospital accounting data not otherwise specified	Direct costing	implemented		no	
Peard, L. Goodwin, J. Hensley, P. Dugan, A. Bylund, J. Harris, A. M.	2019	US	US; Kentucky	275 patients	Surgical, robot, Robot-Assisted Laparoscopic Radical Prostatectomy	Surgical	Prostatectomy	partial care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified generic	implemented		no	
Patel, M. I. Ramirez, D. Agajanian, R. Agajanian, H. Bhattacharya, J. Bundorf, K. M.	2020	US	US; California	425 enrollees	Oncology	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges	no	
Harris, A. M. Hensley, P. Goodwin, J. Dugan, A. Peard, L. Bell, J. R. Stearns, L. J. Narang, S. Albright, R. E. Hammond, K. Xia, Y. Richter, H. B. McCreary, D. L.	2019	US	US; Kentucky	215 patients	Urology, surgical, Nephrectomy	Surgical	kidney	partial care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified generic	implemented		no	
Dugarte, A. J. Vang, S. Pflowman, B. Williams, B. R. Parikh, H. R.	2019	US	US; Minnesota	67 patients	orthopedics	Surgical	Orthopedic fracture	partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet	
Yamasaki, A. Callans, K. M. Shah, M. Kaplan, R. S. Hartnick, C.	2020	US	US; Massachusetts	10 patients	Neonatal, pediatrics, tracheostomy, surgical	Pediatrics	Pediatric Neonatal	partial care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet	
Navarro, S. M. Wang, E. Y. Haeblerle, H. S. Mont, M. A. Krebs, V. E. Patterson, B. M. Skell, N. J.	2018	US	US; New York	141446 patients	orthopedics, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path (surgical episode)	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
Butler, J. O'Brien, D. C. Kays, J. K. Kubal, C. Liangpunskul, S.	2019	US	US; Indiana	44 patients	Oncology, renal	Oncology		partial care path	Direct and indirect	provider (proxy)	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
Robinson, Jamie R. Avritscher, Elenir B. C. Gay, James C. Willis, Zachary I. Putnam, Luke R. Anglemeyer, Andrew Bodrogi, Elizabeth Lubowitz, J. M. Kominski, G. F.	2017	US	US; Tennessee	313 patients	Appendicitis, Pediatrics	Pediatrics	Pediatric appendicitis	partial care path (surgical episode)	Direct and indirect	provider, payer	provider, payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	Absorption costing - unspecified generic	N/A	charges	no
	2016	US	US; California	unspecified	Diabetes	Internal Medicine		unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	

1	Johnson, J. T. Scholtens, D. M. Kuang, A. Feng, X. Y. Elaysh, O. M. Post, L. A. Marano, D. S. Karnata, J. M. Navarro, S. M. Haeblerle, H. S. Helm, J. M. Kamath, A. F. Schaffler, J. L. Krauss, M. T. Saifi, C. Cazzulino, A. Park, C. Laratta, J. Louie, P. K. Shillingford, J. N. Lehman, R. Ning, M. S. Palmer, M. B. Shah, A. K. Chambers, L. C. Garlock, L. B. Melson, B. B. Lewicki, E. Mukdad, L. Mantha, A. Aguayo, E. Sanaitha, Y. Jao, Y. Y. Ziaecian, B. Shannon, M. J. Frankel, W. C. Navarro, S. M. Haeblerle, H. S. Ramanathan, D. Ranikumar, P. N.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Does value vary by center surgical volume for neonates with truncus arteriosus? A multicenter study	US	US; various states	1024 neonates	Neonatal, pediatrics, surgical, cardiology, thoracic surgery	Pediatrics	Pediatric Neonatal	full care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
19	Boucek, D. M. Lal, A. K. Eckhauser, A. W. Wong, H. Y. C. Sheng, X. Wilkes, J. F. Keller, D. S. Zhang, J. Chand, M.	20 21 22 23	Resource Utilization for Initial Hospitalization in Pediatric Heart Transplantation in the United States	US	US; Pennsylvania	1629 patients	Pediatrics, cardiology	Pediatrics	Pediatric surgical	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
24	Reilly, R. F.	24	Creating a Value Dashboard for orthopedic Surgical Procedures	Lebanon	Lebanon	6 surgeons' data	Orthopedics, total knee arthroplasty, total hip arthroplasty	Surgical	Orthopedic, arthroplasty	unspecified	Direct	provider	provider	unspecified; Hospital accounting data not otherwise specified	Direct costing	implemented		no
25	Miller, P. E. Guba, A. Khera, R. Chouairi, F. Ahmad, T. Nasir, K. Addison, D.	25 26 27 28 29	National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions	US	US; various states	1788982 hospitalizations	Cardiology, cardiovascular	Cardiology		unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
30	Konda, Sanjit R. Lott, Ariana Egol, Kenneth A.	30 31	The coming hip and femur fracture bundle: A new inpatient risk stratification tool for care providers	US	US; New York	173 patients	Orthopedics, Geriatrics, total hip arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path	Direct	provider	provider	unspecified; Hospital accounting data not otherwise specified	Direct costing	implemented		no
32	Winegar, A. L. Jackson, L. W. Sambare, T. D. Liu, T. C. Banks, S. R. Erlinger, T. P. Cochran, W. R. Rocque, G. B. Williams, C. P. Kenzi, K. M. Jackson, B. E. Halilova, K. I. Sullivan, M. M. Laratta, J. L. Reddy, H. Lombardi, J. M. Shillingford, J. N. Saifi, C. Fischer, C. R. Lehman, R. A. Karnata, J. M. Golubovsky, J. L. Haeblerle, H. S. Rajan, P. V. Navarro, S. M. Kamath, A. F. Schaffler, J. L.	32 33 34 35 36 37 38 39 40 41 42	A Surgeon Scorecard Is Associated with Improved Value in Elective Primary Hip and Knee Arthroplasty	US	US; Texas	470 patients	Surgical, total hip arthroplasty, knee arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented		no
43	Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?	43		US	US; Alabama	3427 patients from 12 cancer centers	Oncology	Oncology		partial care path	Direct and indirect	payer	payer	none; reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no
44	Utilization of Interspinous Devices Throughout the United States Over a Recent Decade: An Analysis of the Nationwide Inpatient Sample	44		US	US; various states	14225 patients	Surgical, spine	Surgical	Spine	partial care path (surgical episode)	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
45	Can a machine learning model accurately predict patient resource utilization following lumbar spinal fusion?	45		US	US; various states	38070 patients	Spine, lumbar spinal fusion	Surgical	Spine	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no

1	Karmuta, J. M. Navarro, S. M. Haberle, H. S. Billow, D. G. Krebs, V. E. Ranikumar, P. N.	2019	US	US; New York	9856 patients	orthopedics, hip fracture, trauma	Surgical	Orthopedic fracture	partial care path	Direct and indirect	provider (proxy)	payer	none; estimation, cost-to-charge ratio, SPARCS data	Charges/Reimburse ment t-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
2	Cicchini, M. Vollstsky, S. McCann, G. Mancini, M. Sanzari, L. Yannopoulos, A.	2020	US	US; Connecticut	433 patients	surgical, elective laminectomy	Surgical	Spine	partial care path	Direct	provider	provider	direct costs	Direct costing	unspecified		no
3	Navarro, S. M. Ranikumar, P. N. Egger, A. C. Goodwin, R. C.	2018	US	US; New York	3224 patients	Orthopedic, Pediatrics, Adolescent Idiopathic Scoliosis	Pediatrics	Pediatric other	partial care path	Direct and indirect	provider (proxy)	payer	none; estimation, cost-to-charge ratio, SPARCS data	Charges/Reimburse ment t-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
4	Batenti, S. B. Gingrich, A. A. Hoch, J. S. Canter, R. J. Bold, R. J.	2019	US	US; California	2786 patients, 157 hospitals	Oncology, pancreatic cancer	Oncology		unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimburse ment t-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
5	Xiao, R. Miller, J. A. Zafra, W. J. Goretski, E. Z. Young, J. B.	2018	US	US; unspecified	6363 patients	Multiple	multiple		partial care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimburse ment t-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
6	Ramshaw, B. Forman, B. R. Moore, K. Heidel, E. Fabian, M. Mancini, G.	2017	US	US; Texas	102 patients	Surgical, complex abdominal wall reconstruction	Surgical	Abdominal	full care path (surgical episode)	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented		no
7	Heinzelman, M. Schumann, S. O. Riley, J. Zhang, J. Marsden, J. E. Mauldin, P. D.	2016	US	US; unspecified	7571 patients	Internal medicine	Internal Medicine		unspecified	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented		no
8	Sheetz, K. H. Kenney, B. Dupree, J. M. Campbell, D. A. Englesbe, M. J.	2019	US	US; Michigan	1923 patients	Surgical, Laparoscopic Cholecystectomy	Surgical	Gallbladder	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimburse ment t-based	N/A	reimbursements	no
9	Zolin, S. J. Tastaldi, L. Alkhatib, H. Lampert, E. J. Brown, K. Fafaj, A.	2020	US	US; various states	All medicare shoulder surgeries 2002-2018	orthopedics, Surgical, Shoulder surgery	Surgical	Abdominal	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimburse ment t-based	N/A	reimbursements	no
10	Ahluwalia, R. Vainieri, E. Tam, J. Sait, S. Sinha, A. Mani, C. A.	2019	UK	UK; London	single center, retrospective, direct observation, pre and post comparison 53 patients	Surgical, diabetic foot infection, diabetes	Surgical	Diabetes	partial care path (full surgical episode)	Direct and indirect	payer	payer	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet
11	Ramly, E. P. Laurentzakis, A. Bolnen, J. D. Mavros, M. Chang, Y. Lee, J. Sarkar, D. P.	2015	US	US; Massachusetts	9111 patients	surgical, abdominal surgery	Surgical	Abdominal	unspecified	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented		no
12	Orbanu, V. Urits, I. Olusunmade, M. Owais, K. Jones, M. Galasso, A.	2018	US	US; unspecified	115976 patients	Surgical, depression, psychiatry	Pain medicine		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimburse ment t-based	N/A		no
13	Hollenbeck, B. Hoffman, M. A. Trommhauser, S. G.	2020	US	US; various states	1651354 total hip or total knee arthroplasties	orthopedics, surgical, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	unspecified	Direct and indirect	provider (proxy)	payer	none; charges	Charges/Reimburse ment t-based	N/A	charges per quartile, discuss how it should be costs in discussion	no
14	Loftus, T. J. Rosenthal, M. D. Croft, C. A. Stephen Smith, R. Efron, P. A. Moore, F. A. Lobo, A. M.	2018	US	US; Florida	800 patients	Acute care, appendicitis, surgical laparotomy for intra-abdominal sepsis with temporary abdominal closure	Surgical	Appendicitis	full care path (surgical episode)	unspecified	payer	payer	none, reimbursements	Charges/Reimburse ment t-based	N/A	charges, discuss shortcoming in discussion	no

1	Buell, J. F. Sigmon, D. Dacon, C. Shapiro, M. Teja, N. Wynter, E. Jain, N. Phillips, F. M. Shimer, A. L. Khan, S. N.	2017	US	US, Louisiana	73 patients	Surgical, complex abdominal wall reconstruction	Surgical	Abdominal	full care path (surgical episode)	unspecified	payer	payer	none, charges	Charges/Reimbursements-based	N/A	no
2																
3																
4																
5																
6																
7																
8	Stull, J. D. Bhat, S. B. Kane, J. M. Raikan, S. M.	2017	US	US, unspecified	76 cases/patients, and 48044 retrospective patient files	orthopedics, Surgical, ankle fractures	Surgical	Orthopedic fracture	unspecified	unspecified	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursement no
9																
10																
11																
12																
13																
14																
15																
16																
17																
18																
19																
20																
21																
22																
23																
24																
25																
26																
27																
28																
29																
30																
31																
32																
33																
34																
35																
36																
37																
38																
39																
40																
41																
42																
43																
44																
45																
46																

1	Kaplan, A. L., Agarwal, N., Setlur, N. P., Tian, H. J., Niedzwiecki, D., McLaughlin, N., Pong, J., Crawford, K., Faraji, R., Ramsay, C., Kemp, A., Califano, J. A.	2015	US	US, California	Measuring the cost of care in benign prostatic hyperplasia using time driven activity-based costing (TDABC)	single center, retrospective, direct observation	one care pathway, 5 surgical options	Urology, benign prostatic hyperplasia	Urology	partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified	yes see second sheet		
2	Lobatto, D. J., van den Hout, W. B., de Vries, F. F., Schutte, P. J., Patel, M. I., Ramirez, D., Agajanian, R., Agajanian, H., Coker, T.	2020	US	US; various states	An Analysis of 1-Year Charges for Head and Neck Cancer: Targets for Value-Based Interventions	196 consecutive patients	Oncology, head and neck cancer	Oncology	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement-based	N/A	charges	no		
3	Lobatto, D. J., van den Hout, W. B., de Vries, F. F., Schutte, P. J., Patel, M. I., Ramirez, D., Agajanian, R., Agajanian, H., Coker, T.	2020	The Netherlands	The Netherlands	Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery	prospective, observational study, process mapping	155 patients	Endocrinology, surgical, pituitary	endocrinology	partial care path (full surgical episode)	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	Paper only	no		
4	Jalilian, H., Doshmangir, L., Ajami, S., Mir, H., Siraneh, Y., Hasanpoor, E.	2019	Iran	Iran	Economic burden of gastric cancer in the first six months after diagnosis	118 patients	Oncology, bowel, gastric cancer	Oncology	unspecified	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	Paper only	no			
5	Lobatto, D. J., van den Hout, W. B., Najafabadi, A. H. Z., Steffens, A. N. V., Andela, C. D., Pereira, A. M., Gray, C. F., Prieto, H. A., Deen, J. T., Parvataneni, H. K.	2019	The Netherlands	The Netherlands	Healthcare utilization and costs among patients with non-functioning pituitary adenomas	167 patients	Endocrinology, Pituitary adenoma	endocrinology	partial care path	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	N/A	no			
6	Kurt, P., Saban, M., Cankaya, F., Annac, M. C.	2019	US	US, Florida	Bundled Payment "Creep": Institutional Redesign for Primary Arthroplasty Positively Affects Revision Arthroplasty	168 patients	orthopedics, total joint arthroplasty	Surgical	Orthopedic, arthroplasty	full care path (surgical episode)	Direct and indirect	payer, provider	payer	provider	none; charges	Charges/Reimbursement-based	Direct costing	N/A	no
7	Thaci, B., McGirt, M. J., Ammerman, J. M., Thome, C., Kim, K. D., Ament, J. D.	2019	Turkey	Turkey	Time-Driven Activity-Based Costing in the Ophthalmology Department of State Hospital: A Case Study	single center, retrospective, case study	case study; 5 surgical procedures in one department	Ophthalmology	ophthalmology	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet		
8	Karns, M. R., Jones, D. L., Todd, D. C., Maak, T. G., Aoki, S. K., Barks, R. T., Robinson, J. R., Carter, N. H., Gibson, C., Brinkman, A. S., Van Arendonk, K., Speck, K. E., Gupta, P., Rettiganti, M.	2018	US	US, California	Reduction of direct costs in high-risk lumbar discectomy patients during the 90-day post-operative period through amular closure	randomized controlled trial	272 patients	Surgical, high-risk lumbar discectomy	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement-based	N/A	no	
9	Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mahajan, A.	2018	US	US, Tennessee	Patient- and Procedure-Specific Variables Driving Total Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction	Retrospective cohort, single center, economic and decision analysis	434 patients	orthopedic, surgical, Anterior Cruciate Ligament Reconstruction, sports medicine	Surgical	Orthopedic	partial care path (full surgical episode)	Direct	provider	provider	VDO tool, total direct costs	Direct costing	implemented	yes see second sheet	
10	Robinson, J. R., Carter, N. H., Gibson, C., Brinkman, A. S., Van Arendonk, K., Speck, K. E., Gupta, P., Rettiganti, M.	2018	US	US, Tennessee	Improving the value of care for appendectomy through an individual surgeon-specific approach	prospective observational study	216 patients	Appendicitis, surgical	Surgical	Appendicitis	partial care path (full surgical episode)	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	N/A	yes see second sheet	
11	Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mahajan, A.	2017	US	US; various states	Relationship of Hospital Costs With Mortality in Pediatric Critical Care: A Multi-Institutional Analysis	single center, pre and post intervention (dashboard)	917,663 patients, 47 hospitals	Acute care, pediatrics	pediatrics	Pediatric acute care	partial care path	unspecified	payer	payer	unspecified	Charges/Reimbursement-based	N/A	charges	no
12	Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mahajan, A.	2016	US	US, California	Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer	single center, retrospective, process mapping, direct observation	2 treatment options	Oncology, prostate cancer, brachytherapy	Oncology	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet		
13	Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mahajan, A.	2014	US	US, California	Time-driven activity-based costing: a driver for provider engagement in costing activities and redesign initiatives	single center, process mapping	2 pilots	Urology, neurosurgery	Surgical	Neurosurgery	partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	implemented	no	

1	Keating, C. L., Dixon, J. B., Moodie, M. L., Pieters, A., Playfair, J., O'Brien, P. E.	2009	Australia	Australia	randomized controlled trial	40 patients, 23 surgical, 7 medical	Surgical, Diabetes	Internal Medicine	unspecified	Direct	provider	provider	direct costs	Direct costing	Paper only	no		
2	Nelson, A. A., Pearce, D. J., Fleischer, A. B., Balkrishnan, R., Feldman, S. R.	2005	US	US; Ohio	208 inpatient admissions		Psoriasis, Dermatology	Dermatology	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements t-based	N/A	charges	no	
3	Yanik, John M., Bedard, Nicholas A., Hanley, Jessica M., Otero, Jesse E., Callaghan, John J., Marsh, John L.	2018	US	US; Iowa	78 patients		orthopedics, total hip arthroplasty, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	unspecified	no	
4	Zhang, Steven, Vora, Molly, Harris, Alex H. S., Baker, Laurence, Curtin, Catherine, Kamal, Robin N.	2016	US	US; California	16 million patient records		Carpal Tunnel Release	Surgical	Carpal Tunnel Release	full care path (surgical episode)	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements t-based	N/A	reimbursements	no
5	A. Adenkinju, R. Ranson, S. A. Rettig, K. A. Egol and S. R. Konda	2021	US	US; New York			Orthopedic, Geriatric, Operative Distal Radius Fractures	Surgical	Orthopedic fracture	unspecified	Direct and indirect	payer	payer	unspecified; Hospital accounting data not otherwise specified	Charges/Reimbursements t-based	N/A	index admission cost, per category	no
6	A. Albrahim, Y. Abdulsalam, S. Al Mutawa, H. Behbehani, D. Alhuwaii and S. Al Jenai	2021	Kuwait	Kuwait	single center, observation, interviews	one pharmacy	Diabetes, pharmacy	Internal Medicine	partial care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		yes see second sheet	
7	D. J. Baughman, A. Waheed, M. N. Khan and J. M. Nicholson	2021	US	US; Pennsylvania			Emergency care	emergency care & acute care	unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements t-based	N/A	average charges	no	
8	J. A. Berinstein, S. A. Cohen-Mekelburg, G. M. Greenberg, D. Wray, S. K. Berry, S. D. Saini, A. M. Fendrick, M. A. Adams, A. K. Wajjee and D. D. Hwang	2021	US	US; Michigan			IBS/IBD inflammatory bowel disease	Internal Medicine	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements t-based	N/A	charges	no	
9	A. Beschloss, C. Dicindio, J. Lombardi, A. Varthi, A. Ozurk, R. Lehman, L. Lenke and C. Saifi	2021	US	US; various states			Orthopedic, Spinal Deformity Surgery	Surgical	Spine	full care path	Direct and indirect	provider	provider	none; charges	Charges/Reimbursements t-based	N/A	unspecified	no
10	H. Baeno, J. L. Bernal, V. Jimenez-Jimenez, F. J. Martin-Sanchez, X. Rosello, G. Moreno, C. Goni, V. Gil, P. Llorens, N. Naranjo, J. Lopez, D. Hernandez, R. A. Burnett Iii, J. Yang, P. M. Courtney, E. B. Terhune, C. P. Hamon and C. J. Della Valle	2021	Spain	Spain	Retrospective, multi-center	30 day period of heart failure patients	heart failure, cardiovascular	Cardiology	partial care path	Direct and indirect	provider	provider	DRG costs	Absorption costing - unspecified/generic	implemented		yes see second sheet	
11	M. Casey, D. Perera, J. Enticott, H. Vo, S. Cubra, A. Gravell, M. Waerea and G. Habib	2021	US	US; various states			Total knee arthroplasty, orthopedic	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	provider	provider	none; reimbursements	Charges/Reimbursements t-based	N/A	reimbursement	no
12	K. A. Chovancec, C. Arsene, A. Beck and B. Liddel	2022	Australia	Australia			Emergency care	emergency care & acute care	partial care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	N/A		yes see second sheet	
13	R. V. Cohen, A. M. Nishikawa, R. A. Ribeiro, F. M. Oliveira, P. C. Andrade, S. M. Junqueira and B. Toldo	2021	Brazil	Brazil			Obesity, surgical, bariatric surgery	Surgical	Bariatric	full care path	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	N/A		yes see second sheet

1	A. P. B. da Silva Etges, L. N. Cruz, R. Schlatter, J. Neyeloff, R. B. Cardoso, L. Koppik, A. A. Nunes, J. A. Neto, J. L. Nogueira, R. M. de Aguiar, J. S. D. Tobias, M. Dziemianowicz, J. Burneister and M. Dominello	2022	Brazil	Brazil	multi center, retrospective, process mapping, 5 hospitals, 90 patients	5	Interventional Coronary Procedures	Cardiology	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified	yes see second sheet	
2																	
3																	
4																	
5																	
6																	
7																	
8	C. Fang, A. Hagar, M. Gordon, C. T. Talamo, D. A. Mattingly and E. L. Smith	2021	US	US; Michigan	single center, retrospective, patient comparison	889	Geriatrics, Orthopedic, Primary Total Joint Arthroplasty	Surgical	Orthopedic fracture	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet
9																	
10																	
11																	
12																	
13																	
14																	
15																	
16																	
17																	
18																	
19																	
20																	
21																	
22																	
23																	
24																	
25																	
26																	
27																	
28																	
29																	
30																	
31																	
32																	
33																	
34																	
35																	
36																	
37																	
38																	
39																	
40																	
41																	
42																	
43																	
44																	
45																	
46																	

H. Ko, D. S. Brodtk, M. E. Vanneman, A. J. Schoenfeld and B. I. Martin	Is Discretionary Care Associated with Safety Among Medicare Beneficiaries Undergoing Spine Surgery?	2021	US	US; various		spine surgery, surgical	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none; reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no	
S. R. Konda, J. R. Johnson, N. Dethia, E. A. Kelly and K. A. Egol	Can We Stratify Quality and Cost for Older Patients With Proximal and Midshaft Humerus Fractures?	2021	US	US; various		Humerus Fractures, geriatrics, orthopedic	Surgical	Orthopedic fracture	unspecified	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	N/A		no	
A. T. Malik, S. N. Khan, R. T. Voskuil, J. H. Alexander, J. P. Drain and T. J. Scharschmidt	What Is the Value of Undergoing Surgery for Spinal Metastases at Dedicated Cancer Centers?	2021	US	US; various		Orthopedic, spine surgery	Oncology		partial care path	Direct and indirect	payer	payer	none; reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no	
T. R. McClintock, D. F. Friedlander, A. Y. Feng, M. A. Shah, D. J. Pallin, S. L. Chang, A. M. Bader, T. W. Feeley, R. S. Kaplan and G. E. Lathrop	Determining Variable Costs in the Acute Urolithiasis Cycle of Care Through Time-Driven Activity-Based Costing	2021	US	US; Boston	multi center, retrospective, process mapping, unspecified number of patients, acute stone episodes	Acute Urolithiasis	emergency care & acute care		full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		yes see second sheet	
R. Negrini, R. D. da Silva Ferreira and D. Z. Guimaraes	Value-based care in obstetrics: comparison between vaginal birth and caesarean section	2021	Brazil	Brazil	single center, retrospective, process mapping	9345 deliveries	Obstetrics, birth, vaginal birth, caesarean birth	gynecology & obstetrics	full care path	Direct and indirect	provider	provider	direct and indirect costs	Absorption costing - unspecified/generic	Paper only		yes see second sheet	
T. V. Newman, K. D. Munshi, L. M. Neilson, C. B. Good, E. C. S. Swart, Y. Huang, R. Henderson and N. Parekh	Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2: an observational cohort study	2021	US	US; various		Diabetes	Internal Medicine		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
N. Panda, L. Shagabayeva, C. E. Comrie, N. Phan, P. Moonssamy, C. F. Jeffrey Yang, F. G. Fernandez and C. R. Moore	Drivers of Cost Associated With Minimally Invasive Esophagectomy	2022	US	US; Boston		esophagectomy, surgical, thoracic surgery	Surgical	Cardiac/Thoracic	full care path	Direct	provider	provider	direct costs	Direct costing	N/A		no	
S. K. Pasquall, D. Thibault, M. Hall, K. Chiswell, J. C. Romano, J. W. Gaynor, D. M. Shahian, M. L. Jacobs, M. G. Gales, S. M. Glickson, R. K. Sethi, R. P. Pumpian, C. E. Drolet and P. K. Louie	Evolving Cost-Quality Relationship in Pediatric Heart Surgery	2021	US	US; Boston	Retrospective, multi-center	45315 patients, 32 hospitals	pediatrics, surgical, pediatric heart surgery	Pediatrics	Pediatric surgical	full care path	direct and indirect	provider	provider	CHD-method standardized costs	Absorption costing - unspecified/generic	Paper only		no
N. G. Thaker, D. Boyce-Fappiano, M. S. Ning, D. Pasalic, A. Guzman, G. Smith, E. B. Holliday, J. Incalcaterra, A. S. Gaudan, S. P. S. Tomicki, G. Dieguez, H. Latimer, P. Cockrum and G. Kim	Utilizing Lean Methodology and Time-Driven Activity-Based Costing Together: An Observational Pilot Study of Hip Replacement Surgery Utilizing a New Method to Study Value-Based Health Care	2021	US	US; Washington	single center, retrospective, surgeon comparison	346 patients	surgical, orthopedic, hip replacement surgery, anterior hip arthroplasty	Surgical	Orthopedic, arthroplasty	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet
W. Wang, E. Li, K. Campbell, A. McBride and S. D'Amato	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer	2021	US	US; Texas	single center, process mapping, matched sample	50 patients (matched pairs)	oncology, radiation oncology	Oncology		partial care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	implemented		yes see second sheet
K. L. Wise, H. R. Parikh, B. Okelana, A. J. Only, M. Reams, A. Harrison, J. Braman, E. Craig and B. P. Cunningham	Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies	2021	US	US; various		oncology, metastatic pancreatic cancer	Oncology		full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
W. Wang, E. Li, K. Campbell, A. McBride and S. D'Amato	Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework	2021	US	US; New Jersey		oncology, Nonmyeloid Cancer	Oncology		partial care path	Direct	provider	provider	direct costs	Direct costing	N/A		no	
K. L. Wise, H. R. Parikh, B. Okelana, A. J. Only, M. Reams, A. Harrison, J. Braman, E. Craig and B. P. Cunningham	Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care	2022	US	US; Minnesota	single center, retrospective, process mapping	396 patients	orthopedic, surgical, rotator cuff repair	Surgical	Orthopedic rotator cuff repair	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		yes see second sheet
C. Iloabachi, N. Dwibedi, T. LeMasters, C. Shen, A. Ladani and U. Sambamoorthi	Low-value care and excess out-of-pocket expenditure among older adults with incident cancer – A machine learning approach	2021	US	US; various		oncology, incident cancer	Oncology		full care path	Direct	patient	patient	total out of pocket expenditures (SEER data)	Charges/Reimbursements-based patient OoO	N/A		no	

N. Seyidova, A. D. Chen, D. del Valle, D. Chi, R. P. Casley, B. T. Lee and S. J. Lin	Nationwide cost variation for lower extremity flap reconstruction	2021	US	US; various		lower extremity flap reconstruction, surgical, plastic surgery	Surgical	Plastic surgery	full care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursement t-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
A. Jacir, D. Mendoza, E. Dean and H. Gritlow	The cost of care during times of COVID: Case study of TDABC and minimum utilization cost analysis in a medicare advantage population	2021	US	US; Florida	single center, process mapping, case study	case study, telehealth visits	Covid	Infectious disease	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		no	
D. Fürstenau, H. Hanke, C. Spies, T. Walz, K. Schewina, M. Hüft, R. Müggeli and F. Balzer	Tackling the frailty burden with an integrative value-based approach: results from a mixed-methods study	2021	Germany	Germany			surgical, perioperative process	Surgical	other	partial care path	unspecified	provider	provider	bottom-up clinical costing approach	Unspecified	N/A	no	
J. F. Buehl, A. N. Flaris, S. Raju, A. Haach, M. Darden and G. G. Parker	Long-Term Outcomes in Complex Abdominal Wall Reconstruction Repaired with Absorbable Biologic Polymer Scaffold (Poly-4-Hydroxybutyrate)	2021	US	US; North Carolina			Surgical, abdominal wall reconstruction, reherniation, complex abdominal wall hernia	Surgical	Abdominal	partial care path	Direct	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	no	
V. J. Siu, T. Varkey, U. N. Khan, J. B. Ding and S. Gandhi	Lend Me a Hand: A Value-Based Care Case Study on Pan Plexopathy of Unknown Origin	2021	US	US; Texas			pan plexopathy, neurology, brachial plexus injury	Neurology		unspecified	Direct	patient	patient	out of pocket costs to patient	Charges/Reimbursement t-based patient O&O	N/A	no	
J. B. Kulejca, M. A. Seif, M. W. Mery, J. R. Incalcaterra, A. M. Kamat, C. P. Dinney, J. B. Shah, T. W. Feeley and N. Navai	Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers	2021	US	US; Texas	single center, retrospective, process mapping	100 patients	open radical cystectomy, urology, oncology, bladder cancer	Oncology		full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	
King, B. C. Richardson, T. Patel, R. M. Lee, H. C. Bamat, N. A. Hall, M. Schabas, L. L. L. Fernando-Campan, A. Gust, A. Hsueh, A. Tran-Duy, M. Kirk, P. Brooks and J. Knight	Prioritization framework for improving the value of care for very low birth weight and very preterm infants	2021	US	US; Texas	Retrospective cohort, multi center	26098 preterm or low birth weight infants	Preterm infants, neonatal, perinatology, pediatrics	Pediatrics	Pediatric Neonatal	partial care path	Direct and indirect	payer	payer	charges standardized across hospitals	Charges/Reimbursement t-based	N/A	charges	no
H. Skibicki, M. Yayac, C. A. Krueger and P. M. Courtney	Target Price Adjustment for Hip Fractures Is Not Sufficient in the Bundled Payments for Care Improvement Initiative	2021	Australia	Australia	single center, retrospective, mixed methods observational study	93 056 cases	emergency care, hospital acquired complications	emergency care & acute care		partial care path	Direct and indirect	provider	provider	bottom-up clinical costing approach	Absorption costing - unspecified/generic	unspecified		yes see second sheet
D. Clewley, V. Iftikhar, M. E. Horn and D. I. Rhon	Do the Number of Visits and the Cost of Musculoskeletal Care Improve Outcomes? More May Not Be Better	2020	US	US; Pennsylvania			arthroplasty, hip fractures, orthopedics	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	charges (EOC costs)	no
B. Walker, L. Wilfong, J. Frytak and N. Robert	Practice patterns among oncologists participating in the oncology care model after three years	2021	US	US; Louisiana	Retrospective, clinical trial	98 patients	Subacromial pain syndrome	Pain medicine		partial care path	Direct and indirect	payer	payer	none; reimbursements	Charges/Reimbursement t-based	N/A	reimbursements	no
C. A. Krueger, M. Yayac, C. Vannello, J. Wilsman, M. S. Austin and P. M. Courtney	Are We at the Bottom? BPCI Programs Now Disincentivize Providers Who Maintain Quality Despite Caring for Increasingly Complex Patients	2021	US	US; Pennsylvania			oncology, cancer	Oncology		full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	charges	no
B. S. Horton, J. D. Marland, H. S. West and J. D. Wylie	Transition to Telehealth Physical Therapy After Hip Arthroscopy for Femoroacetabular Impingement: A Pilot Study With Retrospective Matched-Cohort Analysis	2021	US	US; Utah	Pilot		orthopedic, total hip arthroplasty, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path	Direct and indirect	payer	payer	none; reimbursement	Charges/Reimbursement t-based	N/A	reimbursement	no
N. H. Nguyen, J. Luo, L. Ohno-Machado, W. J. Sandborn and S. Singh	Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort	2021	US	US; California			orthopedics, hip arthroscopy, physical therapy	Orthopedic		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	charges	no
							Gastroenterology, Inflammatory Bowel Diseases	Internal Medicine		full care path	Direct and indirect	provider (proxy)	payer	none; charges HCUP data	Charges/Reimbursement t-based	N/A	charges	no

1	Y. Sanaia, P. Downey, R. Lyons, A. Nsaif, R. J. Shemin and P. Benharash	Trends in utilization, mortality, and resource use after implantation of left ventricular assist devices in the United States	2021	US	US; various		cardiovascular, left ventricular assist devices	Surgical	Cardiac/Thoracic	full care path	Direct and indirect	provider (proxy)	payer	none; reimbursements, cost-charge-ratio, NIS data	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio	no
2	Khanjow, A. N. Wood, L. N. Xie, R. Theiss, L. M. Hollis, R. H. Hardiman, K. M. Gonzalez, D. J.	The impact of an enhanced recovery program (ERP) on the costs of colorectal surgery	2021	US	US; Alabama	single center, retrospective	616 surgical cases	surgical, colorectal surgery	Surgical	Colon/Rectal	partial care path (full surgical episode)	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	Paper only	yes see second sheet
3	Jacobs, K. Dewilde, T. Vandoren, C. Cardoen, B. Vansteenkiste, N. Scheys, L. Roelofs, F. Matar, D.	Variability in Hospital Costs of Adult Spinal Deformity Care	2020	The Netherlands	The Netherlands	single center, retrospective	139 patients	Surgical, spine, Adult Spinal Deformity	Surgical	Spine	full care path	Direct	provider	provider	ABC (excluding overheads)	Absorption costing - ABC	Paper only	yes see second sheet
4	Di Filippo, A. Invento, A. Radice, D. Bucuta, M. Bignardi, V. Mazzanti, E. Weir, T. B.	Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology	2021	Italy	Italy	single center, retrospective, clinical trial, compare pre and post	3912 patients	oncology, breast cancer, cancer, sentinel lymph node biopsy	Oncology		partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	implemented	yes see second sheet
5	Usmani, M. F. Camacho, J. Sokolow, M. Bruckner, J. Jazini, E. Lorenzini, L. T.	Effect of Surgical Setting on Cost and Hospital Reported Outcomes for Single-Level Anterior Cervical Discectomy and Fusion	2021	US	US; Maryland	multi center, retrospective	301 patients	Spine, surgical, Anterior Cervical Discectomy and Fusion	Surgical	Spine	full care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	Paper only	no

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

SUPPLEMENT DIGITAL CONTENT

1 Search strategy

2003-1/1/2022

embase.com

(((value-based OR valuebased) NOT ((value-based OR valuebased) NEXT/2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR vbhc OR vb-hc):ab,ti) AND ('cost'/de OR 'health care cost'/de OR 'time driven activity based costing'/de OR 'activity based costing'/de OR (cost OR costs OR costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource NEAR/3 assignment*) OR (direct* NEAR/3 estimat*)):ab,ti) NOT (cost NEXT/1 (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)):ti NOT [conference abstract]/lim AND ([dutch]/lim OR [English]/lim)

Medline Ovid

(((value-based OR valuebased) NOT ((value-based OR valuebased) ADJ2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR vbhc OR vb-hc).ab,ti.) AND ("Costs and Cost Analysis"/ OR Health Care Costs/ OR (cost OR costs OR costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource ADJ3 assignment*) OR (direct* ADJ3 estimat*)):ab,ti.) NOT (cost ADJ (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)):ti. AND (dutch.la. OR english.la.)

CINAHL EBSCOhost

(((TI(value-based OR valuebased) OR AB (value-based OR valuebased)) NOT (TI((value-based OR valuebased) N2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR AB((value-based OR valuebased) N2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*))) OR TI(vbhc OR vb-hc) OR AB(vbhc OR vb-hc))) AND ((MH "Costs and Cost Analysis" OR MH Health Care Costs OR MH Value-Based Health Care OR AB(costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource N2 assignment*) OR (direct* N2 estimat*))) OR (TI(cost OR costs) NOT TI(cost N1 (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)))) AND LA(dutch OR english)

Web of science

TS=(((value-based OR valuebased) NOT ((value-based OR valuebased) NEAR/2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR vbhc OR vb-hc)) AND ((cost OR costs OR costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource NEAR/2 assignment*) OR (direct* NEAR/2 estimat*))) AND (care OR health* OR medicine OR clinical OR hospital* OR surger* OR therap* OR patient* OR oncolog* OR drugs OR medication* OR cancer* OR pharmac*) NOT TI=(cost NEAR/1 (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)) AND DT=(article) AND LA=(dutch OR english)

SUPPLEMENT DIGITAL CONTENT

2 Inclusion/exclusion criteria, data extracted

Eligibility criteria

Language	English or Dutch
Publication date	Between 2003 and 1.1.2022
Research type	Original, peer-reviewed, empirical research
Terms	Any variation of the terms “cost” and “value-based” in title or abstract
Full text content	Costs of an intervention, treatment, care path, or other healthcare activity must have been measured or estimated.

Variables collected

Descriptive	Name, year published, authors, medical specialty, location
Costs included	Based on author reporting we classify studies into one of two categories: <ul style="list-style-type: none"> • Direct costs only • Direct and indirect costs
Cost perspective	We inductively classify studies into one or more categories: <ul style="list-style-type: none"> • Provider costs (e.g. hospital) • Payer costs (reimbursements, charges, payments) • Patient costs (out-of-pocket costs to patient)
Care path length	We inductively classify studies into one of the following categories: <ul style="list-style-type: none"> • Full care path • Full care path, full surgical episode (FSE) • Partial care path, full surgical episode (PSE) • Partial care path
Costing method label	Costing method used, as labelled by the authors. These include traditional cost accounting, ABC, or ABC excluding overheads, TDABC, or TDABC with some cost categories omitted, microcosting, bottom-up clinical costing, reference pricing, relative value units or DRG costs, direct variable costs, or direct costs as an estimate of total cost, reimbursements, charges, claims, payments, and cost-to-charge ratio.
Costing method applied	Costing method applied, based on method described by authors. We classified studies using management accounting literature (e.g., Zimmerman, 2015). We found the following categories represented in the literature. <ul style="list-style-type: none"> • Direct costing • Absorption costing, which includes: <ul style="list-style-type: none"> ○ ABC ○ TDABC. ○ Other <p>Cases using reimbursements or charges to estimate costs were coded as ‘reimbursements’ or ‘cost-to-charge ratio’.</p>
Facilitating factors	If the study discussed the consequences of the costing information generated, we collected the consequences. After we collected all consequences, we categorized these inductively.

Note: ABC: Activity-based costing; TDABC: Time-driven activity-based costing

Supplement digital content table 1. Eligibility criteria and data collected.

SUPPLEMENT DIGITAL CONTENT

3 All studies included in RQ1

Perspective	Method	n	studies
<i>Provider</i>	Direct costs only		
	Direct costing	23	[1–23]
	Absorption costing		
	ABC	7	[24–30]
	TDABC	31	[31–61]
	Other	47	[62–108]
	Not specified	3	[109–111]
<i>Insurer</i>	Charges & reimbursements		
	Charges, reimbursements, claims	81	[23,39,112–190]
	Charges adjusted with cost-to charge ratio	25	[108,191–214]
<i>Patient</i>	Out-of-pocket costs to patient	5	[106,126,130,215,216]

Note: Total number of studies here is 222; seven studies measure two cost types[23,38,39,106,108,126,130]. Studies are classified based on actual costs included and methods described, not necessarily the labels used by authors.

Supplement digital content table 2. Overview of cost measurement methods used in value-based healthcare with references

References of all studies included in research question 1

Reference numbers start at 1, these differ from the manuscript.

- 1 Chatfield SC, Volpicelli FM, Adler NM, *et al.* Bending the cost curve: Time series analysis of a value transformation programme at an academic medical centre. *BMJ Qual Saf* 2019;**28**:449–58.
- 2 Featherall J, Brigati DP, Arney AN, *et al.* Effects of a Total Knee Arthroplasty Care Pathway on Cost, Quality, and Patient Experience: Toward Measuring the Triple Aim. *J Arthroplasty* 2019;**34**:2561–8.
- 3 Karns MR, Jones DL, Todd DC, *et al.* Patient- and Procedure-Specific Variables Driving Total Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction. *Orthop J Sports Med* 2018;**6**:2325967118788543.
- 4 Tan RYC, Met-Domestici M, Zhou K, *et al.* Using quality improvement methods and time-driven activity-based costing to improve value-based cancer care delivery at a Cancer Genetics clinic. *J Oncol Pract* 2016;**12**:e320–31.
- 5 Ravikumar TS, Sharma C, Marini C, *et al.* A validated value-based model to improve hospital-wide perioperative outcomes: Adaptability to combined medical/surgical inpatient cohorts. *Ann Surg* 2010;**252**:486–96.

- 6 Fortmann AL, Walker C, Barger K, *et al.* Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care. *Popul Health Manag* 2020;**23**:467–75.
- 7 Ryan SP, Plate JF, Black CS, *et al.* Value-Based Care Has Not Resulted in Biased Patient Selection: Analysis of a Single Center’s Experience in the Care for Joint Replacement Bundle. *J Arthroplasty* 2019;**34**:1872–5.
- 8 Plate JF, Ryan SP, Black CS, *et al.* No Changes in Patient Selection and Value-Based Metrics for Total Hip Arthroplasty After Comprehensive Care for Joint Replacement Bundle Implementation at a Single Center. *J Arthroplasty* 2019;**34**:1581–4.
- 9 Jakovljevic M, Zugic A, Rankovic A, *et al.* Radiation therapy remains the key cost driver of oncology inpatient treatment. *J Med Econ* 2015;**18**:29–36.
- 10 Siu A, Patel J, Prentice HA, *et al.* A Cost Analysis of Regional Versus General Anesthesia for Carotid Endarterectomy. *Ann Vasc Surg* 2017;**39**:189–94.
- 11 Monroe GR, Frederix GW, Savelberg SMC, *et al.* Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. *Genet Med* 2016;**18**:949–56.
- 12 Lott A, Haglin J, Saleh H, *et al.* Using a Validated Middle-Age and Geriatric Risk Tool to Identify Early (<48 Hours) Hospital Mortality and Associated Cost of Care. *J Orthop Trauma* 2018;**32**:349–53.
- 13 Reilly CA, Doughty HP, Werth PM, *et al.* Creating a Value Dashboard for Orthopaedic Surgical Procedures. *J Bone Joint Surg Am* 2020;**102**:1849–56.
- 14 Konda SR, Lott A, Egol KA. The Coming Hip and Femur Fracture Bundle: A New Inpatient Risk Stratification Tool for Care Providers. *Geriatr Orthop Surg Rehabil* 2018;**9**:215145931879531.
- 15 Cremins M, Vellanky S, McCann G, *et al.* Considering healthcare value and associated risk factors with postoperative urinary retention after elective laminectomy. *Spine J* 2020;**20**:701–7.
- 16 Edholm K, Lappé K, Kukhareva P, *et al.* Reducing Diabetic Ketoacidosis Intensive Care Unit Admissions Through an Electronic Health Record-Driven, Standardized Care Pathway. *J Healthc Qual* 2020;**42**:e66–74.
- 17 Keating CL, Dixon JB, Moodie ML, *et al.* Cost-Efficacy of Surgically Induced Weight Loss for the Management of Type 2 Diabetes A randomized controlled trial. *Diabetes Care* 2009;**32**:580–4.
- 18 Feizpour CA, Patel, Syed MA, *et al.* Enhanced recovery in liver transplantation: A value-based approach to complex surgical care. *Surgery* 2021;**170**:1830–7.

- 19 Gillis HC, Dolan K, Sargel CL, *et al.* A quality improvement approach to influence value-based mucolytic use in the PICU. *Pediatr Qual Saf* 2021;**6**:e438.
- 20 Konda SR, Johnson JR, Dedhia N, *et al.* Can We Stratify Quality and Cost for Older Patients With Proximal and Midshaft Humerus Fractures? *Geriatr Orthop Surg Rehabil* 2021;**12**:2151459321992742.
- 21 Panda N, Shagabayeva L, Comrie CE, *et al.* Drivers of Cost Associated With Minimally Invasive Esophagectomy. *Ann Thorac Surg* 2022;**113**:264–70.
- 22 Wang W, Li E, Campbell K, *et al.* Economic analysis on adoption of biosimilar granulocyte colony-stimulating factors in patients with nonmyeloid cancer at risk of febrile neutropenia within the Oncology Care Model framework. *JCO Oncol Pract* 2021;**17**:e1139–49.
- 23 Gray CF, Prieto HA, Deen JT, *et al.* Bundled Payment Creep: Institutional Redesign for Primary Arthroplasty Positively Affects Revision Arthroplasty. *J Arthroplasty* 2019;**34**:206–10.
- 24 Wise, Blaschke BL, Parikh HR, *et al.* Variation of the Inpatient Cost of Care in the Treatment of Isolated Geriatric Intertrochanteric Hip Fractures. *Geriatr Orthop Surg Rehabil* 2020;**11**. doi:10.1177/2151459320976533
- 25 McLaughlin N, Upadhyaya P, Buxey F, *et al.* Value-based neurosurgery: measuring and reducing the cost of microvascular decompression surgery. *J Neurosurg* 2014;**121**:700–8.
- 26 Abbott MM, Meara JG. A microcosting approach for isolated, unilateral cleft lip care in the first year of life. *Plast Reconstr Surg* 2011;**127**:333–9.
- 27 McLaughlin N, Martin NA, Upadhyaya P, *et al.* Assessing the cost of contemporary pituitary care. *Neurosurg Focus* 2014;**37**:E7.
- 28 Vanni F, Foglia E, Pennestrì F, *et al.* Introducing enhanced recovery after surgery in a high-volume orthopaedic hospital: a health technology assessment. *BMC Health Serv Res* 2020;**20**:773.
- 29 Jacobs K, Dewilde T, Vandoren C, *et al.* Variability in hospital costs of Adult Spinal Deformity care. *Spine* 2020;**45**:1221–8.
- 30 Kaul S, Korgenski EK, Ying J, *et al.* A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. *Cancer Med* 2016;**5**:221–9.
- 31 Etges, Cruz LN, Schlatter R, *et al.* Time-driven activity-based costing as a strategy to increase efficiency: An analyses of interventional coronary procedures. *Int J Health Plann Manage* Published Online First: 9 September 2021. doi:10.1002/hpm.3320
- 32 Martin JA, Mayhew CR, Morris AJ, *et al.* Using Time-Driven Activity-Based Costing as a Key Component of the Value Platform: A Pilot Analysis of Colonoscopy, Aortic Valve Replacement and Carpal Tunnel Release Procedures. *J Clin Med Res* 2018;**10**:314–20.

- 1
2
3 33 Bodar YJL, Srinivasan AK, Shah AS, *et al.* Time-Driven activity-based costing identifies opportunities for process efficiency and cost optimization for robot-assisted laparoscopic pyeloplasty. *J Pediatr Urol* 2020;**16**:460.e1-460.e10.
- 4
5
6
7
8 34 French KE, Guzman AB, Rubio AC, *et al.* Value based care and bundled payments: Anesthesia care costs for outpatient oncology surgery using time-driven activity-based costing. *Healthc (Amst)* 2016;**4**:173–80.
- 9
10
11
12 35 Isaacson D, Ahmad T, Metzler I, *et al.* Defining the Costs of Reusable Flexible Ureteroscope Reprocessing Using Time-Driven Activity-Based Costing. *J Endourol* 2017;**31**:1026–31.
- 13
14
15
16 36 Ilg AM, Laviana AA, Kamrava M, *et al.* Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer. *Brachytherapy* 2016;**15**:760–7.
- 17
18
19
20 37 Dziemianowicz M, Burmeister J, Dominello M. Examining the Financial Impact of Altered Fractionation in Breast Cancer: An Analysis Using Time-Driven Activity-Based Costing. *Pract Radiat Oncol* 2021;**11**:245–51.
- 21
22
23
24 38 Fang, Shaker J, Drew JM, *et al.* The Cost of Hip and Knee Revision Arthroplasty by Diagnosis-Related Groups: Comparing Time-Driven Activity-Based Costing and Traditional Accounting. *J Arthroplasty* 2021;**36**:2674-2679.e2673.
- 25
26
27
28 39 Fang, Shaker J, Hart P-A, *et al.* Variation in the profit margin for different types of total joint arthroplasty. *J Bone Joint Surg Am* 2021;**Publish Ahead of Print**. doi:10.2106/JBJS.21.00223
- 29
30
31
32 40 Ahluwalia R, Cook J, Raheman F, *et al.* Improving the efficiency of ankle fracture care through home care and day-surgery units: Delivering safe surgery on a value-based healthcare model. *Surgeon* Published Online First: November 2020. doi:10.1016/j.surge.2020.08.004
- 33
34
35
36 41 Wise KL, Parikh HR, Okelana B, *et al.* Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care. *J Shoulder Elbow Surg* 2022;**31**:72–80.
- 37
38
39
40 42 Hernandez A, Kaplan RS, Witkowski ML, *et al.* Navy Medicine Introduces Value-Based Health Care. *Health Aff* 2019;**38**:1393–400.
- 41
42
43
44 43 Ning MS, Venkatesan AM, Stafford RJ, *et al.* Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. *Brachytherapy* 2020;**19**:427–37.
- 45
46
47
48 44 Yu YR, Abbas PI, Smith CM, *et al.* Time-driven activity-based costing: A dynamic value assessment model in pediatric appendicitis. *J Pediatr Surg* 2017;**52**:1045–9.
- 49
50
51
52 45 Basto J, Chahal R, Riedel B. Time-driven activity-based costing to model the utility of parallel induction redesign in high-turnover operating lists. *Healthc Pap* 2019;**7**. doi:10.1016/j.hjdsi.2019.01.003
- 53
54
55
56
57
58
59
60

- 1
2
3 46 McCreary DL, Dugarte AJ, Vang S, *et al.* Patient-Level Value Analysis: An Innovative
4 Approach to Optimize Care Delivery. *J Orthop Trauma* 2019;**33**:S49–52.
5
6
7 47 Caloway C, Yamasaki A, Callans KM, *et al.* Quantifying the benefits from a care
8 coordination program for tracheostomy placement in neonates. *Int J Pediatr*
9 *Otorhinolaryngol* 2020;**134**. doi:10.1016/j.ijporl.2020.110025
10
11 48 Ahluwalia R, Vainieri E, Tam J, *et al.* Surgical Diabetic Foot Debridement: Improving
12 Training and Practice Utilizing the Traffic Light Principle. *Int J Low Extrem Wounds*
13 2019;**18**:279–86.
14
15 49 Kaplan AL, Agarwal N, Setlur NP, *et al.* Measuring the cost of care in benign prostatic
16 hyperplasia using time-driven activity-based costing (TDABC). *Healthcare*. 2015;**3**:43–8.
17 doi:10.1016/j.hjdsi.2014.09.007
18
19 50 Kurt P, Saban M, Cankaya F, *et al.* Time-Driven Activity-Based Costing in the
20 Ophthalmology Department of State Hospital: a Case Study. *Fresenius Environ Bull*
21 2019;**28**:2754–70.
22
23 51 Alibrahim A, Abdulsalam Y, Al Mutawa S, *et al.* Towards value-based healthcare:
24 Establishing baseline pharmacy care costs for diabetes management. *Int J Health Plann*
25 *Manage* 2022;**37**:790–803.
26
27 52 Fang C, Hagar A, Gordon M, *et al.* Differences in Hospital Costs among Octogenarians and
28 Nonagenarians Following Primary Total Joint Arthroplasty. *Geriatrics* 2021;**6**:26.
29
30 53 Fang C, Pagani N, Gordon M, *et al.* Episode-of-Care Costs for Revision Total Joint
31 Arthroplasties by Decadal Age Groups. *Geriatrics* 2021;**6**:49.
32
33 54 Ganske IM, Sanchez K, Le E, *et al.* Time-Driven, Activity-Based Costing of Presurgical
34 Infant Orthopedics: A Critical Component of Establishing Value of Latham Appliance and
35 Nasoalveolar Molding. *Plastic & Reconstructive Surgery* 2021;**147**:444–54.
36
37 55 McClintock TR, Friedlander DF, Feng AY, *et al.* Determining Variable Costs in the Acute
38 Urolithiasis Cycle of Care Through Time-Driven Activity-Based Costing. *Urology*
39 2021;**157**:107–13.
40
41 56 Sethi RK, Pumpian RP, Drolet CE, *et al.* Utilizing Lean Methodology and Time-Driven
42 Activity-Based Costing Together: An Observational Pilot Study of Hip Replacement
43 Surgery Utilizing a New Method to Study Value-Based Health Care. *J Bone Joint Surg Am*
44 Published Online First: 14 October 2021. doi:10.2106/JBJS.21.00129
45
46 57 Thaker NG, Boyce-Fappiano D, Ning, *et al.* Activity-Based Costing of Intensity-Modulated
47 Proton versus Photon Therapy for Oropharyngeal Cancer. *International Journal of Particle*
48 *Therapy* 2021;**8**:374–82.
49
50 58 Kukreja JB, Seif MA, Mery MW, *et al.* Utilizing time-driven activity-based costing to
51 determine open radical cystectomy and ileal conduit surgical episode cost drivers. *Urologic*
52 *Oncology: Seminars and Original Investigations* 2021;**39**:237.e1-237.e5.
53
54
55
56
57
58
59
60

- 1
2
3 59 Mattar D, Di Filippo A, Invento A, *et al.* Economic implications of ACOSOG Z0011 trial
4 application into clinical practice at the European Institute of Oncology. *Eur J Surg Oncol*
5 2021;**47**:2499–505.
6
7 60 McLaughlin N, Burke MA, Setlur NP, *et al.* Time-driven activity-based costing: a driver for
8 provider engagement in costing activities and redesign initiatives. *Neurosurg Focus*
9 2014;**37**:E3.
10
11 61 Jacir A, Mendoza D, Dean E. The cost of care during times of COVID: Case study of
12 TDABC and minimum utilization cost analysis in a medicare advantage population. *Journal*
13 *of Health Care*
14 2021;**48**.<http://www.healthfinancejournal.com/index.php/johcf/article/view/264>
15
16 62 Danilyants N, MacKoul P, van der Does L, *et al.* A value-based evaluation of minimally
17 invasive hysterectomy approaches. *Gynecol Surg* 2019;**16**:5.
18
19 63 Parra E, Arenas MD, Alonso M, *et al.* Assessing value-based health care delivery for
20 haemodialysis. *J Eval Clin Pract* 2017;**23**:477–85.
21
22 64 Danilyants N, MacKoul P, Baxi R, *et al.* Value-based assessment of hysterectomy
23 approaches. *J Obstet Gynaecol Res* 2019;**45**:389–98.
24
25 65 Lenfant L, Sawczyn G, Kim S, *et al.* Single-institution Cost Comparison: Single-port Versus
26 Multiport Robotic Prostatectomy. *European Urology Focus* Published Online First: 2020.
27 doi:10.1016/j.euf.2020.06.010
28
29 66 Robinson JR, Carter NH, Gibson C, *et al.* Improving the value of care for appendectomy
30 through an individual surgeon-specific approach. *J Pediatr Surg* 2018;**53**:1181–6.
31
32 67 Bueno H, Bernal JL, Jimenez-Jimenez V, *et al.* The Clinical outcomes, healthcare resource
33 utilization, and related costs (COHERENT) model. Application in heart failure patients. *Rev*
34 *Esp Cardiol* Published Online First: 20 October 2021. doi:10.1016/j.rec.2021.08.009
35
36 68 Casey M, Perera D, Enticott J, *et al.* High utilisers of emergency departments: the profile
37 and journey of patients with mental health issues. *Int J Psychiatry Clin Pract* 2021;**25**:316–
38 24.
39
40 69 Cohen RV, Nishikawa AM, Ribeiro RA, *et al.* Surgical Management of Obesity in Brazil:
41 Proposal for a Value-Based Healthcare Model and Preliminary Results. *Value in Health*
42 *Regional Issues* 2021;**26**:10–4.
43
44 70 Hennink SD, Hofland N, Gopie JP, *et al.* Value-based healthcare in Lynch syndrome. *Fam*
45 *Cancer* 2013;**12**:347–54.
46
47 71 Medbery RL, Chadid TS, Sweeney JF, *et al.* Laparoscopic vs open right hepatectomy: A
48 value-based analysis. *J Am Coll Surg* 2014;**218**:929–39.
49
50 72 Gabriel L, Casey J, Gee M, *et al.* Value-based healthcare analysis of joint replacement
51 surgery for patients with primary hip osteoarthritis. *BMJ Open Quality* 2019;**8**:e000549.
52
53
54
55
56
57
58
59
60

- 1
2
3 73 Ionov MV, Zhukova OV, Yudina YS, *et al.* Value-based approach to blood pressure
4 telemonitoring and remote counseling in hypertensive patients. *Blood Press* 2021;**30**:20–30.
5
6
7 74 Goretti G, Marinari GM, Vanni E, *et al.* Value-Based Healthcare and Enhanced Recovery
8 After Surgery Implementation in a High-Volume Bariatric Center in Italy. *Obes Surg*
9 2020;**30**:2519–27.
10
11 75 Konda SR, Lott A, Egol KA. Development of a Value-based Algorithm for Inpatient Triage
12 of Elderly Hip Fracture Patients. *J Am Acad Orthop Surg* 2020;**28**:e566–72.
13
14 76 Verberne WR, Dijkers J, Kelder JC, *et al.* Value-based evaluation of dialysis versus
15 conservative care in older patients with advanced chronic kidney disease: A cohort study.
16 *BMC Nephrol* 2018;**19**. doi:10.1186/s12882-018-1004-4
17
18 77 Hersh EH, Yaeger KA, Neifert SN, *et al.* Patterns of health care costs due to external
19 ventricular drain infections. *World Neurosurg* 2019;**128**:e31–7.
20
21 78 Meara JG, Hughes CD, Sanchez K, *et al.* Optimal Outcomes Reporting (OOR): A New
22 Value-Based Metric for Outcome Reporting Following Cleft Palate Repair. *Cleft Palate*
23 *Craniofac J* 2021;**58**:19–24.
24
25 79 Kirsch DB, Yang H, Maslow AL, *et al.* Association of Positive Airway Pressure Use With
26 Acute Care Utilization and Costs. *J Clin Sleep Med* 2019;**15**:1243–50.
27
28 80 van Dijke JTJM, van Essen TA, Dijkman MD, *et al.* Functional and patient-reported
29 outcome versus in-hospital costs after traumatic acute subdural hematoma (t-ASDH): a
30 neurosurgical paradox? *Acta Neurochir* Published Online First: 2019. doi:10.1007/s00701-
31 019-03878-5
32
33 81 Lentz TA, Rhon DI, George SZ. Predicting Opioid Use, Increased Health Care Utilization
34 and High Costs for Musculoskeletal Pain: What Factors Mediate Pain Intensity and
35 Disability? *Journal of Pain* 2020;**21**:135–45.
36
37 82 Silva-Velazco J, Dietz DW, Stocchi L, *et al.* Considering Value in Rectal Cancer Surgery:
38 An Analysis of Costs and Outcomes Based on the Open, Laparoscopic, and Robotic
39 Approach for Proctectomy. *Ann Surg* 2017;**265**:960–8.
40
41 83 Vuong B, Dehal A, Uppal A, *et al.* What Are the Most Significant Cost and Value Drivers
42 for Pancreatic Resection in an Integrated Healthcare System? *J Am Coll Surg* 2018;**227**:45–
43 53.
44
45 84 Chawla SS, Whitson AJ, Schiffman CJ, *et al.* Drivers of lower inpatient hospital costs and
46 greater improvements in health-related quality of life for patients undergoing total shoulder
47 and ream-and-run arthroplasty. *J Shoulder Elbow Surg* Published Online First: 2021.
48 doi:10.1016/j.jse.2020.10.030
49
50 85 Peard L, Goodwin J, Hensley P, *et al.* Examining and Understanding Value: The Impact of
51 Preoperative Characteristics, Intraoperative Variables, and Postoperative Complications on
52 Cost of Robot-Assisted Laparoscopic Radical Prostatectomy. *J Endourol* 2019;**33**:541–8.
53
54
55
56
57
58
59
60

- 1
2
3 86 Harris AM, Hensley P, Goodwin J, *et al.* Examining and understanding value: The cost of
4 preoperative characteristics, intraoperative variables and postoperative complications of
5 minimally invasive partial nephrectomy. *Urol Pract* 2019;**6**:215–21.
6
7
8 87 Winegar AL, Jackson LW, Sambare TD, *et al.* A surgeon scorecard is associated with
9 improved value in elective primary hip and knee arthroplasty. *Journal of Bone and Joint*
10 *Surgery - American Volume* 2019;**101**:152–9.
11
12 88 Ramshaw B, Forman BR, Moore K, *et al.* Real-World Clinical Quality Improvement for
13 Complex Abdominal Wall Reconstruction. *Surg Technol Int* 2017;**30**:155–64.
14
15 89 Heincelman M, Schumann SO, Riley J, *et al.* Identification of High Utilization Inpatients on
16 Internal Medicine Services. *Am J Med Sci* 2016;**352**:63–70.
17
18 90 Ramly EP, Larentzakis A, Bohnen JD, *et al.* The financial impact of intraoperative adverse
19 events in abdominal surgery. *Surgery* 2015;**158**:1382–8.
20
21 91 Geerdink TH, Haverlag R, van Veen RN, *et al.* [Direct discharge from the ED for patients
22 with simple stable injuries: a Dutch pilot study]. *Ned Tijdschr Geneesk*
23 2020;**164**.<https://www.ncbi.nlm.nih.gov/pubmed/32391996>
24
25
26 92 Abdulla AG, Ituarte PH, Wiggins R, *et al.* Endocrine surgery as a model for value-based
27 health care delivery. *Surg Neurol Int* 2012;**3**:163.
28
29 93 van der Meulen M, Zamanipoor Najafabadi AH, Lobatto DJ, *et al.* Healthcare utilization
30 and costs among prolactinoma patients: a cross-sectional study and analysis of determinants.
31 *Pituitary* 2021;**24**:79–95.
32
33 94 Lobatto DJ, Vliet Vlieland TPM, van den Hout WB, *et al.* Feasibility, safety, and outcomes
34 of a stratified fast-track care trajectory in pituitary surgery. *Endocrine* 2020;**69**:175–87.
35
36 95 Jalilian H, Doshmangir L, Ajami S, *et al.* Economic burden of gastric cancer in the first six
37 months after diagnosis. *Int J Pharm Healthc Mark* 2019;**13**:436–46.
38
39 96 Lobatto DJ, van den Hout WB, Najafabadi AHZ, *et al.* Healthcare utilization and costs
40 among patients with non-functioning pituitary adenomas. *Endocrine* 2019;**64**:330–40.
41
42 97 Yanik JM, Bedard NA, Hanley JM, *et al.* Rapid Recovery Total Joint Arthroplasty is Safe,
43 Efficient, and Cost-Effective in the Veterans Administration Setting. *J Arthroplasty*
44 2018;**33**:3138–42.
45
46 98 Weir TB, Usmani MF, Camacho J, *et al.* Effect of surgical setting on cost and hospital
47 reported outcomes for single-level anterior cervical discectomy and fusion. *Int J Spine Surg*
48 2021;**15**:701–9.
49
50 99 Gálvez ACM, Sánchez FJ, Moreno CA, *et al.* Value-based healthcare in ostomies. *Int J*
51 *Environ Res Public Health* 2020;**17**:1–15.
52
53
54
55
56
57
58
59
60

- 1
2
3 100 Burnhope E, Waring M, Guilder A, *et al.* A systematic approach towards implementing
4 value-based health care in heart failure: Understandings from retrospective analysis methods
5 in South London. *Health Serv Manage Res* Published Online First: 2020.
6 doi:10.1177/0951484820971442
7
- 8
9 101 Kirsch DB, Yang H, Maslow AL, *et al.* Association of positive airway pressure use with
10 acute care utilization and costs. *J Clin Sleep Med* 2019;**15**:1243–50.
11
- 12 102 Khanijow AN, Wood LN, Xie R, *et al.* The impact of an enhanced recovery program (ERP)
13 on the costs of colorectal surgery. *Am J Surg* 2021;**222**:186–92.
14
- 15 103 Fernando-Canavan L, Gust A, Hsueh A, *et al.* Measuring the economic impact of hospital-
16 acquired complications on an acute health service. *Aust Health Rev* 2021;**45**:135–42.
17
- 18 104 Pasquali SK, Thibault D, Hall M, *et al.* Evolving Cost-Quality Relationship in Pediatric
19 Heart Surgery. *Ann Thorac Surg* Published Online First: 8 June 2021.
20 doi:10.1016/j.athoracsur.2021.05.050
21
- 22 105 Negrini R, da Silva Ferreira RD, Guimaraes DZ. Value-based care in obstetrics: comparison
23 between vaginal birth and caesarean section. *BMC Pregnancy Childbirth* 2021;**21**:333.
24
- 25 106 Islam MK, Ruths S, Jansen K, *et al.* Evaluating an integrated care pathway for frail elderly
26 patients in Norway using multi-criteria decision analysis. *BMC Health Serv Res* 2021;**21**:1–
27 16.
28
- 29 107 Fontebasso AM, Figueira S, Thavorn K, *et al.* Financial implications of trauma patients at a
30 Canadian level 1 trauma center: a retrospective cohort study. *Trauma Surg Acute Care Open*
31 2020;**5**:e000568.
32
- 33 108 Robinson JR, Avritscher EBC, Gay JC, *et al.* Measuring the Value of a Clinical Practice
34 Guideline for Children with Perforated Appendicitis. *Ann Surg* 2017;**266**:195–200.
35
- 36 109 Sun LL, Cao DY, Yang JX, *et al.* Value-based medicine analysis on loop electrosurgical
37 excision procedure and CO2 laser vaporization for the treatment of cervical intraepithelial
38 neoplasia 2. *J Obstet Gynaecol Res* 2012;**38**:1064–70.
39
- 40 110 Fürstenau D, Haneke H, Spies C, *et al.* Tackling the frailty burden with an integrative value-
41 based approach: results from a mixed-methods study. *J Public Health* 2022;**30**:99–110.
42
- 43 111 Ebinger JE, Strauss CE, Garberich RR, *et al.* Value-based ST-segment-elevation myocardial
44 infarction care using risk-guided triage and early discharge. *Circ Cardiovasc Qual*
45 *Outcomes* 2018;**11**. doi:10.1161/CIRCOUTCOMES.118.004553
46
- 47 112 Jain N, Brock JL, Phillips FM, *et al.* Chronic preoperative opioid use is a risk factor for
48 increased complications, resource use, and costs after cervical fusion. *Spine J*
49 2018;**18**:1989–98.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 113 Rice-Townsend S, Barnes JN, Hall M, *et al.* Variation in practice and resource utilization
4 associated with the diagnosis and management of appendicitis at freestanding children's
5 hospitals: Implications for value-based comparative analysis. *Ann Surg* 2014;**259**:1228–34.
6
7
8 114 Burnett RA Iii, Yang J, Courtney PM, *et al.* Costs of unicompartmental compared with total
9 knee arthroplasty : a matched cohort study over ten years. *Bone Joint J* 2021;**103-B**:23–31.
10
11 115 Cronin KJ, Mair SD, Hawk GS, *et al.* Increased Health Care Costs and Opioid Use in
12 Patients with Anxiety and Depression Undergoing Rotator Cuff Repair. *Arthroscopy -*
13 *Journal of Arthroscopic and Related Surgery* 2020;**36**:2655–60.
14
15 116 Robles AJ, Kornblith LZ, Hendrickson CM, *et al.* Health care utilization and the cost of
16 posttraumatic acute respiratory distress syndrome care. *J Trauma Acute Care Surg*
17 2018;**85**:148–54.
18
19 117 Brown MM, Brown GC, Brown HC, *et al.* A Value-Based Medicine Analysis of
20 Ranibizumab for the Treatment of Subfoveal Neovascular Macular Degeneration.
21 *Ophthalmology* 2008;**115**:1039-1045.e5.
22
23
24 118 Chovanec KA, Arsene C, Beck A, *et al.* Why not home?: A study of the impact of an effort
25 to reduce postacute expenditures. *Prof Case Manag* 2022;**27**:3–11.
26
27 119 Brown GC, Brown MM, Brown HC, *et al.* A Value-Based Medicine Comparison of
28 Interventions for Subfoveal Neovascular Macular Degeneration. *Ophthalmology*
29 2007;**114**:1170–8.
30
31 120 van Deen WK, Spiro A, Burak Ozbay A, *et al.* The impact of value-based healthcare for
32 inflammatory bowel diseases on healthcare utilization: a pilot study. *Eur J Gastroenterol*
33 *Hepatol* 2017;**29**:331–7.
34
35
36 121 Annabathula R, Dugan A, Bhalla V, *et al.* Value-based assessment of implementing a
37 Pulmonary Embolism Response Team (PERT). *J Thromb Thrombolysis* 2021;**51**:217–25.
38
39 122 Ennis RD, Parikh AB, Sanderson M, *et al.* Interpreting oncology care model data to drive
40 value-based care: A prostate cancer analysis. *J Oncol Pract* 2019;**15**:E238–46.
41
42 123 Denny JC, Cyr DD, Witsell DL, *et al.* A pathway to value-based care of chronic
43 rhinosinusitis using a claims database. *Laryngoscope Investigative Otolaryngology*
44 2019;**4**:193–206.
45
46 124 Peele P, Keyser D, Lovelace J, *et al.* Advancing Value-Based Population Health
47 Management Through Payer-Provider Partnerships: Improving Outcomes for Children with
48 Complex Conditions. *J Healthc Qual* 2018;**40**:e26–32.
49
50 125 Khullar OV, Jiang R, Force SD, *et al.* Transthoracic versus transhiatal resection for
51 esophageal adenocarcinoma of the lower esophagus: A value-based comparison. *J Surg*
52 *Oncol* 2015;**112**:517–23.
53
54
55
56
57
58
59
60

- 1
2
3 126 Ramirez MM, Brennan GP. Using the value-based care paradigm to compare physical
4 therapy access to care models in cervical spine radiculopathy: a case report. *Physiother*
5 *Theory Pract* 2020;**36**:1476–84.
6
7 127 Regan DK, Manoli A, Hutzler L, *et al.* Impact of Diabetes Mellitus on Surgical Quality
8 Measures After Ankle Fracture Surgery: Implications for Value-Based Compensation and
9 Pay for Performance. *J Orthop Trauma* 2015;**29**:e483-486.
10
11 128 Kadakia RJ, Ahearn BM, Tenenbaum S, *et al.* Costs Associated With Geriatric Ankle
12 Fractures. *Foot Ankle Spec* 2017;**10**:26–30.
13
14 129 Barkley R, Soobader MJ, Wang J, *et al.* Reducing cancer costs through symptom
15 management and triage pathways. *J Oncol Pract* 2019;**15**:E91–7.
16
17 130 Suidan RS, He W, Sun CC, *et al.* Total and out-of-pocket costs of different primary
18 management strategies in ovarian cancer. *Am J Obstet Gynecol* 2019;**221**:136.e1-136.e9.
19
20 131 Hemmila MR, Cain-Nielsen AH, Wahl WL, *et al.* Regional collaborative quality
21 improvement for trauma reduces complications and costs. *J Trauma Acute Care Surg*
22 2015;**78**:78–85.
23
24 132 AlAshqar A, Goktepe ME, Kilic GS, *et al.* Predictors of the cost of hysterectomy for benign
25 indications. *J Gynecol Obstet Hum Reprod* 2021;**50**:101936.
26
27 133 Naghavi AO, Gonzalez RJ, Scott JG, *et al.* Staged reconstruction brachytherapy has lower
28 overall cost in recurrent soft-tissue sarcoma. *J Contemp Brachytherapy* 2017;**9**:20–9.
29
30 134 Puvanesarajah V, Kirby DJ, Jain A, *et al.* Cost Variation of Anterior Cervical Fusions in
31 Elderly Medicare Beneficiaries. *Spine* 2017;**42**:E1010–5.
32
33 135 Passias PG, Poorman GW, Bortz CA, *et al.* Predictors of adverse discharge disposition in
34 adult spinal deformity and associated costs. *Spine J* 2018;**18**:1845–52.
35
36 136 Manriquez E, Mandelbaum A, Aguayo E, *et al.* Factors associated with high-cost
37 hospitalizations in elderly ovarian cancer patients. *Gynecol Oncol* 2020;**159**:767–72.
38
39 137 Rocque GB, Pisu M, Jackson BE, *et al.* Resource Use and Medicare Costs During Lay
40 Navigation for Geriatric Patients With Cancer. *JAMA Oncol* 2017;**3**:817–25.
41
42 138 Brixner D, Rubin DT, Mease P, *et al.* Patient support program increased medication
43 adherence with lower total health care costs despite increased drug spending. *Journal of*
44 *Managed Care and Specialty Pharmacy* 2019;**25**:770–9.
45
46 139 Alli VV, Zhang J, Telem DA. Impact of incisional hernia development following abdominal
47 operations on total healthcare cost. *Surg Endosc* 2018;**32**:2381–6.
48
49 140 Thakore RV, Greenberg SE, Shi H, *et al.* Surgical site infection in orthopedic trauma: A
50 case-control study evaluating risk factors and cost. *Journal of Clinical Orthopaedics and*
51 *Trauma* 2015;**6**:220–6.
52
53
54
55
56
57
58
59
60

- 1
2
3 141 Smith BD, Jiang J, Shih YC, *et al.* Cost and complications of local therapies for early-stage
4 breast cancer. *J Natl Cancer Inst* 2017;**109**. doi:10.1093/jnci/djw178
5
6 142 Klink AJ, Chmielowski B, Feinberg B, *et al.* Health care resource utilization and costs in
7 first-line treatments for patients with metastatic melanoma in the United States. *Journal of*
8 *Managed Care and Specialty Pharmacy* 2019;**25**:869–77.
9
10 143 Chotai S, Sivaganesan A, Parker SL, *et al.* Drivers of Variability in 90-Day Cost for
11 Elective Anterior Cervical Discectomy and Fusion for Cervical Degenerative Disease. *Clin*
12 *Neurosurg* 2018;**83**:898–904.
13
14 144 Ackerman RS, Hirschi M, Alford B, *et al.* Enhanced REVENUE after surgery? A cost-
15 standardized enhanced recovery pathway for mastectomy decreases length of stay. *World J*
16 *Surg* 2019;**43**:839–45.
17
18 145 Williams SB, Shan Y, Jazzar U, *et al.* Comparing Survival Outcomes and Costs Associated
19 with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive
20 Bladder Cancer. *JAMA Surg* 2018;**153**:881–9.
21
22 146 Schilling PL, He J, Chen S, *et al.* Risk-Adjusted Cost Performance for 90-Day Total Hip
23 Arthroplasty Episodes: Comparing US Hospitals Nationwide Before CJR. *J Arthroplasty*
24 2020;**35**:3452–63.
25
26 147 Ackerman SJ, Knight T, Wahl PM, *et al.* Health care utilization and costs following
27 amplified versus non-amplified molecular probe testing for symptomatic patients with
28 suspected vulvovaginitis: A us commercial payer population. *Clinicoecon Outcomes Res*
29 2019;**11**:179–89.
30
31 148 Patel MI, Ramirez D, Agajanian R, *et al.* Lay health worker-led cancer symptom screening
32 intervention and the effect on patient-reported satisfaction, health status, health care use, and
33 total costs: Results from a tri-part collaboration. *J Oncol Pract* 2020;**16**:E19–28.
34
35 149 Stearns LJ, Narang S, Albright RE, *et al.* Assessment of Health Care Utilization and Cost of
36 Targeted Drug Delivery and Conventional Medical Management vs Conventional Medical
37 Management Alone for Patients With Cancer-Related Pain. *JAMA Netw Open*
38 2019;**2**:e191549.
39
40 150 Skill NJ, Butler J, O'Brien DC, *et al.* Financial Burden of Liver Transplant vs Resection for
41 Hepatocellular Carcinoma. *Transplant Proc* 2019;**51**:1907–12.
42
43 151 Karnuta JM, Navarro SM, Haeberle HS, *et al.* Predicting Inpatient Payments Prior to Lower
44 Extremity Arthroplasty Using Deep Learning: Which Model Architecture Is Best? *J*
45 *Arthroplasty* 2019;**34**:2235-2241.e1.
46
47 152 Ning MS, Palmer MB, Shah AK, *et al.* Three-Year Results of a Prospective Statewide
48 Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient
49 Access to Care. *JCO Oncol Pract* 2020;**16**:e966–76.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 153 Keller DS, Zhang J, Chand M. Opioid-free colorectal surgery: a method to improve patient
4 & financial outcomes in surgery. *Surg Endosc* 2019;**33**:1959–66.
5
6 154 Rocque GB, Williams CP, Kenzik KM, *et al.* Where are the opportunities for reducing
7 health care spending within alternative payment models? *J Oncol Pract* 2018;**14**:e375–83.
8
9 155 Sheetz KH, Kenney B, Dupree JM, *et al.* Targeting Value-Driven Quality Improvement for
10 Laparoscopic Cholecystectomy in Michigan. *Ann Surg* 2019;**269**:127–32.
11
12 156 Zolin SJ, Tastaldi L, Alkhatib H, *et al.* Open retromuscular versus laparoscopic ventral
13 hernia repair for medium-sized defects: where is the value? *Hernia* 2020;**24**:759–70.
14
15 157 Orhurhu V, Urits I, Olusunmade M, *et al.* Trends of Co-Morbid Depression in Hospitalized
16 Patients with Failed Back Surgery Syndrome: An Analysis of the Nationwide Inpatient
17 Sample. *Pain and Therapy* 2018;**7**:217–26.
18
19 158 Hollenbeck B, Hoffman MA, Tromanhauser SG. High-Volume Arthroplasty Centers
20 Demonstrate Higher Composite Quality Scores and Enhanced Value: Perspective on Higher-
21 Volume Hospitals Performing Arthroplasty from 2001 to 2011. *Journal of Bone and Joint*
22 *Surgery - American Volume* 2020;**102**:362–7.
23
24 159 Loftus TJ, Rosenthal MD, Croft CA, *et al.* Effect of time to operation on value of care in
25 acute care surgery. *World J Surg* 2018;**42**:2356–63.
26
27 160 Buell JF, Sigmon D, Ducoin C, *et al.* Initial Experience with Biologic Polymer Scaffold
28 (Poly-4-hydroxybuturate) in Complex Abdominal Wall Reconstruction. *Ann Surg*
29 2017;**266**:185–8.
30
31 161 Jain N, Phillips FM, Shimer AL, *et al.* Surgeon Reimbursement Relative to Hospital
32 Payments for Spinal Fusion: Trends From 10-year Medicare Analysis. *Spine* 2018;**43**:720–
33 31.
34
35 162 Stull JD, Bhat SB, Kane JM, *et al.* Economic Burden of Inpatient Admission of Ankle
36 Fractures. *Foot Ankle Int* 2017;**38**:997–1004.
37
38 163 Lewis RB, Hariri O, Elliott ME, *et al.* Financial Analysis of Closed Femur Fractures in 3- to
39 6-Year-Olds Treated with Immediate Spica Casting Versus Intramedullary Fixation. *Journal*
40 *of Pediatric Orthopaedics* 2019;**39**:E114–9.
41
42 164 Murphy WS, Cheng T, Lin B, *et al.* Higher Volume Surgeons Have Lower Medicare
43 Payments, Readmissions, and Mortality After THA. *Clin Orthop Relat Res* 2019;**477**:334–
44 41.
45
46 165 King AM, Danagouliau S, Lynch M, *et al.* The Effect of a Medical Toxicology Inpatient
47 Service in an Academic Tertiary Care Referral Center. *J Med Toxicol* 2019;**15**:12–21.
48
49 166 Click B, Lopez R, Arrigain S, *et al.* Shifting Cost-drivers of Health Care Expenditures in
50 Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2020;**26**:1268–75.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 167 Padilla JA, Gabor JA, Ryan SP, *et al.* Total Hip Arthroplasty for Femoral Neck Fracture:
4 The Economic Implications of Orthopedic Subspecialty Training. *J Arthroplasty*
5 2020;**35**:S101–6.
6
7
8 168 Pang J, Crawford K, Faraji F, *et al.* An Analysis of 1-Year Charges for Head and Neck
9 Cancer: Targets for Value-Based Interventions. *Otolaryngol Head Neck Surg*
10 2020;**163**:546–53.
11
12 169 Patel MI, Ramirez D, Agajanian R, *et al.* Association of a Lay Health Worker Intervention
13 With Symptom Burden, Survival, Health Care Use, and Total Costs Among Medicare
14 Enrollees With Cancer. *JAMA Netw Open* 2020;**3**:e201023.
15
16 170 Thaci B, McGirt MJ, Ammerman JM, *et al.* Reduction of direct costs in high-risk lumbar
17 discectomy patients during the 90-day post-operative period through annular closure.
18 *Clinicoecon Outcomes Res* 2019;**11**:191–7.
19
20 171 Gupta P, Rettiganti M. Relationship of Hospital Costs With Mortality in Pediatric Critical
21 Care: A Multi-Institutional Analysis. *Pediatr Crit Care Med* 2017;**18**:541–9.
22
23 172 Nelson AA, Pearce DJ, Fleischer AB, *et al.* Infliximab for inpatient psoriasis management -
24 is there a role? *J Dermatolog Treat* 2005;**16**:314–8.
25
26 173 Zhang S, Vora M, Harris AHS, *et al.* Cost-Minimization Analysis of Open and Endoscopic
27 Carpal Tunnel Release. *J Bone Joint Surg Am* 2016;**98**:1970–7.
28
29 174 Adenikinju A, Ranson R, Rettig SA, *et al.* Ability of a Risk Prediction Tool to Stratify
30 Quality and Cost for Older Patients With Operative Distal Radius Fractures. *Geriatr Orthop*
31 *Surg Rehabil* 2021;**12**:2151459321999634.
32
33 175 Baughman DJ, Waheed A, Khan MN, *et al.* Enhancing Value-Based Care With a Walk-in
34 Clinic: A Primary Care Provider Intervention to Decrease Low Acuity Emergency
35 Department Overutilization. *Cureus* 2021;**13**:e13284.
36
37 176 Berinstein JA, Cohen-Mekelburg SA, Greenberg GM, *et al.* A Care Coordination
38 Intervention Improves Symptoms But Not Charges in High-Risk Patients With
39 Inflammatory Bowel Disease. *Clinical Gastroenterology & Hepatology* Published Online
40 First: 28 August 2021. doi:10.1016/j.cgh.2021.08.034
41
42 177 Beschloss A, Dicindio C, Lombardi J, *et al.* Marked increase in Spinal Deformity Surgery
43 throughout the United States. *Spine* 2021;**46**:1402–8.
44
45 178 Jang DW, Lee HJ, Chen PG, *et al.* Geographic variations in healthcare utilization and
46 expenditure for chronic rhinosinusitis: A population-based approach. *Laryngoscope*
47 2021;**131**:2641–8.
48
49 179 Ko H, Brodke DS, Vanneman ME, *et al.* Is discretionary care associated with safety among
50 Medicare beneficiaries undergoing spine surgery? *J Bone Joint Surg Am* 2021;**Publish**
51 **Ahead of Print**. doi:10.2106/JBJS.21.00389
52
53
54
55
56
57
58
59
60

- 1
2
3 180 Malik AT, Khan SN, Voskuil RT, *et al.* What is the value of undergoing surgery for spinal
4 metastases at Dedicated Cancer Centers? *Clin Orthop Relat Res* 2021;**479**:1311–9.
5
6 181 Newman TV, Munshi KD, Neilson LM, *et al.* Health care utilization and costs associated
7 with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
8 *Journal of Managed Care & Specialty Pharmacy* 2021;**27**:435–43.
9
10 182 Tomicki S, Dieguez G, Latimer H, *et al.* Real-World Cost of Care for Commercially Insured
11 versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-
12 Recommended Therapies. *American Health & Drug Benefits* 2021;**14**:70–8.
13
14 183 Buell JF, Flaris AN, Raju S, *et al.* Long-Term Outcomes in Complex Abdominal Wall
15 Reconstruction Repaired With Absorbable Biologic Polymer Scaffold (Poly-4-
16 Hydroxybutyrate). *Annals of Surgery Open* 2021;**2**:e032.
17
18 184 King BC, Richardson T, Patel RM, *et al.* Prioritization framework for improving the value
19 of care for very low birth weight and very preterm infants. *J Perinatol* 2021;**41**:2463–73.
20
21 185 Skibicki H, Yayac M, Krueger CA, *et al.* Target price adjustment for hip fractures is not
22 sufficient in the Bundled Payments for Care Improvement initiative. *J Arthroplasty*
23 2021;**36**:47–53.
24
25 186 Clewley D, Iftikhar Y, Horn ME, *et al.* Do the number of visits and the cost of
26 musculoskeletal care improve outcomes? More may not be better. *J Orthop Sports Phys*
27 *Ther* 2020;**50**:642–8.
28
29 187 Walker B, Wilfong L, Frytak J, *et al.* Practice patterns among oncologists participating in
30 the oncology care model after three years. *J Cancer Policy* 2021;**29**:100294.
31
32 188 Krueger CA, Yayac M, Vannello C, *et al.* Are we at the bottom? BPCI programs now
33 disincentivize providers who maintain quality despite caring for increasingly complex
34 patients. *J Arthroplasty* 2021;**36**:13–8.
35
36 189 Horton BS, Marland JD, West HS, *et al.* Transition to telehealth physical therapy after hip
37 arthroscopy for femoroacetabular impingement: A pilot study with retrospective matched-
38 cohort analysis. *Orthop J Sports Med* 2021;**9**:2325967121997469.
39
40 190 Nguyen NH, Luo J, Ohno-Machado L, *et al.* Burden and outcomes of fragmentation of care
41 in hospitalized patients with inflammatory bowel diseases: A nationally representative
42 cohort. *Inflamm Bowel Dis* 2021;**27**:1026–34.
43
44 191 Gregory D, Scotti DJ, de Lissovoy G, *et al.* A value-based analysis of hemodynamic support
45 strategies for high-risk heart failure patients undergoing a percutaneous coronary
46 intervention. *Am Health Drug Benefits* 2013;**6**:88–99.
47
48 192 Schwartz DA, Shah AA, Zogg CK, *et al.* Operative delay to laparoscopic cholecystectomy:
49 Racking up the cost of health care. *J Trauma Acute Care Surg* 2015;**79**:15–21.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 193 Aguayo E, Sanaiha Y, Seo YJ, *et al.* Heparin-induced thrombocytopenia in cardiac surgery:
4 Incidence, costs, and duration of stay. *Surgery* 2018;**164**:1377–81.
5
6 194 Canizares MF, Feldman L, Miller PE, *et al.* Complications and Cost of Syndactyly
7 Reconstruction in the United States: Analysis of the Pediatric Health Information System.
8 *Hand* 2017;**12**:327–34.
9
10 195 Sanaiha Y, Mantha A, Ziaieian B, *et al.* Trends in Readmission and Costs After
11 Transcatheter Implantation Versus Surgical Aortic Valve Replacement in Patients With
12 Renal Dysfunction. *Am J Cardiol* 2019;**123**:1481–8.
13
14 196 Sanaiha Y, Kavianpour B, Downey P, *et al.* National Study of Index and Readmission
15 Mortality and Costs for Thoracic Endovascular Aortic Repair in Patients With Renal
16 Disease. *Ann Thorac Surg* 2020;**109**:458–64.
17
18 197 Labovitz JM, Kominski GF. Forecasting the value of podiatric medical care in newly
19 insured diabetic patients during implementation of the affordable care act in California. *J*
20 *Am Podiatr Med Assoc* 2016;**106**:163–71.
21
22 198 Johnson JT, Scholtens DM, Kuang A, *et al.* Does Value Vary by Center Surgical Volume
23 for Neonates With Truncus Arteriosus? A Multicenter Study. *Ann Thorac Surg* Published
24 Online First: 2021. doi:10.1016/j.athoracsur.2020.05.178
25
26 199 Saifi C, Cazzulino A, Park C, *et al.* National Trends for Primary and Revision Lumbar Disc
27 Arthroplasty Throughout the United States. *Global Spine Journal* 2018;**8**:172–7.
28
29 200 Boucek DM, Lal AK, Eckhauser AW, *et al.* Resource Utilization for Initial Hospitalization
30 in Pediatric Heart Transplantation in the United States. *Am J Cardiol* 2018;**121**:981–5.
31
32 201 Laratta JL, Reddy H, Lombardi JM, *et al.* Utilization of Interspinous Devices Throughout
33 the United States Over a Recent Decade: An Analysis of the Nationwide Inpatient Sample.
34 *Global Spine Journal* 2018;**8**:382–7.
35
36 202 Karnuta JM, Golubovsky JL, Haeberle HS, *et al.* Can a machine learning model accurately
37 predict patient resource utilization following lumbar spinal fusion? *Spine J* 2020;**20**:329–36.
38
39 203 Karnuta JM, Navarro SM, Haeberle HS, *et al.* Bundled Care for Hip Fractures: A Machine-
40 Learning Approach to an Untenable Patient-Specific Payment Model. *J Orthop Trauma*
41 2019;**33**:324–30.
42
43 204 Navarro SM, Ramkumar PN, Egger AC, *et al.* Evidence-Based Thresholds for the Volume-
44 Value Relationship in Adolescent Idiopathic Scoliosis: Outcomes and Economies of Scale.
45 *Spine Deformity* 2018;**6**:156–63.
46
47 205 Bateni SB, Gingrich AA, Hoch JS, *et al.* Defining Value for Pancreatic Surgery in Early-
48 Stage Pancreatic Cancer. *JAMA Surg* 2019;**154**. doi:10.1001/jamasurg.2019.3019
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 206 Xiao R, Miller JA, Zafirau WJ, *et al.* Impact of Home Health Care on Health Care Resource
4 Utilization Following Hospital Discharge: A Cohort Study. *Am J Med* 2018;**131**:395-
5 407.e35.
6
7 207 Gandjian M, Williamson C, Sanaiha Y, *et al.* Continued Relevance of Minimum Volume
8 Standards for Elective Esophagectomy: A National Perspective. *Ann Thorac Surg* Published
9 Online First: 23 August 2021. doi:10.1016/j.athoracsur.2021.07.061
10
11 208 Hadaya J, Sanaiha Y, Hernandez R, *et al.* Impact of hospital volume on resource use after
12 elective cardiac surgery: A contemporary analysis. *Surgery* 2021;**170**:682–8.
13
14 209 Seyidova N, Chen AD, del Valle D, *et al.* Nationwide cost variation for lower extremity flap
15 reconstruction. *Eur J Plast Surg* 2021;**44**:475–82.
16
17 210 Sanaiha Y, Downey P, Lyons R, *et al.* Trends in utilization, mortality, and resource use after
18 implantation of left ventricular assist devices in the United States. *J Thorac Cardiovasc Surg*
19 2021;**161**:2083-2091.e4.
20
21 211 Frankel WC, Navarro SM, Haeberle HS, *et al.* Optimizing the Volume–Value Relationship
22 in Laminectomy. *Spine* 2019;**44**:659–69.
23
24 212 Miller PE, Guha A, Khera R, *et al.* National Trends in Healthcare-Associated Infections for
25 Five Common Cardiovascular Conditions. *Am J Cardiol* 2019;**124**:1140–8.
26
27 213 Mukdad L, Mantha A, Aguayo E, *et al.* Readmission and resource utilization after
28 orthotopic heart transplant versus ventricular assist device in the National Readmissions
29 Database, 2010–2014. *Surgery* 2018;**164**:274–81.
30
31 214 Navarro SM, Wang EY, Haeberle HS, *et al.* Machine Learning and Primary Total Knee
32 Arthroplasty: Patient Forecasting for a Patient-Specific Payment Model. *J Arthroplasty*
33 2018;**33**:3617–23.
34
35 215 Iloabuchi C, Dwibedi N, LeMasters T, *et al.* Low-value care and excess out-of-pocket
36 expenditure among older adults with incident cancer – A machine learning approach.
37 *Journal of Cancer Policy* 2021;**30**:100312.
38
39 216 Siu VJ, Varkey T, Khan UN, *et al.* Lend Me a Hand: A Value-Based Care Case Study on
40 Pan Plexopathy of Unknown Origin. *Cureus* 2021;**13**.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	pg 0
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	pg1-3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	pg 3
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	pg 4 and supplement
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pg 4 and supplement
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplement
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	pg 6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	pg 6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	pg 4, supplement
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	pg 4, supplement
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	pg 4, supplement
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	pg 4
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	pg 8
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	N/A
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	pg 8
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	pg 4
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	N/A
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	N/A
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	N/A, discussed pg 23
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	N/A



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	pg 5,6, 7
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	pg 5 (flowchart)
Study characteristics	17	Cite each included study and present its characteristics.	pg 7-14, and supplement
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	N/A
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	N/A
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	N/A
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	N/A
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	pg 7-9
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	N/A
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	N/A
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	N/A
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	pg 18-21
	23b	Discuss any limitations of the evidence included in the review.	pg 21
	23c	Discuss any limitations of the review processes used.	pg 21, 4
	23d	Discuss implications of the results for practice, policy, and future research.	pg 18-21
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	pg 4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	supplement
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Funding statement
Competing interests	26	Declare any competing interests of review authors.	Author statement
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Data availability statement

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>
For more information, visit: <http://www.prisma-statement.org/>



PRISMA 2020 for Abstracts Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	no
Synthesis of results	6	Specify the methods used to present and synthesise results.	yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	yes
Interpretation	10	Provide a general interpretation of the results and important implications.	yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	yes
Registration	12	Provide the register name and registration number.	N/A

For more information, visit: <http://www.prisma-statement.org/>

BMJ Open

Cost measurement in value-based health care: a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-066568.R1
Article Type:	Original research
Date Submitted by the Author:	21-Oct-2022
Complete List of Authors:	Leusder, Maura; Erasmus University Rotterdam, Department of Health Services Management & Organisation Porte, Petra; Erasmus University Rotterdam, Department of Health Services Management & Organisation Ahaus, Kees; Erasmus University Rotterdam, Department of Health Services Management & Organisation van Elten, Hilco; Nyenrode Business Universiteit, Center for Corporate Reporting, Finance & Tax
Primary Subject Heading:	Health services research
Secondary Subject Heading:	Health services research
Keywords:	Organisation of health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title: Cost measurement in value-based health care: a systematic review

Running head: Cost measurement in value-based healthcare

Authors: Maura Leusder, Petra Porte, Kees Ahaus, and Hilco van Elten

Maura Leusder, MSc.

Department Health Services Management & Organisation, Erasmus University Rotterdam
The Netherlands

Petra J. Porte, PhD.

Department Health Services Management & Organisation, Erasmus University Rotterdam
The Netherlands

C.T.B. (Kees) Ahaus, Prof. Dr. Ir.

Department Health Services Management & Organisation, Erasmus University Rotterdam
The Netherlands

Hilco J. van Elten, PhD.

Center for Corporate Reporting, Finance & Tax, Nyenrode Business University, Breukelen, The
Netherlands

Corresponding author; Maura Leusder, MSc.

leusder@eshpm.eur.nl.

+31 06 38002149

J6-41, Bayle Building (J) Burgemeester Oudlaan 50, 3062 PA Rotterdam

Postbus 1738, 3000 DR Rotterdam

Word count: 4161

Tables and figures: 5

Keywords: Costs, value-based healthcare, cost accounting, process improvements, time-driven activity-based costing, activity-based costing, decision-making

ABSTRACT

Objective Although value-based healthcare (VBHC) views accurate cost information to be crucial in the pursuit of value, little is known about how the costs of care should be measured. The aim of this review is to identify how costs are currently measured in VBHC, and which cost measurement methods can facilitate VBHC or value-based decision making.

Design Two reviewers systematically search the PubMed/MEDLINE, Embase, EBSCOhost, and Web of Science databases for publications up to 1/1/2022 and follow PRISMA guidelines to identify relevant studies for further analysis.

Eligibility criteria Studies should measure the costs of an intervention, treatment, or care path and label the study as 'value-based'. An inductive qualitative approach was used to identify studies that adopted management accounting techniques to identify if or how cost information facilitated VBHC by aiding decision-making.

Results We identified 1,930 studies, of which 215 measured costs in a VBHC setting. Half of these studies measured hospital costs (110, 51.2%) and the rest relied on reimbursement amounts. Sophisticated costing methods that allocate both direct and indirect costs to care paths were seen as able to provide valuable managerial information by facilitating care path adjustments (40), benchmarking (39), the identification of cost drivers (47), and the measurement of total costs or cost savings (26). We found three best practices that were key to success in cost measurement: process mapping (34), expert input (16), and observations (24).

Conclusions Cost information can facilitate VBHC. Time-driven activity-based costing (TDABC) is viewed as the best method although its ability to inform decision-making depends on how it is implemented. While costing short, or partial, care paths and surgical episodes produces accurate cost information, it provides only limited decision-making information. Practitioners are advised to focus on costing full care cycles and to consider both direct and indirect costs through TDABC.

Strengths and limitations

- Using two independent reviewers, this systematic review analyzes all value-based healthcare studies that have to date measured costs to provide a comprehensive comparison of cost measurement methods.
- This research operationalizes the benefits of cost measurement to practitioners by identifying four mechanisms through which cost information facilitates value-based healthcare.
- By comparing the methods used in literature to collect cost information, this study identifies three best practices for practitioners and researchers.
- By limiting the search to studies labelled as ‘value-based’ in their title or abstract, this review overlooks studies that measure healthcare costs but do not explicitly relate this to value-based healthcare.
- The included studies may have achieved value-based healthcare without reporting this explicitly, and therefore may be overlooked when answering Research Question 2.

INTRODUCTION

To make sound value-based decisions in healthcare, hospital practitioners and healthcare providers require patient-level information on the costs incurred and outcomes achieved in hospitals and other healthcare organizations [1]. This will enable care providers to steer towards better patient-reported outcome measures, better patient-reported experience measures, and clinical outcomes at equal or lower cost [2]. With detailed cost and outcome information, care paths can be continuously optimized [3]. Consequently, value-based healthcare (VBHC) is considered one solution to the financial pressures our global healthcare system places on managers and administrators [1,4,5] based on its promise to streamline care by focusing on desirable outcomes. Additionally, hospitals can benefit from cost information by gaining insight into the sources of costs that can then guide cost-containment strategies. Cost information may therefore facilitate process and quality improvement initiatives pursued by management [6–10]. Furthermore, insight into patient-level or treatment-level costs enables hospitals to negotiate appropriate prices with insurance firms, especially given the trend towards new payment models and away from fee-for-service payments [11,12]. Finally, it is suggested that such treatment-level cost information enables market-based competition among hospitals based on outcomes and prices [13].

Considerable research has addressed the outcome side of Porter's value equation [14]. This value equations suggests that healthcare should pursue 'value', where value is defined as desirable and relevant patient level outcomes divided by the costs of delivering care [1, 2]. Many studies have measured patient-level outcomes from both the patient perspective (e.g., patient-reported outcome measures, patient-reported experience measures) and clinical outcome perspective [15,16]. Less is known about the cost side of this equation. Often, the term 'cost' is conflated with the price paid by insurance firms or patients to the hospital [17,18]. However, prices do not reflect

1
2
3 the costs incurred by hospitals [6,19–21]. Prices paid by insurance firms are negotiated sums that
4 include profit margins for both the insurer and the hospital [22]. They are also impacted by political
5 factors, such as the hospital-payor mix [23] that refers to the range of private and public insurance
6 schemes that make up the hospital's income stream. Finally, fee-for-service payments fail to
7 account for patient-level differences in required care. Reimbursements are therefore considered a
8 poor indicator of costs.
9

10
11
12 Some authors argue for time-driven activity-based costing (TDABC) as the 'gold standard'
13 of cost measurement in healthcare organizations [3,5,15]. TDABC, in a fine-grained way, matches
14 direct and indirect costs to activities based on the time an activity takes. A care path is made up of
15 many activities, each generating costs. The costs of a care path can thus be calculated by first
16 identifying all costs relevant to each activity, and then summing these costs across the activities
17 [22].
18
19

20
21
22 Although the research is growing and results are promising, there is relatively little
23 empirical evidence to support TDABC being the best costing method to enable VBHC since
24 studies rarely compare methods, and often simply use whichever system the investigated hospital
25 or care provider uses. Costing methods differ by how they allocate indirect costs to products or
26 services [24]. Moreover, indirect costs cannot causally be attributed to patients and therefore need
27 to be appropriately allocated. An example of such indirect costs are the salaries of administrative
28 personnel such as the front office staff who welcome patients, coordinate schedules, and manage
29 equipment. While some costing methods ignore this (e.g., direct costing), other methods average
30 indirect costs across days or months, or systematically allocate them to patients. These methods
31 range from imprecise to fine-grained, with TDABC towards the fine-grained end of the scale. This
32 insight is particularly relevant to healthcare since indirect costs are high. The most fine-grained
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

1
2
3 method is known as activity-based costing (ABC) and allocates indirect costs based on actual units
4
5 of resources used per activity. In comparison, TDABC allocates indirect costs based on a per-
6
7 minute cost, making it considerably easier to implement. Costing methods that ignore the indirect
8
9 costs of a care path underestimate the true costs of the care delivered.
10
11

12
13 Previous systematic reviews have found that TDABC was able to facilitate VBHC, often
14
15 highlighting cost savings as a result but without comparing it to alternative methods [3,4,15].
16
17 Therefore, we do not know how TDABC compares to other cost measurement methods currently
18
19 in use. While TDABC may be able to facilitate VBHC [5,15], it is unclear how its benefits compare
20
21 to other costing methods. For these reasons, the cost side of the value equation remains unclear.
22
23 To address this challenge, we pose two research questions:
24
25

26
27 RQ1: Which costing methods are currently being used by practitioners to facilitate VBHC?

28
29 RQ2: What are the consequences of applying a specific costing method in VBHC? These
30
31 consequences may include whether the method enables a cost reduction with equal or better
32
33 health outcomes or provides sufficient information to further improve a care path.
34

35
36 This comprehensive review draws on management accounting literature to categorize costing
37
38 methods reported in empirical VBHC literature published over the last two decades (January 1,
39
40 2003 to January 1, 2022) into cost measurement methods defined in the literature [24], such as
41
42 direct costing and absorption costing. Compiling studies in this way revealed four ways through
43
44 which cost information facilitates VBHC and three best practices.
45
46

47 **MATERIALS AND METHODS**

48 **Literature search strategy**

49
50 To identify relevant studies, we systematically searched four major databases: Embase, Medline,
51
52 Web of Science, and CINAHL EBSCOhost. Our search string (**online supplementary appendix**)
53
54
55
56
57

1
2
3 was developed by assessing previously identified relevant papers and was designed to catch all
4 studies that address VBHC and measure the costs of an intervention, care path, or treatment by
5
6 including the following specific terms:
7

8
9
10 *cost*, microcost*, macrocost* AND [meaning in combination with] value-based, value
11 based, OR valuebased
12

13 Initial search string testing showed that restricting the search to the phrase “value-based
14 healthcare” excluded too many relevant studies because authors use phrases such as “value-based
15 perspective” or “value-based equation” when referring to VBHC. Conversely, the term “value”
16 was too broad and yielded more than 40,000 mostly non-specific results. By using wildcard terms
17 indicated by stars we included many variations on the term ‘cost’.
18
19
20
21
22
23
24
25
26

27 **Eligibility criteria, record selection, and data collection**

28
29 We limited ourselves to peer-reviewed empirical research that measured or estimated costs in a
30 VBHC context. All the inclusion criteria and variables extracted are detailed in the **online**
31 **supplementary appendix**. The following variables, inspired by Porter [2] and the cost
32 measurement methods defined in the accounting literature, were noted:
33
34
35
36
37

- 38 • Cost types included (direct vs. indirect).
- 39 • Cost perspective (provider, payer, patient).
- 40 • Portion of the care path costed (full, partial).
- 41 • Cost measurement method used (as labelled by authors, verbatim).
- 42 • Cost measurement categories based on accounting definitions, e.g., direct costing,
43 absorption costing, step-down allocation, and other recognized methods [24].
- 44 • Consequences of the costing information generated.

51 **Patient and public involvement**

52
53
54
55 This study did not involve patients or the public in designing, executing, or reporting the research.
56
57

RESULTS

Record selection

Our four-person (ML, PP, HvE, KA) research group identified 3,275 relevant papers, of which 1,930 remained after removal of duplicates. We conducted a trial screening of 30 papers to test and further specify screening criteria. The screening process comprised two rounds as shown in **Figure 1**. In Round 1, ML and PP screened the titles and abstracts independently. When there was uncertainty about the eligibility of a paper, it was retained for full-text screening following Bramer [25]. We accepted 674 studies based on titles and abstracts, with a Cohen's kappa inter-rater reliability score of 0.78, indicating substantial agreement [26].

In Round 2, both ML and PP screened the full text of all 674 studies independently. Of these, 215 studies were seen as relevant for RQ1, with a Cohen's kappa of 0.76 between ML and PP. HvE was included in any resolution discussions needed. Finally, we assessed whether each paper discussed if or how the costing information facilitated VBHC (RQ2), yielding 49 instances where the costing method facilitated VBHC. This review was not registered.

Figure 1 here

Figure 1. PRISMA flowchart depicting the screening, exclusion and inclusion processes with two reviewers.

Descriptive characteristics

An overview of the included studies is provided in **Table 1**. Our earliest study is from 2005, with an upsurge in studies from 2017 onwards. Just under half (n=98, 45.6%) of studies were published in the last two years. An overwhelming majority are from the US (n= 178, 82.8%). Europe is the second most common continent with 22 (10.6%) studies of which 9 (4.2%) relate to Dutch healthcare.

The three largest medical specialty groups represented are surgical (n=99; 46.0%), oncology (n=37; 17.2%), and pediatrics (n=19; 8.8%). A complete list of the 215 studies included is summarized in the **online supplementary appendix**. Extracted data are available in the **supplementary file**.

Characteristic	n	%	Characteristic	n	%
Year published			Topic		
2005-2009	3	1.4%	Cardiology	5	2.3%
2010-2013	6	2.8%	Dermatology	1	0.5%
2014	6	2.8%	Emergency & acute care	11	5.1%
2015	7	3.3%	Endocrinology	3	1.4%
2016	9	4.2%	Surgical, <i>of which</i>	99	46.0%
2017	17	7.9%	Appendicitis, 2		
2018	28	13.0%	Abdominal, 6		
2019	41	19.1%	Bariatric, 2		
2020	43	20.0%	Cardiac/Thoracic, 12		
2021	51	23.7%	Colon/Rectal, 2		
2022 as per 1/1/2022	4	1.9%	Endocrine, 2		
Geography			Ear/Nose/Throat, 2		
Americas		84.3%	Gallbladder, 2		
Brazil	3		Liver, 2		
Canada	1		Neurosurgical, 5		
US <i>of which</i>	178		Orthopedic arthroplasty, 25		
Boston, 8			Orthopedic fracture, 12		
California, 18			Orthopedic rotator cuff repair, 2		
New York, 23			Orthopedic other, 3		
Texas, 12			Plastic surgery, 2		
Pennsylvania, 9			Spine, 13		
Other states, 108			other surgical, 5		
Asia		2.3%	Geriatrics	1	0.5%
China	1		Gynecology & obstetrics	8	3.7%
Iran	1		Infectious disease	1	0.5%
Kuwait	1		Internal medicine	12	5.6%
Lebanon	1		Multiple	3	1.4%
Singapore	1		Nephrology	1	0.5%
Europe		10.6%	Neurology	2	0.9%
Andalusia	1		Oncology	37	17.2%
Germany	1		Ophthalmology	3	1.4%
Italy	3		Orthopedic	1	0.5%
Norway	1		Pain medicine	3	1.4%
Serbia	1		Pediatrics <i>of which</i>	19	8.8%
Spain	2		Appendicitis, 3		
Netherlands	9		Emergency & acute care, 2		
UK	4		Neonatal, 3		
Oceania		1.9%	Oncology, 1		
Australia	4		Surgical, 5		
Transcontinental		0.9%	Surgical, plastic surgery, 2		
Russia	1		Other pediatric, 3		
Turkey	1		Toxicology	1	0.5%
			Urology	4	1.9%

Table 1. Characteristics of value-based healthcare studies that measure costs (n=215).

Which cost measurement methods are currently being used to facilitate VBHC?

To answer RQ1, we look at how costs were measured. A summary of our findings is presented in **Table 2**. The literature contains many overlapping and contradictory terms, as ‘costs’ can refer to insurer costs, reimbursements, hospital costs, or patient costs. About half of the studies (n=110, 51.2%) take a provider perspective, with costs calculated for the hospital or care facility. Many studies use charges or payments because hospital cost data are unavailable, considering charges to be a relevant proxy. Some studies use terms such as ‘costs’, ‘charges’, ‘prices’, ‘payments’, and ‘reimbursements’ interchangeably, making it difficult to differentiate [17,18,27–30]. For example, Jain et al. [17] stated, “The terms reimbursement, cost, and payment have been used interchangeably throughout the text to represent actual amounts paid by insurers.” Similarly, Robles et al, [30] explained, “Total hospital charges were utilized in this standardized costing analysis. Hospital charge data provides a relative measure of the ‘cost’ of episodes of care, as actual cost data are generally not ascertainable in the healthcare setting.” When calculating costs using TDABC, Ahluwalia et al. [31] called these costs ‘prices.’ To try to address this confusion, some recent studies refer to provider costs as the ‘true cost’ of care [6,7,9,19]. Some studies that compare several cost types [19,20] also differentiate ‘traditional hospital accounting’ costs from ‘true costs’ calculated with TDABC [6,9,20,32,33].

Characteristic	Studies		Perspectives	
	n	%	n	%
Cost perspective				
Provider	110	51.2%	111	51.6%
Insurer	103	47.9%	106	49.3%
Patient	2	0.9%	5	2.3%
N*	215		222	
		All studies (n=215)	Provider only	Payer only
Cost types included				
Direct	28	13.0%	24	2
Direct and indirect	177	81.9%	84	93
Unspecified	10	4.6%	2	8
Costs measurement implementation				
No, costs measured for purpose of study	34	15.7%	33	
Yes, costing method is implemented	39	17.6%	39	
Unspecified or not applicable	142	66.2%	38	102
Costs coverage				
Full care path	47	21.8%	30	16
Full care path (full surgical episode)	17	7.4%	13	4
Partial care path (full surgical episode)	22	8.3%	19	3
Partial care path	86	42.1%	37	49
Unspecified	43	19.9%	11	31

Note: N differs between studies and perspectives because seven studies measured two cost types.

Table 2. Characteristics of costing methods in value-based health care

We categorized studies based on the cost types included. Both direct and indirect costs were considered in 177 (81.9%) studies, while 28 (13.0%) papers only included direct costs.

Next, we looked at whether costs were calculated for a complete care path. We found 64 (29.8%) studies that measured costs for a full care path, of which 16 (7.4%) refer to full surgical episodes and label them as such without considering all the pre- or post-surgical costs. The remaining 86 (42.1%) measure costs of a partial care path.

Table 3 categorizes studies based on the costing method used. In those papers measuring costs within a care provider, we identified two clear categories that were in line with the

1
2
3 management accounting literature [24]. The first is ‘direct costing’ (n=23), where direct costs of
4 care are summed and indirect costs ignored. This implies that, if costs cannot be causally attributed
5 to the treatment of a specific patient, they are not considered and hence overlooked when making
6 managerial decisions [24].
7
8
9
10
11
12

13 The second category of studies considers both direct and indirect costs and uses ‘absorption
14 costing’, whereby indirect costs are allocated to patients based on an allocation key (a type of
15 formula used for allocating indirect costs) [31]. These studies include but are not limited to
16 TDABC (n=31) and ABC (n=7), where costs are allocated to individual care activities (such as a
17 consultation or treatment step). The remaining absorption costing papers (n=47) also consider
18 direct and indirect costs but do not report how indirect costs are allocated to activities. In the
19 absorption costing studies, authors may state that cost information was calculated based on
20 diagnosis-related group costs, micro-costing, bottom-up clinical costing, or hospital accounting
21 systems not further classified. A full list of all the terms used is presented in the **online**
22 **supplementary appendix.**
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Perspective	Method	n
<i>Provider</i>	Direct costs only	
	Direct costing	23
	Absorption costing	
	ABC	7
	TDABC	31
	Other	47
	Not specified	3
<i>Insurer</i>	Charges and reimbursements	
	Charges, reimbursements, claims	81
	Charges adjusted with cost-to-charge ratio	25
<i>Patient</i>	Out-of-pocket costs to patient	5

Note: The total number of studies here is 222 because 7 studies measure two cost types. Studies are classified based on actual costs included and methods described, not necessarily the labels used by the studies' authors.

Table 3. Overview of cost measurement methods used in value-based healthcare

How do these costing methods facilitate VBHC?

To answer RQ2, we extracted all the consequences related to the costing method as described in the papers. Here, like Etges et al. [3], we were looking for how the costing information facilitated VBHC. Note that not all the studies included to address RQ1 describe facilitating VBHC or the consequences of the cost information generated. The reported consequences were grouped inductively, revealing four categories:

1. Identification of cost drivers, in terms of cost items (e.g., staff costs, material costs) or activities (e.g., surgery, initial consult; n=48).
2. Comparison of costs across patient groups, care providers, or procedures (n=39).
3. Measured cost difference, or cost saving, while achieving equal or better care (n=26).
4. Suggested or measured care path improvements (n=40).

These studies are presented in **Table 4**. The studies reporting these facilitators used ABC (n=6), TDABC (n=29), other absorption costing methods (n=12), or direct costing (n=3).

Study Characteristics					Best practices				Value-Based consequences of costing information				
	Medical Specialty	Costing method	period	Centre	Study type	PM	EI	DO	CG	Compare costs across	ICD	MPS	Care path adjustment
[34]	Internal medicine	TDABC	partial	single	retro	yes	yes		items, activities		yes		suggested
[33]	Surgical, orthopedic, rotator cuff repair	TDABC	full (FSE)	single	retro	yes		yes	items, activities	surgeons, two alternative treatments	yes	yes, ± \$727 about the mean per patient	suggested
[4]	Cardiology, surgical	TDABC	full (FSE)	multi	retro	yes	yes	yes	items, activities	hospitals, procedures	yes	yes, estimate 51.0% of procedure cost	yes
[10]	Oncology	TDABC	full	single	retro	yes	yes	yes	items, activities	treatment care paths	yes	\$2,302 (25.0%) difference across treatments	suggested
[35]	Surgical, orthopedic	TDABC	full (FSE)	single	retro	yes			items, activities	patients	yes		suggested
[36]	Surgical, orthopedic	TDABC	full (FSE)	single	retro	yes			items, activities	patients	yes		suggested
[19]	Surgical, orthopedic	TDABC	full (FSE)	single	retro	yes		yes	items, activities	costing methods (TA and TDABC)	yes		suggested
[20]	Surgical, orthopedic	TDABC	full (FSE)	single	retro	yes		yes	items, activities	five treatments, cost vs. reimbursement	yes		
[37]	Pediatric, surgical, plastic surgery	TDABC	full (FSE)	multi	pro	yes		yes	items, activities	treatment care paths	yes	up to \$8900, but long-term outcomes yet unknown	suggested
[38]	Emergency & acute care	TDABC	full (multiple)	multi	retro	yes	yes	yes	items, activities	eight care paths for acute ureteral stones (patient journeys)	yes	yes, \$6614 difference across care paths	suggested
[39]	Surgical, orthopedic	TDABC	full (FSE)	single	retro	yes		yes	items, activities	surgeons	yes		suggested
[40]	Oncology	TDABC	partial	single	pro	yes	yes	yes	items, activities	treatments and individual care paths	yes	yes, cost difference of up to 3.33 times, depending on case mix	suggested
[41]	Oncology (incl. surgery)	TDABC	full	single	retro	yes		yes	items, activities		yes		suggested
[42]	Oncology	TDABC	partial (FSE)	single	retro	yes			items	pre and post implementation	yes	yes, mean cost savings of €309 per patient	yes
[43]	Cardiology	AC (other)	partial	multi	retro				items	patient journeys	yes		suggested
[44]	Emergency & acute care	AC (other)	partial	single	retro	yes			items	surgeons	yes		
[45]	Surgical, bariatric	AC (other)	full (FSE)	single	retro				items	treatment	yes		
[46]	Gynecology & obstetrics	AC (other)	full	single	retro	yes			items, activities	procedures	yes	yes, \$967 per patient	suggested
[47]	Emergency & acute care	AC (other)	partial	single	retro				items, activities		yes		
[48]	Surgical, colorectal	AC (other)	partial (FSE)	single	retro				items	intervention	yes	yes, reduced variable cost, similar total cost	yes
[21]	Surgical, orthopedics, fracture	ABC	partial (FSE)	single	retro				items	patients, patient groups, demographics	yes		
[49]	Surgical, orthopedic, arthroplasty	ABC	full (FSE)	single	both		yes	yes	items, activities	treatment care paths	yes	estimate €2,054,000 annually	yes
[50]	Surgical, spine	ABC	Full	single	retro	yes			items, activities	patients, patient groups	yes		suggested
[6]	Pediatric, surgical	TDABC	full (FSE)	single	both	yes		yes	items, activities	costing methods (TA and TDABC)	yes	20.0% and without care path alteration	suggested
[51]	Oncology	TDABC	full (FSE)	single	retro	yes	yes	yes	items, activities	treatment care paths	yes	yes, estimate for each 10.0% decrease in case duration, total costs could decrease by about 8.0%.	suggested
[31]	Surgical, orthopedic	TDABC	full (FSE)	single	pro	yes	yes	yes	items, activities	treatment care paths	yes	£2,018 per patient	suggested
[52]	Pediatric, neonatal	TDABC	partial	single	retro	yes	yes	yes	items, activities	Pre and post intervention	yes	yes, 36.0% or \$92,000 per tracheostomy care cycle	yes
[53]	Surgical, cardiac/thoracic	AC (other)	partial	multi	retro	yes			items	patients, implant devices	yes		suggested

[54]	Oncology, surgical	AC (other)	partial	single	retro				items		yes	yes, multiple		
[55]	Multiple	TDABC	full	multi, pilot	retro	yes	yes	yes	items, activities	before and after intervention (IPUs)	yes	yes, quarterly costs declined	suggested	
[56]	Oncology	TDABC	partial (PSE)	single	pro	yes		yes	items, activities	treatment care paths (parallel vs. induction design in OR)	yes	yes, estimate OR time reduction of 55 min, or \$,2818 missed revenue	suggested	
[57]	Surgical, orthopedics fracture	TDABC	partial (FSE)	single	both	yes			items		yes		suggested	
[58]	Surgical, foot debridement	TDABC	partial (FSE)	single	retro			yes	items	before and after intervention	yes		yes	
[59]	Ophthalmology	TDABC	full	single	retro	yes	yes	yes	items, activities		yes		suggested	
[60]	Gynecology & obstetrics, surgical	AC (other)	partial (FSE)	single	retro				items		yes		suggested	
[61]	Gynecology & obstetrics, surgical	AC (other)	partial (FSE)	single	retro				items		yes			
[62]	Multiple	Direct costing	partial	single	retro				items		yes			
[63]	Surgical, orthopedic	Direct costing	full (FSE)	multi	retro				items	intervention		yes, £255 per patient	yes	
[5]	Surgical, carpal tunnel release	TDABC	partial (FSE)	multi	retro	yes		yes	items, activities	multiple treatment care paths	yes	yes, 70.9% (\$27,103) and 31.6% (\$178)	yes	
[64]	Surgical, appendicitis	AC (other)	partial (FSE)	single	pro		yes	yes	items	pre and post intervention (dashboard)	yes	yes, decreased by \$496 per operation	yes	
[65]	Surgical, orthopedic	Direct costing	partial (FSE)	single	retro	yes			items	intervention	yes			
[8]	Urology	TDABC	partial	single	pro	yes		yes	items, activities		yes	yes, estimate two hours per cycle	suggested	
[66]	Pediatrics, appendicitis	TDABC	full (FSE)	single	pro	yes	yes	yes	items, activities	treatment care paths (pre and post intervention)	yes	11.0% cost reduction, and 51.0% hospitalization time reduction	yes, several	
[67]	Urology	AC (other)	partial	multi	retro		yes		items					
[7]	Oncology, surgical, 11 surgeries	TDABC	Partial (FSEs)	single	retro	yes			items, activities	potential staffing ratios	yes	estimate 13.0-28.0% per surgery type	modelled and suggested	
[9]	Oncology	TDABC	full	single	retro	yes	yes	yes	items, activities	treatments (high-dose vs. low-dose brachytherapy)	yes	\$2,668 difference across treatments	yes	
[68]	Urology	TDABC	partial (FSE)	single	retro	yes	yes		items, activities	five treatment care paths	yes	yes, 400.0% increase from least to most expensive pathways	suggested	
[32]	Surgical, neurosurgery	ABC	partial (FSE)	single	retro	yes			items, activities	patients	yes	yes, 25.0%	yes, several	
[69]	Surgical, neurosurgery	ABC	partial (FSE)	single	retro	yes			items, activities	patients	yes		suggested	
[70]	Pediatric plastic surgery	ABC	partial, 1 year	single	retro				items	patients	yes		suggested	
						Count	34	16	24		39	47	26	40

Note: ABC: Activity-Based costing; TDABC: Time-Driven activity-based costing; FSE: Full surgical episode; AC (other): Absorption costing, other; PSE: Partial surgical episode; Retro: Retrospective; Pro: Prospective; PM: Process mapping; EI: Expert input; DO: Direct Observation; CG: Cost grouping, cost items only or activities; ICD: Identify cost drivers; MPS: Measured provider cost savings (at equal or better care). Costing methods are classified based on actual reported costs and methods applied, not necessarily the labels used by authors.

Table 4. Costing method applications, method used, and consequences (ordered by year).

Activity-based costing

The six studies applying ABC justified this on the basis that it was the care provider's existing costing method. Three of these studies measured costs for a full surgical episode [21,32,69] as part of a longer care path, two measured costs for a full care path [49,50], and one measured costs of a partial care path [70]. While these studies all applied ABC, the ability to facilitate VBHC differed. Jacobs et al. [50] measured costs for a complete care path for patients with adult spinal deformity, a complex care path spanning about one year. The authors compared costs across patient groups and patients, identified major cost drivers, and suggested where to concentrate cost containment. Similarly, McLaughlin and colleagues [32,69] measured costs, identified cost drivers, and evaluated targeted cost containment initiatives. In one paper [32], the cost containment initiatives were informed by the cost information: activities with the highest costs were targeted for savings and a 25% reduction in total costs was achieved. In the other paper [69] they identified comorbidities and demographics that were strongly related to the total costs of patients undergoing neurosurgery, whereas Wise et al. [21] did not for geriatric hip-fracture patients while identifying cost drivers and comparing costs across patient groups. Vanni et al. [49] successfully predicted about €2 million annual cost savings associated with an enhanced recovery pathway.

Time-driven activity-based costing

The majority of the papers used to answer RQ2 involved TDABC. Significant cost drivers were identified linked to activities in a care path, and some suggested where to target improvement initiatives [4,6–8,10,33,40,59]. Many of the TDABC studies were able to suggest [6,8,10,19,33–38,40,41,51,55–59,68] or measure [5,9,31,42,52,66] care path improvements (see **Table 4**).

The lengths and specificities of the care path costs varied widely. Some studies were narrow in scope, calculating costs for subsections of a single care path or surgical procedure [6,8,38,39,56].

1
2
3 Isaacson et al. [8] calculated costs for cleaning a single reusable piece of equipment, while others
4
5 costed single surgical days [6], compared alternative surgeons [39], or anesthesia solutions within
6
7 a care path [56]. Within this group, McClintock et al. [38] took the broadest perspective by
8
9 mapping individual patient journeys.
10
11

12
13 The largest group (n=10) of TDABC studies measured costs across care paths within a
14
15 single provider and for a single diagnosis [9,10,31,33,37,40–42,51,66]. Typically, these studies
16
17 compared costs between a new intervention and the ‘usual’ care [9,10,31,51,52,66], or between
18
19 alternative care paths [33,37,40,42] in order to measure cost savings.
20
21

22
23 Some studies were broader in scope, costing multiple care paths or treatments within one
24
25 specialty [5,7,20,68], an entire department [34,59], multiple practice units [55], or providers [4].
26
27 Some compared ‘true costs’ calculated using TDABC across care providers within specialties or
28
29 care paths [4,37], while others argued that TDABC costs were too subjective to be compared across
30
31 hospitals [10,38]. While most studies compared costs across care paths, some also compared costs
32
33 across patient groups [19,35,36], or even individual patient journeys [38,40].
34
35
36

37
38 Technology played a prominent role in studies aiming to reduce costs. One study was able
39
40 to suggest how to use technology more efficiently [6], and some, by integrating technological
41
42 investments in the calculated TDABC costs, show how technology can reduce costs [37,40,51].
43
44

45
46 Conversely, studies using unspecified absorption methods [60,61] did not include
47
48 investments in technology, and this is surprising since absorption costing methods require indirect
49
50 costs to be allocated.
51

52
53 ***Analyses enabled by activity-based and time-driven activity-based costing***
54
55
56
57

1
2
3 Several of the ABC and TDABC studies compared costs calculated using traditional accounting
4 costs [6,19,20] or reimbursement amounts [20,21] and found that prices do not equal costs. Some
5 carried out quantitative analyses using cost information generated using ABC or TDABC
6 including regression analyses to identify correlations [7,33,35,36,40], compare patient groups
7 [20,35,36], and compare costs and outcomes across a matched patient sample [40].
8
9

10
11
12
13
14
15 Two recent studies [33,57] have conducted patient-level value analyses (PLVAs),
16 comparing patient-reported outcomes with patient-level TDABC costs. Wise et al. [33] did so for
17 rotator cuff repair surgery over a period of one year, while McCreary et al. [57] analyzed ankle
18 fractures. Both studies found costs to be unrelated to patient-reported outcome measures,
19 highlighting the need for further research. This suggests that patient-reported outcome measures
20 are not strongly associated with the costs of the care delivered, and that patient satisfaction may
21 depend on other factors such as their perceived experience with healthcare professionals.
22
23
24
25
26
27
28
29

30 31 *Other absorption costing methods and direct costing*

32
33
34 Other absorption costing methods reported in the studies were labelled as micro-costing (n=5),
35 bottom-up clinical costing [47], or were described but not labelled (n=6). Most were able to
36 identify cost drivers (n=12, for details see **Table 4**) and some compared costs within providers.
37
38
39 Notably, Robinson et al. [64] used the cost information to build and evaluate a dashboard that
40 provides real-time feedback to surgeons during operations and monthly summaries and thereby
41 decreases costs significantly. Some studies omitted certain cost categories such as equipment [61].
42
43
44
45
46
47
48 Direct costing enabled cost drivers to be identified [62,63,65], and in some cases granular cost
49 measurement.
50

51 52 *Best practices*

1
2
3 Having identified these four facilitators, we compared studies to find common practices. This is
4 particularly useful because costing methods are not labelled consistently. For example, many
5 studies refer to ABC as ‘bottom-up costing.’ To look beyond labels, we compared the actual
6 methodologies used to measure costs. We found that studies that were able to facilitate VBHC
7 used process mapping (n=34), expert input (n=17), and/or direct observations (n=24) when
8 measuring costs. These practices overlap with TDABC best practices, but are not exclusive to
9 TDABC, as shown in **Table 4**.
10
11
12
13
14
15
16
17
18
19

20 Studies that made specific care path improvement suggestions used process mapping, and
21 especially those involving multidisciplinary teams reported significant benefits [4,9,10,19]. This
22 approach enabled experts (doctors, care professionals, administrators) with the required
23 knowledge and experience to reflect critically on the process [4,9,10,19], resulting in actionable
24 suggestions. In comparison, studies that did not use process mapping tended to suggest minimizing
25 high-cost items (e.g., total operating time, nursing costs) but were unable to couple these
26 suggestions to specific activities or to chronological points in the care path. Commenting only on
27 cost items, and not identifying chronological points, limits the ability of cost information to steer
28 management towards where to focus process improvement initiatives.
29
30
31
32
33
34
35
36
37
38
39
40

41 Expert input while creating process maps or measuring costs was often cited by authors as
42 valuable, especially for estimating preparation time or other behind-the-scenes activities that do
43 not involve the patient but are critical to delivering care. Some studies that could not call on expert
44 input cited this as a limitation. A few cases also evaluated the impact of costing information, for
45 example by involving experts to evaluate a dashboard [64].
46
47
48
49
50
51
52

53 Finally, some studies involved direct observations, particularly those that calculated
54 process times to the minute or measured the costs of individual patient journeys.
55
56
57

DISCUSSION

This review focused on VBHC studies that have measured or estimated costs, and on identifying which costing methods can facilitate VBHC. By assessing the consequences of the costing methods used, we were able to identify characteristics of costing methods that do facilitate VBHC.

Previous research found that TDABC can facilitate VBHC through cost containment and process improvements [3,15]. We built on this by comparing value-based consequences across costing methods. While the field is young and alternatives seem limited, we have found considerable evidence that TDABC and ABC can indeed facilitate VBHC. As previously noted, TDABC is considerably easier to implement than ABC, which leads us to recommend it over ABC. We found no well-documented alternatives to TDABC or ABC in our review. However, not all the TDABC studies delivered the facilitating factors we have identified. We therefore emphasize the need to follow TDABC guidelines carefully and to explicitly document methods used. Several of the studies in this review simply stated that TDABC was applied, outsourced, used with incomplete costs, or used without listing exact cost rates.

The start and end points of care paths tend to be well documented by authors but are inconsistent. To view costs in relation to outcomes, as suggested by Porter [2], the total costs from start to finish of a trajectory should be included [71]. In many studies, the start and end points of cost measurement windows seem somewhat arbitrary but are still labeled as full care paths. Consequently, this results in inconsistencies across studies, hindering comparisons. Encouragingly, some of the more recent studies have measured costs across a genuine full care path and future research should do the same, explicitly defining start and end points. This would enable consistent comparisons across providers. As with the ICHOM standard outcome sets produced by the International Consortium for Health Outcomes Measurement, costs could be

1
2
3 catalogued and compared over full care paths. Indeed, in a recent expert consensus study, experts
4
5 agreed on the need to focus on full care paths [71].
6
7

8
9 Furthermore, we can see a trade-off in the specificity and length of the care path costed.
10
11 Studies that measure costs for elements of a care path (such as a surgical operation) can provide
12
13 detailed costs for that portion of the care path, but not total care costs for a patient because the
14
15 remainder of the care path is not included. Some surgical studies measured costs for partial care
16
17 paths, and often concluded that operating theatre time should be minimized due to high surgeon
18
19 and operating theatre costs. However, this conclusion has limited relevance for the value equation
20
21 [13] because it does not provide cost information for an entire care path, or advice on how to
22
23 circumvent surgery.
24
25

26
27
28 Studies that cost complete care paths appear to use less-detailed costing methods (due to
29
30 the sheer length of the care path) but are able to compute total costs of a patient's care. This enabled
31
32 benchmarking across providers, as well as cost comparisons of new vs. standard care, or of
33
34 treatment alternatives. This allowed providers to steer towards lower-cost outcomes to maximize
35
36 value. Future research should focus on measuring costs for full care paths, and on comparing costs
37
38 to outcomes as demonstrated in some of the more recently published studies in our review
39
40 [33,40,57].
41
42
43

44
45 Our review highlights the need to involve medical professionals in this process, both when
46
47 implementing costing methods as well as when evaluating the results. Future cost measurement
48
49 studies, and hospitals looking to implement TDABC, should involve multidisciplinary teams.
50
51 Studies that have involved medical professionals in the process of measuring costs and then using
52
53 the findings were able to improve care paths through improvement initiatives and/or dashboards.
54
55 This suggests that generating and using costing information should be viewed as a process. Future
56
57

1
2
3 qualitative research should follow this process to better understand the mechanisms through which
4
5 cost information impacts decision making, and the impact that staff involvement has on cost
6
7 containment. Previous research suggests that staff involvement is critical as it builds trust in the
8
9 accuracy of the data [72].
10

11 12 **Limitations and future research**

13
14
15
16 We must acknowledge several limitations related to the scope, breadth, and quality of the included
17
18 studies. First, our search strategy will have missed studies that measure costs but do not label the
19
20 study as VBHC-oriented. Not all TDABC studies make value-based claims or contributions and
21
22 may therefore be overlooked in our review. Additionally, not all studies explicitly discuss the
23
24 impact or consequences of the costing method applied, which may impact our findings. Future
25
26 qualitative research could usefully investigate TDABC implementations and evaluate whether the
27
28 facilitating factors found in this review are achieved. Second, sophisticated methods such as
29
30 TDABC are currently only used with predictable and/or short care paths such as orthopedic
31
32 surgery. Further research testing the feasibility and practicality of TDABC in different settings,
33
34 such as emergency on-call care, or longer care paths such as fertility treatment, is warranted.
35
36 Further, our findings may have limited generalizability across medical specialties as indicated in
37
38 **Table 1**. Finally, we have relied on the reporting of authors whose style and quality differs across
39
40 disciplines and journals. To an extent we circumvented this limitation by looking beyond the cost
41
42 measurement labels used by authors, extracting the costs included and methods used, and then
43
44 categorizing them using established accounting definitions. However, we cannot exclude the
45
46 possibility of errors due to a lack of explicit reporting in some of the studies reviewed.
47
48
49
50
51

52 53 **Conclusions**

1
2
3 This systematic review reveals that cost information, at the treatment or patient level, for complete
4 care paths does enable value-based decision making through several mechanisms. Such cost
5 information can direct quality and process improvement initiatives alongside informing
6 appropriate reimbursement levels. In the pursuit of VBHC, practitioners and academics are advised
7 to apply ABC or TDABC to estimate costs, using process mapping, expert input, and observations,
8 rather than relying on pricing information.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Patient and public involvement:** This study did not involve patients or the public in designing,
4 executing or reporting of the research.
5

6 **Acknowledgements:** We thank W.M. Bramer, biomedical information specialist from the
7 Erasmus MC. We also thank our fellow members of the value-based healthcare consortium,
8 involving Amsterdam UMC, Erasmus MC, Radboudumc and Erasmus University Rotterdam, led
9 by J.G.M. Jelsma and M.C. de Bruijne.
10

11
12 **Funding:** This work was supported by the Dutch Ministry of Health, Welfare and Sport (VWS)
13 through grant number 330843.
14

15 **Data sharing:** The supplementary appendix and data file are available from the Erasmus Data
16 Repository (DOI: 10.25397/eur.20279883).
17

18
19 **Competing interests:** The third author, KA, was a speaker at the 2022 TDABC conference and
20 was reimbursed for his stay in Lisbon by the TDABC consortium. Other authors: none declared.
21

22 **Contributors:** ML: study design, screening of titles and abstracts for inclusion, data analysis and
23 interpretation, writing. PP: screening of titles and abstracts for inclusion, assisted in writing. KA:
24 study design, assisted in interpretation of results, assisted in writing. HvE: study design,
25 screening of titles and abstracts for inclusion, data analysis and interpretation, assisted in writing.
26
27

28 **Patient consent for publication:** Not applicable.
29

30 **Ethics approval:** Ethical approval was not required for this systematic review as this review
31 used data from the public domain (published articles).
32
33

34 **ORCID ID**

35 Maura Leusder 0000-0001-7134-1003

36 Petra Porte 0000-0003-0228-1013

37 Kees Ahaus 0000-0001-9973-3746

38 Hilco van Elten 0000-0003-3909-5521
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Kaplan, Porter. How to solve the cost crisis in health care. *Harv Bus Rev* 2011;**89**:46–52, 54, 56-61 passim. <https://www.ncbi.nlm.nih.gov/pubmed/21939127>
- 2 Porter ME. What Is Value in Health Care? *N Engl J Med* 2010;**363**:2477–81. doi:10.1056/NEJMp1011024
- 3 Etges APB da S, Ruschel KB, Polanczyk CA, *et al.* Advances in Value-Based Healthcare by the Application of Time-Driven Activity-Based Costing for Inpatient Management: A Systematic Review. *Value Health* 2020;**23**:812–23. doi:10.1016/j.jval.2020.02.004
- 4 Etges, Cruz LN, Schlatter R, *et al.* Time-driven activity-based costing as a strategy to increase efficiency: An analyses of interventional coronary procedures. *Int J Health Plann Manage* Published Online First: 9 September 2021. doi:10.1002/hpm.3320
- 5 Martin JA, Mayhew CR, Morris AJ, *et al.* Using Time-Driven Activity-Based Costing as a Key Component of the Value Platform: A Pilot Analysis of Colonoscopy, Aortic Valve Replacement and Carpal Tunnel Release Procedures. *J Clin Med Res* 2018;**10**:314–20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=inleurlib_fft&cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=29511420
- 6 Bodar YJL, Srinivasan AK, Shah AS, *et al.* Time-Driven activity-based costing identifies opportunities for process efficiency and cost optimization for robot-assisted laparoscopic pyeloplasty. *J Pediatr Urol* 2020;**16**:460.e1-460.e10. doi:10.1016/j.jpuro.2020.05.146
- 7 French KE, Guzman AB, Rubio AC, *et al.* Value based care and bundled payments: Anesthesia care costs for outpatient oncology surgery using time-driven activity-based costing. *Healthc (Amst)* 2016;**4**:173–80. doi:10.1016/j.hjdsi.2015.08.007
- 8 Isaacson D, Ahmad T, Metzler I, *et al.* Defining the Costs of Reusable Flexible Ureteroscope Reprocessing Using Time-Driven Activity-Based Costing. *J Endourol* 2017;**31**:1026–31. doi:10.1089/end.2017.0463
- 9 Ilg AM, Laviana AA, Kamrava M, *et al.* Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer. *Brachytherapy* 2016;**15**:760–7. <https://www.ncbi.nlm.nih.gov/pubmed/27720202>
- 10 Dziemianowicz M, Burmeister J, Dominello M. Examining the Financial Impact of Altered Fractionation in Breast Cancer: An Analysis Using Time-Driven Activity-Based Costing. *Pract Radiat Oncol* 2021;**11**:245–51. doi:10.1016/j.prro.2021.01.003
- 11 Cattel D, Eijkenaar F. Value-Based Provider Payment Initiatives Combining Global Payments With Explicit Quality Incentives: A Systematic Review. *Med Care Res Rev* 2020;**77**:511–37. doi:10.1177/1077558719856775

- 12 Counte MA, Howard SW, Chang L, *et al.* Global Advances in Value-Based Payment and Their Implications for Global Health Management Education, Development, and Practice. *Front Public Health* 2018;**6**:379. doi:10.3389/fpubh.2018.00379
- 13 Porter ME, Teisberg EO. Redefining competition in health care. *Harv Bus Rev* 2004;**82**:64–76, 136. <https://www.ncbi.nlm.nih.gov/pubmed/15202288>
- 14 Rathert C, Mittler JN, Lee YSH. Patient-provider therapeutic connections to improve health care: Conceptual development and systematic review of patient measures. *Health Care Manage Rev* Published Online First: 14 February 2022. doi:10.1097/HMR.0000000000000339
- 15 Zanotto BS, Etges APB da S, Marcolino MAZ, *et al.* Value-Based Healthcare Initiatives in Practice: A Systematic Review. *J Healthc Manag* 2021;**66**:340. doi:10.1097/JHM-D-20-00283
- 16 Gibbons C, Porter I, Gonçalves-Bradley DC, *et al.* Routine provision of feedback from patient-reported outcome measurements to healthcare providers and patients in clinical practice. *Cochrane Database Syst Rev* 2021;**10**:CD011589. doi:10.1002/14651858.CD011589.pub2
- 17 Jain N, Brock JL, Phillips FM, *et al.* Chronic preoperative opioid use is a risk factor for increased complications, resource use, and costs after cervical fusion. *Spine J* 2018;**18**:1989–98. doi:10.1016/j.spinee.2018.03.015
- 18 Rice-Townsend S, Barnes JN, Hall M, *et al.* Variation in practice and resource utilization associated with the diagnosis and management of appendicitis at freestanding children's hospitals: Implications for value-based comparative analysis. *Ann Surg* 2014;**259**:1228–34. doi:10.1097/SLA.0000000000000246
- 19 Fang, Shaker J, Drew JM, *et al.* The Cost of Hip and Knee Revision Arthroplasty by Diagnosis-Related Groups: Comparing Time-Driven Activity-Based Costing and Traditional Accounting. *J Arthroplasty* 2021;**36**:2674-2679.e2673. doi:10.1016/j.arth.2021.03.041
- 20 Fang, Shaker J, Hart P-A, *et al.* Variation in the profit margin for different types of total joint arthroplasty. *J Bone Joint Surg Am* 2021;**Publish Ahead of Print**. doi:10.2106/JBJS.21.00223
- 21 Wise, Blaschke BL, Parikh HR, *et al.* Variation of the Inpatient Cost of Care in the Treatment of Isolated Geriatric Intertrochanteric Hip Fractures. *Geriatr Orthop Surg Rehabil* 2020;**11**. doi:10.1177/2151459320976533
- 22 Keel G, Savage C, Rafiq M, *et al.* Time-driven activity-based costing in health care: A systematic review of the literature. *Health Policy* 2017;**121**:755–63. doi:10.1016/j.healthpol.2017.04.013
- 23 Hoenigl M, Lo M, Coyne CJ, *et al.* 4th Generation HIV screening in the emergency department: net profit or loss for hospitals? *AIDS Care* 2021;:1–5. doi:10.1080/09540121.2021.1995838

- 1
- 2
- 3
- 4 24 Zimmerman JL. *Accounting For Decision Making and Control Seventh Edition*. McGraw-Hill 2011. <http://digilib.umpalopo.ac.id:8080/jspui/handle/123456789/151>
- 5
- 6
- 7 25 Bramer WM, Milic J, Mast F. Reviewing retrieved references for inclusion in systematic reviews using endnote. *J Med Libr Assoc* 2017;**105**:84–7. doi:10.5195/jmla.2017.111
- 8
- 9
- 10 26 Pérez J, Díaz J, Garcia-Martin J, *et al*. Systematic literature reviews in software engineering—enhancement of the study selection process using Cohen’s Kappa statistic. *Journal of Systems and Software* 2020;**168**:110657. doi:10.1016/j.jss.2020.110657
- 11
- 12
- 13
- 14 27 Burnett RA Iii, Yang J, Courtney PM, *et al*. Costs of unicompartmental compared with total knee arthroplasty : a matched cohort study over ten years. *Bone Joint J* 2021;**103-B**:23–31. doi:10.1302/0301-620X.103B6.BJJ-2020-2259.R1
- 15
- 16
- 17
- 18 28 Sun LL, Cao DY, Yang JX, *et al*. Value-based medicine analysis on loop electrosurgical excision procedure and CO2 laser vaporization for the treatment of cervical intraepithelial neoplasia 2. *J Obstet Gynaecol Res* 2012;**38**:1064–70. doi:10.1111/j.1447-0756.2011.01832.x
- 19
- 20
- 21
- 22
- 23
- 24 29 Cronin KJ, Mair SD, Hawk GS, *et al*. Increased Health Care Costs and Opioid Use in Patients with Anxiety and Depression Undergoing Rotator Cuff Repair. *Arthroscopy - Journal of Arthroscopic and Related Surgery* 2020;**36**:2655–60. doi:10.1016/j.arthro.2020.05.038
- 25
- 26
- 27
- 28 30 Robles AJ, Kornblith LZ, Hendrickson CM, *et al*. Health care utilization and the cost of posttraumatic acute respiratory distress syndrome care. *J Trauma Acute Care Surg* 2018;**85**:148–54. doi:10.1097/TA.0000000000001926
- 29
- 30
- 31
- 32 31 Ahluwalia R, Cook J, Raheman F, *et al*. Improving the efficiency of ankle fracture care through home care and day-surgery units: Delivering safe surgery on a value-based healthcare model. *Surgeon* Published Online First: November 2020. doi:10.1016/j.surge.2020.08.004
- 33
- 34
- 35
- 36 32 McLaughlin N, Upadhyaya P, Buxey F, *et al*. Value-based neurosurgery: measuring and reducing the cost of microvascular decompression surgery. *J Neurosurg* 2014;**121**:700–8. doi:10.3171/2014.5.JNS131996
- 37
- 38
- 39
- 40 33 Wise KL, Parikh HR, Okelana B, *et al*. Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care. *J Shoulder Elbow Surg* 2022;**31**:72–80. doi:10.1016/j.jse.2021.07.004
- 41
- 42
- 43
- 44 34 Alibrahim A, Abdulsalam Y, Al Mutawa S, *et al*. Towards value-based healthcare: Establishing baseline pharmacy care costs for diabetes management. *Int J Health Plann Manage* 2022;**37**:790–803. doi:10.1002/hpm.3370
- 45
- 46
- 47
- 48 35 Fang C, Hagar A, Gordon M, *et al*. Differences in Hospital Costs among Octogenarians and Nonagenarians Following Primary Total Joint Arthroplasty. *Geriatrics* 2021;**6**:26. doi:10.3390/geriatrics6010026
- 49
- 50
- 51
- 52 36 Fang C, Pagani N, Gordon M, *et al*. Episode-of-Care Costs for Revision Total Joint Arthroplasties by Decadal Age Groups. *Geriatrics* 2021;**6**:49. doi:10.3390/geriatrics6020049
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 37 Ganske IM, Sanchez K, Le E, *et al.* Time-Driven, Activity-Based Costing of Presurgical
4 Infant Orthopedics: A Critical Component of Establishing Value of Latham Appliance and
5 Nasoalveolar Molding. *Plastic & Reconstructive Surgery* 2021;**147**:444–54.
6 doi:10.1097/PRS.00000000000007669
7
- 8
9 38 McClintock TR, Friedlander DF, Feng AY, *et al.* Determining Variable Costs in the Acute
10 Urolithiasis Cycle of Care Through Time-Driven Activity-Based Costing. *Urology*
11 2021;**157**:107–13. doi:10.1016/j.urology.2021.05.102
12
- 13 39 Sethi RK, Pumpian RP, Drolet CE, *et al.* Utilizing Lean Methodology and Time-Driven
14 Activity-Based Costing Together: An Observational Pilot Study of Hip Replacement Surgery
15 Utilizing a New Method to Study Value-Based Health Care. *J Bone Joint Surg Am* Published
16 Online First: 14 October 2021. doi:10.2106/JBJS.21.00129
17
- 18 40 Thaker NG, Boyce-Fappiano D, Ning, *et al.* Activity-Based Costing of Intensity-Modulated
19 Proton versus Photon Therapy for Oropharyngeal Cancer. *International Journal of Particle*
20 *Therapy* 2021;**8**:374–82. doi:10.14338/IJPT-20-00042.1
21
22
- 23 41 Kukreja JB, Seif MA, Mery MW, *et al.* Utilizing time-driven activity-based costing to
24 determine open radical cystectomy and ileal conduit surgical episode cost drivers. *Urologic*
25 *Oncology: Seminars and Original Investigations* 2021;**39**:237.e1-237.e5.
26 doi:10.1016/j.urolonc.2020.11.030
27
- 28 42 Mattar D, Di Filippo A, Invento A, *et al.* Economic implications of ACOSOG Z0011 trial
29 application into clinical practice at the European Institute of Oncology. *Eur J Surg Oncol*
30 2021;**47**:2499–505. doi:10.1016/j.ejso.2021.06.016
31
32
- 33 43 Bueno H, Bernal JL, Jimenez-Jimenez V, *et al.* The Clinical outcomes, healthcare resource
34 utilization, and related costs (COHERENT) model. Application in heart failure patients. *Rev*
35 *Esp Cardiol* Published Online First: 20 October 2021. doi:10.1016/j.rec.2021.08.009
36
- 37 44 Casey M, Perera D, Enticott J, *et al.* High utilisers of emergency departments: the profile and
38 journey of patients with mental health issues. *Int J Psychiatry Clin Pract* 2021;**25**:316–24.
39 doi:10.1080/13651501.2021.1904998
40
- 41 45 Cohen RV, Nishikawa AM, Ribeiro RA, *et al.* Surgical Management of Obesity in Brazil:
42 Proposal for a Value-Based Healthcare Model and Preliminary Results. *Value in Health*
43 *Regional Issues* 2021;**26**:10–4. doi:10.1016/j.vhri.2020.11.005
44
45
- 46 46 Negrini R, da Silva Ferreira RD, Guimaraes DZ. Value-based care in obstetrics: comparison
47 between vaginal birth and caesarean section. *BMC Pregnancy Childbirth* 2021;**21**:333.
48 doi:10.1186/s12884-021-03798-2
49
- 50 47 Fernando-Canavan L, Gust A, Hsueh A, *et al.* Measuring the economic impact of hospital-
51 acquired complications on an acute health service. *Aust Health Rev* 2021;**45**:135–42.
52 doi:10.1071/AH20126
53
54
55
56
57
58
59
60

- 1
2
3 48 Khanijow AN, Wood LN, Xie R, *et al.* The impact of an enhanced recovery program (ERP)
4 on the costs of colorectal surgery. *Am J Surg* 2021;**222**:186–92.
5 doi:10.1016/j.amjsurg.2020.11.034
6
7
8 49 Vanni F, Foglia E, Pennestrì F, *et al.* Introducing enhanced recovery after surgery in a high-
9 volume orthopaedic hospital: a health technology assessment. *BMC Health Serv Res*
10 2020;**20**:773. doi:10.1186/s12913-020-05634-3
11
12 50 Jacobs K, Dewilde T, Vandoren C, *et al.* Variability in hospital costs of Adult Spinal
13 Deformity care. *Spine* 2020;**45**:1221–8. doi:10.1097/BRS.0000000000003497
14
15 51 Ning MS, Venkatesan AM, Stafford RJ, *et al.* Developing an intraoperative 3T MRI-guided
16 brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and
17 value-based analysis. *Brachytherapy* 2020;**19**:427–37. doi:10.1016/j.brachy.2019.09.010
18
19 52 Caloway C, Yamasaki A, Callans KM, *et al.* Quantifying the benefits from a care coordination
20 program for tracheostomy placement in neonates. *Int J Pediatr Otorhinolaryngol* 2020;**134**.
21 doi:10.1016/j.ijporl.2020.110025
22
23 53 Burnhope E, Waring M, Guilder A, *et al.* A systematic approach towards implementing value-
24 based health care in heart failure: Understandings from retrospective analysis methods in
25 South London. *Health Serv Manage Res* Published Online First: 2020.
26 doi:10.1177/0951484820971442
27
28 54 Lenfant L, Sawczyn G, Kim S, *et al.* Single-institution Cost Comparison: Single-port Versus
29 Multiport Robotic Prostatectomy. *European Urology Focus* Published Online First: 2020.
30 doi:10.1016/j.euf.2020.06.010
31
32 55 Hernandez A, Kaplan RS, Witkowski ML, *et al.* Navy Medicine Introduces Value-Based
33 Health Care. *Health Aff* 2019;**38**:1393–400. doi:10.1377/hlthaff.2019.00280
34
35 56 Basto J, Chahal R, Riedel B. Time-driven activity-based costing to model the utility of parallel
36 induction redesign in high-turnover operating lists. *Healthc Pap* 2019;**7**.
37 doi:10.1016/j.hjdsi.2019.01.003
38
39 57 McCreary DL, Dugarte AJ, Vang S, *et al.* Patient-Level Value Analysis: An Innovative
40 Approach to Optimize Care Delivery. *J Orthop Trauma* 2019;**33**:S49–52.
41 doi:10.1097/BOT.0000000000001624
42
43 58 Ahluwalia R, Vainieri E, Tam J, *et al.* Surgical Diabetic Foot Debridement: Improving
44 Training and Practice Utilizing the Traffic Light Principle. *Int J Low Extrem Wounds*
45 2019;**18**:279–86. doi:10.1177/1534734619853657
46
47 59 Kurt P, Saban M, Cankaya F, *et al.* Time-Driven Activity-Based Costing in the
48 Ophthalmology Department of State Hospital: a Case Study. *Fresenius Environ Bull*
49 2019;**28**:2754–70.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 60 Danilyants N, MacKoul P, van der Does L, *et al.* A value-based evaluation of minimally
4 invasive hysterectomy approaches. *Gynecol Surg* 2019;**16**:5. doi:10.1186/s10397-019-1057-
5 9
6
7
8 61 Danilyants N, MacKoul P, Baxi R, *et al.* Value-based assessment of hysterectomy approaches.
9 *J Obstet Gynaecol Res* 2019;**45**:389–98. doi:10.1111/jog.13853
10
11 62 Chatfield SC, Volpicelli FM, Adler NM, *et al.* Bending the cost curve: Time series analysis
12 of a value transformation programme at an academic medical centre. *BMJ Qual Saf*
13 2019;**28**:449–58. doi:10.1136/bmjqs-2018-009068
14
15 63 Featherall J, Brigati DP, Arney AN, *et al.* Effects of a Total Knee Arthroplasty Care Pathway
16 on Cost, Quality, and Patient Experience: Toward Measuring the Triple Aim. *J Arthroplasty*
17 2019;**34**:2561–8. doi:10.1016/j.arth.2019.06.011
18
19 64 Robinson JR, Carter NH, Gibson C, *et al.* Improving the value of care for appendectomy
20 through an individual surgeon-specific approach. *J Pediatr Surg* 2018;**53**:1181–
21 6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994354/pdf/nihms949182.pdf>
22
23 65 Karns MR, Jones DL, Todd DC, *et al.* Patient- and Procedure-Specific Variables Driving
24 Total Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction. *Orthop J Sports*
25 *Med* 2018;**6**:2325967118788543. doi:10.1177/2325967118788543
26
27 66 Yu YR, Abbas PI, Smith CM, *et al.* Time-driven activity-based costing: A dynamic value
28 assessment model in pediatric appendicitis. *J Pediatr Surg* 2017;**52**:1045–9.
29 doi:10.1016/j.jpedsurg.2017.03.032
30
31 67 Parra E, Arenas MD, Alonso M, *et al.* Assessing value-based health care delivery for
32 haemodialysis. *J Eval Clin Pract* 2017;**23**:477–85. doi:10.1111/jep.12483
33
34 68 Kaplan AL, Agarwal N, Setlur NP, *et al.* Measuring the cost of care in benign prostatic
35 hyperplasia using time-driven activity-based costing (TDABC). *Healthcare*. 2015;**3**:43–8.
36 doi:10.1016/j.hjdsi.2014.09.007
37
38 69 McLaughlin N, Martin NA, Upadhyaya P, *et al.* Assessing the cost of contemporary pituitary
39 care. *Neurosurg Focus* 2014;**37**:E7. doi:10.3171/2014.8.FOCUS14445
40
41 70 Abbott MM, Meara JG. A microcosting approach for isolated, unilateral cleft lip care in the
42 first year of life. *Plast Reconstr Surg* 2011;**127**:333–9. doi:10.1097/PRS.0b013e3181f95af3
43
44 71 Steinmann G, Delnoij D, van de Bovenkamp H, *et al.* Expert consensus on moving towards a
45 value-based healthcare system in the Netherlands: a Delphi study. *BMJ Open*
46 2021;**11**:e043367. doi:10.1136/bmjopen-2020-043367
47
48 72 Hoozée S, Bruggeman W. Identifying operational improvements during the design process of
49 a time-driven ABC system: The role of collective worker participation and leadership style.
50 *Manag Acc Res* 2010;**21**:185–98. doi:10.1016/j.mar.2010.01.003
51
52
53
54
55
56
57
58
59
60

Page 33 of 72
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Unique studies identified through database search (n=3,874)
Embase, 1,254
Medline, 1,160
EBSCOhost, 482
Web of Science, 978

Studies screened after removal of duplicates (n=1,930)
Cohen's kappa 0.77 substantial agreement

Studies excluded based on title and/or abstract
(n=1,256)

Full text studies assessed for eligibility (n=674)
Cohen's kappa 0.78 substantial agreement

Studies excluded during a full paper review (n=459)
Outside time frame, 11
Language, 1
Paper unavailable, 26
Not peer reviewed original research, 64
Review, 105
Not about VBHC, 3
No costs measured or estimated, 249

Studies included in qualitative synthesis for research
question 1 (n=215)

Studies included in qualitative synthesis for research
question 2 (n=49)

SUPPLEMENT DIGITAL CONTENT

1 Search strategy

2003-1/1/2022

embase.com

(((value-based OR valuebased) NOT ((value-based OR valuebased) NEXT/2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR vbhc OR vb-hc):ab,ti) AND ('cost'/de OR 'health care cost'/de OR 'time driven activity based costing'/de OR 'activity based costing'/de OR (cost OR costs OR costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource NEAR/3 assignment*) OR (direct* NEAR/3 estimat*)):ab,ti) NOT (cost NEXT/1 (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)):ti NOT [conference abstract]/lim AND ([dutch]/lim OR [English]/lim)

Medline Ovid

(((value-based OR valuebased) NOT ((value-based OR valuebased) ADJ2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR vbhc OR vb-hc).ab,ti.) AND ("Costs and Cost Analysis"/ OR Health Care Costs/ OR (cost OR costs OR costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource ADJ3 assignment*) OR (direct* ADJ3 estimat*)):ab,ti.) NOT (cost ADJ (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)):ti. AND (dutch.la. OR english.la.)

CINAHL EBSCOhost

(((TI(value-based OR valuebased) OR AB (value-based OR valuebased)) NOT (TI((value-based OR valuebased) N2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR AB((value-based OR valuebased) N2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*))) OR TI(vbhc OR vb-hc) OR AB(vbhc OR vb-hc))) AND ((MH "Costs and Cost Analysis" OR MH Health Care Costs OR MH Value-Based Health Care OR AB(costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource N2 assignment*) OR (direct* N2 estimat*))) OR (TI(cost OR costs) NOT TI(cost N1 (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)))) AND LA(dutch OR english)

Web of science

TS=(((value-based OR valuebased) NOT ((value-based OR valuebased) NEAR/2 (insuran* OR purchas* OR pric* OR reimburse* OR contract* OR payment* OR partnership*)) OR vbhc OR vb-hc)) AND ((cost OR costs OR costing OR microcosting OR macrocosting OR tdabc OR abc OR (resource NEAR/2 assignment*) OR (direct* NEAR/2 estimat*))) AND (care OR health* OR medicine OR clinical OR hospital* OR surger* OR therap* OR patient* OR oncolog* OR drugs OR medication* OR cancer* OR pharmac*) NOT TI=(cost NEAR/1 (eval* OR benefit* OR effectiv* OR utilit* OR consequen* OR minimi* OR outcome* OR reduc* OR saving*)) AND DT=(article) AND LA=(dutch OR english)

1
2
3 **SUPPLEMENT DIGITAL CONTENT**

4 **2 Inclusion/exclusion criteria, data extracted**

5 ***Eligibility criteria***

6 Language	English or Dutch
7 Publication date	Between 2003 and 1.1.2022
8 Research type	Original, peer-reviewed, empirical research
9 Terms	Any variation of the terms “cost” and “value-based” in title or abstract
10 Full text content	Costs of an intervention, treatment, care path, or other healthcare activity must have been measured or estimated.

11 ***Variables collected***

12 Descriptive	Name, year published, authors, medical specialty, location
13 Costs included	Based on author reporting we classify studies into one of two categories: <ul style="list-style-type: none"> • Direct costs only • Direct and indirect costs
14 Cost perspective	We inductively classify studies into one or more categories: <ul style="list-style-type: none"> • Provider costs (e.g. hospital) • Payer costs (reimbursements, charges, payments) • Patient costs (out-of-pocket costs to patient)
15 Care path length	We inductively classify studies into one of the following categories: <ul style="list-style-type: none"> • Full care path • Full care path, full surgical episode (FSE) • Partial care path, full surgical episode (PSE) • Partial care path
16 Costing method label	Costing method used, as labelled by the authors. These include traditional cost accounting, ABC, or ABC excluding overheads, TDABC, or TDABC with some cost categories omitted, microcosting, bottom-up clinical costing, reference pricing, relative value units or DRG costs, direct variable costs, or direct costs as an estimate of total cost, reimbursements, charges, claims, payments, and cost-to-charge ratio.
17 Costing method applied	Costing method applied, based on method described by authors. We classified studies using management accounting literature (e.g., Zimmerman, 2015). We found the following categories represented in the literature. <ul style="list-style-type: none"> • Direct costing • Absorption costing, which includes: <ul style="list-style-type: none"> ○ ABC ○ TDABC. ○ Other <p>Cases using reimbursements or charges to estimate costs were coded as ‘reimbursements’ or ‘cost-to-charge ratio’.</p>
18 Facilitating factors	If the study discussed the consequences of the costing information generated, we collected the consequences. After we collected all consequences, we categorized these inductively.

19 *Note:* ABC: Activity-based costing; TDABC: Time-driven activity-based costing

20 **Supplement digital content table 1.** Eligibility criteria and data collected.

SUPPLEMENT DIGITAL CONTENT

3 All studies included in RQ1

Perspective	Method	n	studies
<i>Provider</i>	Direct costs only		
	Direct costing	23	[1–23]
	Absorption costing		
	ABC	7	[24–30]
	TDABC	31	[31–61]
	Other	47	[62–108]
	Not specified	3	[109–111]
<i>Insurer</i>	Charges & reimbursements		
	Charges, reimbursements, claims	81	[23,39,112–190]
	Charges adjusted with cost-to charge ratio	25	[108,191–214]
<i>Patient</i>	Out-of-pocket costs to patient	5	[106,126,130,215,216]

Note: Total number of studies here is 222; seven studies measure two cost types[23,38,39,106,108,126,130]. Studies are classified based on actual costs included and methods described, not necessarily the labels used by authors.

Supplement digital content table 2. Overview of cost measurement methods used in value-based healthcare with references

References of all studies included in research question 1

Reference numbers start at 1, these differ from the manuscript.

- 1 Chatfield SC, Volpicelli FM, Adler NM, *et al.* Bending the cost curve: Time series analysis of a value transformation programme at an academic medical centre. *BMJ Qual Saf* 2019;**28**:449–58.
- 2 Featherall J, Brigati DP, Arney AN, *et al.* Effects of a Total Knee Arthroplasty Care Pathway on Cost, Quality, and Patient Experience: Toward Measuring the Triple Aim. *J Arthroplasty* 2019;**34**:2561–8.
- 3 Karns MR, Jones DL, Todd DC, *et al.* Patient- and Procedure-Specific Variables Driving Total Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction. *Orthop J Sports Med* 2018;**6**:2325967118788543.
- 4 Tan RYC, Met-Domestici M, Zhou K, *et al.* Using quality improvement methods and time-driven activity-based costing to improve value-based cancer care delivery at a Cancer Genetics clinic. *J Oncol Pract* 2016;**12**:e320–31.
- 5 Ravikumar TS, Sharma C, Marini C, *et al.* A validated value-based model to improve hospital-wide perioperative outcomes: Adaptability to combined medical/surgical inpatient cohorts. *Ann Surg* 2010;**252**:486–96.

- 6 Fortmann AL, Walker C, Barger K, *et al.* Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care. *Popul Health Manag* 2020;**23**:467–75.
- 7 Ryan SP, Plate JF, Black CS, *et al.* Value-Based Care Has Not Resulted in Biased Patient Selection: Analysis of a Single Center’s Experience in the Care for Joint Replacement Bundle. *J Arthroplasty* 2019;**34**:1872–5.
- 8 Plate JF, Ryan SP, Black CS, *et al.* No Changes in Patient Selection and Value-Based Metrics for Total Hip Arthroplasty After Comprehensive Care for Joint Replacement Bundle Implementation at a Single Center. *J Arthroplasty* 2019;**34**:1581–4.
- 9 Jakovljevic M, Zugic A, Rankovic A, *et al.* Radiation therapy remains the key cost driver of oncology inpatient treatment. *J Med Econ* 2015;**18**:29–36.
- 10 Siu A, Patel J, Prentice HA, *et al.* A Cost Analysis of Regional Versus General Anesthesia for Carotid Endarterectomy. *Ann Vasc Surg* 2017;**39**:189–94.
- 11 Monroe GR, Frederix GW, Savelberg SMC, *et al.* Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. *Genet Med* 2016;**18**:949–56.
- 12 Lott A, Haglin J, Saleh H, *et al.* Using a Validated Middle-Age and Geriatric Risk Tool to Identify Early (<48 Hours) Hospital Mortality and Associated Cost of Care. *J Orthop Trauma* 2018;**32**:349–53.
- 13 Reilly CA, Doughty HP, Werth PM, *et al.* Creating a Value Dashboard for Orthopaedic Surgical Procedures. *J Bone Joint Surg Am* 2020;**102**:1849–56.
- 14 Konda SR, Lott A, Egol KA. The Coming Hip and Femur Fracture Bundle: A New Inpatient Risk Stratification Tool for Care Providers. *Geriatr Orthop Surg Rehabil* 2018;**9**:215145931879531.
- 15 Cremins M, Vellanky S, McCann G, *et al.* Considering healthcare value and associated risk factors with postoperative urinary retention after elective laminectomy. *Spine J* 2020;**20**:701–7.
- 16 Edholm K, Lappé K, Kukhareva P, *et al.* Reducing Diabetic Ketoacidosis Intensive Care Unit Admissions Through an Electronic Health Record-Driven, Standardized Care Pathway. *J Healthc Qual* 2020;**42**:e66–74.
- 17 Keating CL, Dixon JB, Moodie ML, *et al.* Cost-Efficacy of Surgically Induced Weight Loss for the Management of Type 2 Diabetes A randomized controlled trial. *Diabetes Care* 2009;**32**:580–4.
- 18 Feizpour CA, Patel, Syed MA, *et al.* Enhanced recovery in liver transplantation: A value-based approach to complex surgical care. *Surgery* 2021;**170**:1830–7.

- 19 Gillis HC, Dolan K, Sargel CL, *et al.* A quality improvement approach to influence value-based mucolytic use in the PICU. *Pediatr Qual Saf* 2021;**6**:e438.
- 20 Konda SR, Johnson JR, Dedhia N, *et al.* Can We Stratify Quality and Cost for Older Patients With Proximal and Midshaft Humerus Fractures? *Geriatr Orthop Surg Rehabil* 2021;**12**:2151459321992742.
- 21 Panda N, Shagabayeva L, Comrie CE, *et al.* Drivers of Cost Associated With Minimally Invasive Esophagectomy. *Ann Thorac Surg* 2022;**113**:264–70.
- 22 Wang W, Li E, Campbell K, *et al.* Economic analysis on adoption of biosimilar granulocyte colony-stimulating factors in patients with nonmyeloid cancer at risk of febrile neutropenia within the Oncology Care Model framework. *JCO Oncol Pract* 2021;**17**:e1139–49.
- 23 Gray CF, Prieto HA, Deen JT, *et al.* Bundled Payment Creep: Institutional Redesign for Primary Arthroplasty Positively Affects Revision Arthroplasty. *J Arthroplasty* 2019;**34**:206–10.
- 24 Wise, Blaschke BL, Parikh HR, *et al.* Variation of the Inpatient Cost of Care in the Treatment of Isolated Geriatric Intertrochanteric Hip Fractures. *Geriatr Orthop Surg Rehabil* 2020;**11**. doi:10.1177/2151459320976533
- 25 McLaughlin N, Upadhyaya P, Buxey F, *et al.* Value-based neurosurgery: measuring and reducing the cost of microvascular decompression surgery. *J Neurosurg* 2014;**121**:700–8.
- 26 Abbott MM, Meara JG. A microcosting approach for isolated, unilateral cleft lip care in the first year of life. *Plast Reconstr Surg* 2011;**127**:333–9.
- 27 McLaughlin N, Martin NA, Upadhyaya P, *et al.* Assessing the cost of contemporary pituitary care. *Neurosurg Focus* 2014;**37**:E7.
- 28 Vanni F, Foglia E, Pennestrì F, *et al.* Introducing enhanced recovery after surgery in a high-volume orthopaedic hospital: a health technology assessment. *BMC Health Serv Res* 2020;**20**:773.
- 29 Jacobs K, Dewilde T, Vandoren C, *et al.* Variability in hospital costs of Adult Spinal Deformity care. *Spine* 2020;**45**:1221–8.
- 30 Kaul S, Korgenski EK, Ying J, *et al.* A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. *Cancer Med* 2016;**5**:221–9.
- 31 Etges, Cruz LN, Schlatter R, *et al.* Time-driven activity-based costing as a strategy to increase efficiency: An analyses of interventional coronary procedures. *Int J Health Plann Manage* Published Online First: 9 September 2021. doi:10.1002/hpm.3320
- 32 Martin JA, Mayhew CR, Morris AJ, *et al.* Using Time-Driven Activity-Based Costing as a Key Component of the Value Platform: A Pilot Analysis of Colonoscopy, Aortic Valve Replacement and Carpal Tunnel Release Procedures. *J Clin Med Res* 2018;**10**:314–20.

- 1
2
3 33 Bodar YJL, Srinivasan AK, Shah AS, *et al.* Time-Driven activity-based costing identifies opportunities for process efficiency and cost optimization for robot-assisted laparoscopic pyeloplasty. *J Pediatr Urol* 2020;**16**:460.e1-460.e10.
- 4
5
6
7
8 34 French KE, Guzman AB, Rubio AC, *et al.* Value based care and bundled payments: Anesthesia care costs for outpatient oncology surgery using time-driven activity-based costing. *Healthc (Amst)* 2016;**4**:173–80.
- 9
10
11
12 35 Isaacson D, Ahmad T, Metzler I, *et al.* Defining the Costs of Reusable Flexible Ureteroscope Reprocessing Using Time-Driven Activity-Based Costing. *J Endourol* 2017;**31**:1026–31.
- 13
14
15
16 36 Ilg AM, Laviana AA, Kamrava M, *et al.* Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer. *Brachytherapy* 2016;**15**:760–7.
- 17
18
19
20 37 Dziemianowicz M, Burmeister J, Dominello M. Examining the Financial Impact of Altered Fractionation in Breast Cancer: An Analysis Using Time-Driven Activity-Based Costing. *Pract Radiat Oncol* 2021;**11**:245–51.
- 21
22
23
24 38 Fang, Shaker J, Drew JM, *et al.* The Cost of Hip and Knee Revision Arthroplasty by Diagnosis-Related Groups: Comparing Time-Driven Activity-Based Costing and Traditional Accounting. *J Arthroplasty* 2021;**36**:2674-2679.e2673.
- 25
26
27
28 39 Fang, Shaker J, Hart P-A, *et al.* Variation in the profit margin for different types of total joint arthroplasty. *J Bone Joint Surg Am* 2021;**Publish Ahead of Print**. doi:10.2106/JBJS.21.00223
- 29
30
31
32 40 Ahluwalia R, Cook J, Raheman F, *et al.* Improving the efficiency of ankle fracture care through home care and day-surgery units: Delivering safe surgery on a value-based healthcare model. *Surgeon* Published Online First: November 2020. doi:10.1016/j.surge.2020.08.004
- 33
34
35
36 41 Wise KL, Parikh HR, Okelana B, *et al.* Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care. *J Shoulder Elbow Surg* 2022;**31**:72–80.
- 37
38
39
40 42 Hernandez A, Kaplan RS, Witkowski ML, *et al.* Navy Medicine Introduces Value-Based Health Care. *Health Aff* 2019;**38**:1393–400.
- 41
42
43
44 43 Ning MS, Venkatesan AM, Stafford RJ, *et al.* Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. *Brachytherapy* 2020;**19**:427–37.
- 45
46
47
48 44 Yu YR, Abbas PI, Smith CM, *et al.* Time-driven activity-based costing: A dynamic value assessment model in pediatric appendicitis. *J Pediatr Surg* 2017;**52**:1045–9.
- 49
50
51
52 45 Basto J, Chahal R, Riedel B. Time-driven activity-based costing to model the utility of parallel induction redesign in high-turnover operating lists. *Healthc Pap* 2019;**7**. doi:10.1016/j.hjdsi.2019.01.003
- 53
54
55
56
57
58
59
60

- 1
2
3 46 McCreary DL, Dugarte AJ, Vang S, *et al.* Patient-Level Value Analysis: An Innovative
4 Approach to Optimize Care Delivery. *J Orthop Trauma* 2019;**33**:S49–52.
5
6
7 47 Caloway C, Yamasaki A, Callans KM, *et al.* Quantifying the benefits from a care
8 coordination program for tracheostomy placement in neonates. *Int J Pediatr*
9 *Otorhinolaryngol* 2020;**134**. doi:10.1016/j.ijporl.2020.110025
10
11 48 Ahluwalia R, Vainieri E, Tam J, *et al.* Surgical Diabetic Foot Debridement: Improving
12 Training and Practice Utilizing the Traffic Light Principle. *Int J Low Extrem Wounds*
13 2019;**18**:279–86.
14
15 49 Kaplan AL, Agarwal N, Setlur NP, *et al.* Measuring the cost of care in benign prostatic
16 hyperplasia using time-driven activity-based costing (TDABC). *Healthcare*. 2015;**3**:43–8.
17 doi:10.1016/j.hjdsi.2014.09.007
18
19 50 Kurt P, Saban M, Cankaya F, *et al.* Time-Driven Activity-Based Costing in the
20 Ophthalmology Department of State Hospital: a Case Study. *Fresenius Environ Bull*
21 2019;**28**:2754–70.
22
23 51 Alibrahim A, Abdulsalam Y, Al Mutawa S, *et al.* Towards value-based healthcare:
24 Establishing baseline pharmacy care costs for diabetes management. *Int J Health Plann*
25 *Manage* 2022;**37**:790–803.
26
27 52 Fang C, Hagar A, Gordon M, *et al.* Differences in Hospital Costs among Octogenarians and
28 Nonagenarians Following Primary Total Joint Arthroplasty. *Geriatrics* 2021;**6**:26.
29
30 53 Fang C, Pagani N, Gordon M, *et al.* Episode-of-Care Costs for Revision Total Joint
31 Arthroplasties by Decadal Age Groups. *Geriatrics* 2021;**6**:49.
32
33 54 Ganske IM, Sanchez K, Le E, *et al.* Time-Driven, Activity-Based Costing of Presurgical
34 Infant Orthopedics: A Critical Component of Establishing Value of Latham Appliance and
35 Nasoalveolar Molding. *Plastic & Reconstructive Surgery* 2021;**147**:444–54.
36
37 55 McClintock TR, Friedlander DF, Feng AY, *et al.* Determining Variable Costs in the Acute
38 Urolithiasis Cycle of Care Through Time-Driven Activity-Based Costing. *Urology*
39 2021;**157**:107–13.
40
41 56 Sethi RK, Pumpian RP, Drolet CE, *et al.* Utilizing Lean Methodology and Time-Driven
42 Activity-Based Costing Together: An Observational Pilot Study of Hip Replacement
43 Surgery Utilizing a New Method to Study Value-Based Health Care. *J Bone Joint Surg Am*
44 Published Online First: 14 October 2021. doi:10.2106/JBJS.21.00129
45
46 57 Thaker NG, Boyce-Fappiano D, Ning, *et al.* Activity-Based Costing of Intensity-Modulated
47 Proton versus Photon Therapy for Oropharyngeal Cancer. *International Journal of Particle*
48 *Therapy* 2021;**8**:374–82.
49
50 58 Kukreja JB, Seif MA, Mery MW, *et al.* Utilizing time-driven activity-based costing to
51 determine open radical cystectomy and ileal conduit surgical episode cost drivers. *Urologic*
52 *Oncology: Seminars and Original Investigations* 2021;**39**:237.e1-237.e5.
53
54
55
56
57
58
59
60

- 1
2
3 59 Mattar D, Di Filippo A, Invento A, *et al.* Economic implications of ACOSOG Z0011 trial
4 application into clinical practice at the European Institute of Oncology. *Eur J Surg Oncol*
5 2021;**47**:2499–505.
6
7 60 McLaughlin N, Burke MA, Setlur NP, *et al.* Time-driven activity-based costing: a driver for
8 provider engagement in costing activities and redesign initiatives. *Neurosurg Focus*
9 2014;**37**:E3.
10
11 61 Jacir A, Mendoza D, Dean E. The cost of care during times of COVID: Case study of
12 TDABC and minimum utilization cost analysis in a medicare advantage population. *Journal*
13 *of Health Care*
14 2021;**48**.<http://www.healthfinancejournal.com/index.php/johcf/article/view/264>
15
16 62 Danilyants N, MacKoul P, van der Does L, *et al.* A value-based evaluation of minimally
17 invasive hysterectomy approaches. *Gynecol Surg* 2019;**16**:5.
18
19 63 Parra E, Arenas MD, Alonso M, *et al.* Assessing value-based health care delivery for
20 haemodialysis. *J Eval Clin Pract* 2017;**23**:477–85.
21
22 64 Danilyants N, MacKoul P, Baxi R, *et al.* Value-based assessment of hysterectomy
23 approaches. *J Obstet Gynaecol Res* 2019;**45**:389–98.
24
25 65 Lenfant L, Sawczyn G, Kim S, *et al.* Single-institution Cost Comparison: Single-port Versus
26 Multiport Robotic Prostatectomy. *European Urology Focus* Published Online First: 2020.
27 doi:10.1016/j.euf.2020.06.010
28
29 66 Robinson JR, Carter NH, Gibson C, *et al.* Improving the value of care for appendectomy
30 through an individual surgeon-specific approach. *J Pediatr Surg* 2018;**53**:1181–6.
31
32 67 Bueno H, Bernal JL, Jimenez-Jimenez V, *et al.* The Clinical outcomes, healthcare resource
33 utilization, and related costs (COHERENT) model. Application in heart failure patients. *Rev*
34 *Esp Cardiol* Published Online First: 20 October 2021. doi:10.1016/j.rec.2021.08.009
35
36 68 Casey M, Perera D, Enticott J, *et al.* High utilisers of emergency departments: the profile
37 and journey of patients with mental health issues. *Int J Psychiatry Clin Pract* 2021;**25**:316–
38 24.
39
40 69 Cohen RV, Nishikawa AM, Ribeiro RA, *et al.* Surgical Management of Obesity in Brazil:
41 Proposal for a Value-Based Healthcare Model and Preliminary Results. *Value in Health*
42 *Regional Issues* 2021;**26**:10–4.
43
44 70 Hennink SD, Hofland N, Gopie JP, *et al.* Value-based healthcare in Lynch syndrome. *Fam*
45 *Cancer* 2013;**12**:347–54.
46
47 71 Medbery RL, Chadid TS, Sweeney JF, *et al.* Laparoscopic vs open right hepatectomy: A
48 value-based analysis. *J Am Coll Surg* 2014;**218**:929–39.
49
50 72 Gabriel L, Casey J, Gee M, *et al.* Value-based healthcare analysis of joint replacement
51 surgery for patients with primary hip osteoarthritis. *BMJ Open Quality* 2019;**8**:e000549.
52
53
54
55
56
57
58
59
60

- 1
2
3 73 Ionov MV, Zhukova OV, Yudina YS, *et al.* Value-based approach to blood pressure
4 telemonitoring and remote counseling in hypertensive patients. *Blood Press* 2021;**30**:20–30.
5
6
7 74 Goretti G, Marinari GM, Vanni E, *et al.* Value-Based Healthcare and Enhanced Recovery
8 After Surgery Implementation in a High-Volume Bariatric Center in Italy. *Obes Surg*
9 2020;**30**:2519–27.
10
11 75 Konda SR, Lott A, Egol KA. Development of a Value-based Algorithm for Inpatient Triage
12 of Elderly Hip Fracture Patients. *J Am Acad Orthop Surg* 2020;**28**:e566–72.
13
14 76 Verberne WR, Dijkers J, Kelder JC, *et al.* Value-based evaluation of dialysis versus
15 conservative care in older patients with advanced chronic kidney disease: A cohort study.
16 *BMC Nephrol* 2018;**19**. doi:10.1186/s12882-018-1004-4
17
18 77 Hersh EH, Yaeger KA, Neifert SN, *et al.* Patterns of health care costs due to external
19 ventricular drain infections. *World Neurosurg* 2019;**128**:e31–7.
20
21 78 Meara JG, Hughes CD, Sanchez K, *et al.* Optimal Outcomes Reporting (OOR): A New
22 Value-Based Metric for Outcome Reporting Following Cleft Palate Repair. *Cleft Palate*
23 *Craniofac J* 2021;**58**:19–24.
24
25 79 Kirsch DB, Yang H, Maslow AL, *et al.* Association of Positive Airway Pressure Use With
26 Acute Care Utilization and Costs. *J Clin Sleep Med* 2019;**15**:1243–50.
27
28 80 van Dijk JTJM, van Essen TA, Dijkman MD, *et al.* Functional and patient-reported
29 outcome versus in-hospital costs after traumatic acute subdural hematoma (t-ASDH): a
30 neurosurgical paradox? *Acta Neurochir* Published Online First: 2019. doi:10.1007/s00701-
31 019-03878-5
32
33 81 Lentz TA, Rhon DI, George SZ. Predicting Opioid Use, Increased Health Care Utilization
34 and High Costs for Musculoskeletal Pain: What Factors Mediate Pain Intensity and
35 Disability? *Journal of Pain* 2020;**21**:135–45.
36
37 82 Silva-Velazco J, Dietz DW, Stocchi L, *et al.* Considering Value in Rectal Cancer Surgery:
38 An Analysis of Costs and Outcomes Based on the Open, Laparoscopic, and Robotic
39 Approach for Proctectomy. *Ann Surg* 2017;**265**:960–8.
40
41 83 Vuong B, Dehal A, Uppal A, *et al.* What Are the Most Significant Cost and Value Drivers
42 for Pancreatic Resection in an Integrated Healthcare System? *J Am Coll Surg* 2018;**227**:45–
43 53.
44
45 84 Chawla SS, Whitson AJ, Schiffman CJ, *et al.* Drivers of lower inpatient hospital costs and
46 greater improvements in health-related quality of life for patients undergoing total shoulder
47 and ream-and-run arthroplasty. *J Shoulder Elbow Surg* Published Online First: 2021.
48 doi:10.1016/j.jse.2020.10.030
49
50 85 Peard L, Goodwin J, Hensley P, *et al.* Examining and Understanding Value: The Impact of
51 Preoperative Characteristics, Intraoperative Variables, and Postoperative Complications on
52 Cost of Robot-Assisted Laparoscopic Radical Prostatectomy. *J Endourol* 2019;**33**:541–8.
53
54
55
56
57
58
59
60

- 1
2
3 86 Harris AM, Hensley P, Goodwin J, *et al.* Examining and understanding value: The cost of
4 preoperative characteristics, intraoperative variables and postoperative complications of
5 minimally invasive partial nephrectomy. *Urol Pract* 2019;**6**:215–21.
6
7
8 87 Winegar AL, Jackson LW, Sambare TD, *et al.* A surgeon scorecard is associated with
9 improved value in elective primary hip and knee arthroplasty. *Journal of Bone and Joint*
10 *Surgery - American Volume* 2019;**101**:152–9.
11
12 88 Ramshaw B, Forman BR, Moore K, *et al.* Real-World Clinical Quality Improvement for
13 Complex Abdominal Wall Reconstruction. *Surg Technol Int* 2017;**30**:155–64.
14
15 89 Heincelman M, Schumann SO, Riley J, *et al.* Identification of High Utilization Inpatients on
16 Internal Medicine Services. *Am J Med Sci* 2016;**352**:63–70.
17
18 90 Ramly EP, Larentzakis A, Bohnen JD, *et al.* The financial impact of intraoperative adverse
19 events in abdominal surgery. *Surgery* 2015;**158**:1382–8.
20
21 91 Geerdink TH, Haverlag R, van Veen RN, *et al.* [Direct discharge from the ED for patients
22 with simple stable injuries: a Dutch pilot study]. *Ned Tijdschr Geneesk*
23 2020;**164**.<https://www.ncbi.nlm.nih.gov/pubmed/32391996>
24
25
26 92 Abdulla AG, Ituarte PH, Wiggins R, *et al.* Endocrine surgery as a model for value-based
27 health care delivery. *Surg Neurol Int* 2012;**3**:163.
28
29 93 van der Meulen M, Zamanipoor Najafabadi AH, Lobatto DJ, *et al.* Healthcare utilization
30 and costs among prolactinoma patients: a cross-sectional study and analysis of determinants.
31 *Pituitary* 2021;**24**:79–95.
32
33 94 Lobatto DJ, Vliet Vlieland TPM, van den Hout WB, *et al.* Feasibility, safety, and outcomes
34 of a stratified fast-track care trajectory in pituitary surgery. *Endocrine* 2020;**69**:175–87.
35
36 95 Jalilian H, Doshmangir L, Ajami S, *et al.* Economic burden of gastric cancer in the first six
37 months after diagnosis. *Int J Pharm Healthc Mark* 2019;**13**:436–46.
38
39 96 Lobatto DJ, van den Hout WB, Najafabadi AHZ, *et al.* Healthcare utilization and costs
40 among patients with non-functioning pituitary adenomas. *Endocrine* 2019;**64**:330–40.
41
42 97 Yanik JM, Bedard NA, Hanley JM, *et al.* Rapid Recovery Total Joint Arthroplasty is Safe,
43 Efficient, and Cost-Effective in the Veterans Administration Setting. *J Arthroplasty*
44 2018;**33**:3138–42.
45
46 98 Weir TB, Usmani MF, Camacho J, *et al.* Effect of surgical setting on cost and hospital
47 reported outcomes for single-level anterior cervical discectomy and fusion. *Int J Spine Surg*
48 2021;**15**:701–9.
49
50 99 Gálvez ACM, Sánchez FJ, Moreno CA, *et al.* Value-based healthcare in ostomies. *Int J*
51 *Environ Res Public Health* 2020;**17**:1–15.
52
53
54
55
56
57
58
59
60

- 1
2
3 100 Burnhope E, Waring M, Guilder A, *et al.* A systematic approach towards implementing
4 value-based health care in heart failure: Understandings from retrospective analysis methods
5 in South London. *Health Serv Manage Res* Published Online First: 2020.
6 doi:10.1177/0951484820971442
7
- 8
9 101 Kirsch DB, Yang H, Maslow AL, *et al.* Association of positive airway pressure use with
10 acute care utilization and costs. *J Clin Sleep Med* 2019;**15**:1243–50.
11
- 12 102 Khanijow AN, Wood LN, Xie R, *et al.* The impact of an enhanced recovery program (ERP)
13 on the costs of colorectal surgery. *Am J Surg* 2021;**222**:186–92.
14
- 15 103 Fernando-Canavan L, Gust A, Hsueh A, *et al.* Measuring the economic impact of hospital-
16 acquired complications on an acute health service. *Aust Health Rev* 2021;**45**:135–42.
17
- 18 104 Pasquali SK, Thibault D, Hall M, *et al.* Evolving Cost-Quality Relationship in Pediatric
19 Heart Surgery. *Ann Thorac Surg* Published Online First: 8 June 2021.
20 doi:10.1016/j.athoracsur.2021.05.050
21
- 22 105 Negrini R, da Silva Ferreira RD, Guimaraes DZ. Value-based care in obstetrics: comparison
23 between vaginal birth and caesarean section. *BMC Pregnancy Childbirth* 2021;**21**:333.
24
- 25 106 Islam MK, Ruths S, Jansen K, *et al.* Evaluating an integrated care pathway for frail elderly
26 patients in Norway using multi-criteria decision analysis. *BMC Health Serv Res* 2021;**21**:1–
27 16.
28
- 29 107 Fontebasso AM, Figueira S, Thavorn K, *et al.* Financial implications of trauma patients at a
30 Canadian level 1 trauma center: a retrospective cohort study. *Trauma Surg Acute Care Open*
31 2020;**5**:e000568.
32
- 33 108 Robinson JR, Avritscher EBC, Gay JC, *et al.* Measuring the Value of a Clinical Practice
34 Guideline for Children with Perforated Appendicitis. *Ann Surg* 2017;**266**:195–200.
35
- 36 109 Sun LL, Cao DY, Yang JX, *et al.* Value-based medicine analysis on loop electrosurgical
37 excision procedure and CO2 laser vaporization for the treatment of cervical intraepithelial
38 neoplasia 2. *J Obstet Gynaecol Res* 2012;**38**:1064–70.
39
- 40 110 Fürstenau D, Haneke H, Spies C, *et al.* Tackling the frailty burden with an integrative value-
41 based approach: results from a mixed-methods study. *J Public Health* 2022;**30**:99–110.
42
- 43 111 Ebinger JE, Strauss CE, Garberich RR, *et al.* Value-based ST-segment-elevation myocardial
44 infarction care using risk-guided triage and early discharge. *Circ Cardiovasc Qual*
45 *Outcomes* 2018;**11**. doi:10.1161/CIRCOUTCOMES.118.004553
46
- 47 112 Jain N, Brock JL, Phillips FM, *et al.* Chronic preoperative opioid use is a risk factor for
48 increased complications, resource use, and costs after cervical fusion. *Spine J*
49 2018;**18**:1989–98.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 113 Rice-Townsend S, Barnes JN, Hall M, *et al.* Variation in practice and resource utilization
4 associated with the diagnosis and management of appendicitis at freestanding children's
5 hospitals: Implications for value-based comparative analysis. *Ann Surg* 2014;**259**:1228–34.
6
7
8 114 Burnett RA Iii, Yang J, Courtney PM, *et al.* Costs of unicompartmental compared with total
9 knee arthroplasty : a matched cohort study over ten years. *Bone Joint J* 2021;**103-B**:23–31.
10
11 115 Cronin KJ, Mair SD, Hawk GS, *et al.* Increased Health Care Costs and Opioid Use in
12 Patients with Anxiety and Depression Undergoing Rotator Cuff Repair. *Arthroscopy -*
13 *Journal of Arthroscopic and Related Surgery* 2020;**36**:2655–60.
14
15 116 Robles AJ, Kornblith LZ, Hendrickson CM, *et al.* Health care utilization and the cost of
16 posttraumatic acute respiratory distress syndrome care. *J Trauma Acute Care Surg*
17 2018;**85**:148–54.
18
19 117 Brown MM, Brown GC, Brown HC, *et al.* A Value-Based Medicine Analysis of
20 Ranibizumab for the Treatment of Subfoveal Neovascular Macular Degeneration.
21 *Ophthalmology* 2008;**115**:1039-1045.e5.
22
23
24 118 Chovanec KA, Arsene C, Beck A, *et al.* Why not home?: A study of the impact of an effort
25 to reduce postacute expenditures. *Prof Case Manag* 2022;**27**:3–11.
26
27 119 Brown GC, Brown MM, Brown HC, *et al.* A Value-Based Medicine Comparison of
28 Interventions for Subfoveal Neovascular Macular Degeneration. *Ophthalmology*
29 2007;**114**:1170–8.
30
31 120 van Deen WK, Spiro A, Burak Ozbay A, *et al.* The impact of value-based healthcare for
32 inflammatory bowel diseases on healthcare utilization: a pilot study. *Eur J Gastroenterol*
33 *Hepatol* 2017;**29**:331–7.
34
35
36 121 Annabathula R, Dugan A, Bhalla V, *et al.* Value-based assessment of implementing a
37 Pulmonary Embolism Response Team (PERT). *J Thromb Thrombolysis* 2021;**51**:217–25.
38
39 122 Ennis RD, Parikh AB, Sanderson M, *et al.* Interpreting oncology care model data to drive
40 value-based care: A prostate cancer analysis. *J Oncol Pract* 2019;**15**:E238–46.
41
42 123 Denny JC, Cyr DD, Witsell DL, *et al.* A pathway to value-based care of chronic
43 rhinosinusitis using a claims database. *Laryngoscope Investigative Otolaryngology*
44 2019;**4**:193–206.
45
46 124 Peele P, Keyser D, Lovelace J, *et al.* Advancing Value-Based Population Health
47 Management Through Payer-Provider Partnerships: Improving Outcomes for Children with
48 Complex Conditions. *J Healthc Qual* 2018;**40**:e26–32.
49
50 125 Khullar OV, Jiang R, Force SD, *et al.* Transthoracic versus transhiatal resection for
51 esophageal adenocarcinoma of the lower esophagus: A value-based comparison. *J Surg*
52 *Oncol* 2015;**112**:517–23.
53
54
55
56
57
58
59
60

- 1
2
3 126 Ramirez MM, Brennan GP. Using the value-based care paradigm to compare physical
4 therapy access to care models in cervical spine radiculopathy: a case report. *Physiother*
5 *Theory Pract* 2020;**36**:1476–84.
6
7
8 127 Regan DK, Manoli A, Hutzler L, *et al.* Impact of Diabetes Mellitus on Surgical Quality
9 Measures After Ankle Fracture Surgery: Implications for Value-Based Compensation and
10 Pay for Performance. *J Orthop Trauma* 2015;**29**:e483-486.
11
12 128 Kadakia RJ, Ahearn BM, Tenenbaum S, *et al.* Costs Associated With Geriatric Ankle
13 Fractures. *Foot Ankle Spec* 2017;**10**:26–30.
14
15 129 Barkley R, Soobader MJ, Wang J, *et al.* Reducing cancer costs through symptom
16 management and triage pathways. *J Oncol Pract* 2019;**15**:E91–7.
17
18 130 Suidan RS, He W, Sun CC, *et al.* Total and out-of-pocket costs of different primary
19 management strategies in ovarian cancer. *Am J Obstet Gynecol* 2019;**221**:136.e1-136.e9.
20
21 131 Hemmila MR, Cain-Nielsen AH, Wahl WL, *et al.* Regional collaborative quality
22 improvement for trauma reduces complications and costs. *J Trauma Acute Care Surg*
23 2015;**78**:78–85.
24
25
26 132 AlAshqar A, Goktepe ME, Kilic GS, *et al.* Predictors of the cost of hysterectomy for benign
27 indications. *J Gynecol Obstet Hum Reprod* 2021;**50**:101936.
28
29 133 Naghavi AO, Gonzalez RJ, Scott JG, *et al.* Staged reconstruction brachytherapy has lower
30 overall cost in recurrent soft-tissue sarcoma. *J Contemp Brachytherapy* 2017;**9**:20–9.
31
32 134 Puvanesarajah V, Kirby DJ, Jain A, *et al.* Cost Variation of Anterior Cervical Fusions in
33 Elderly Medicare Beneficiaries. *Spine* 2017;**42**:E1010–5.
34
35 135 Passias PG, Poorman GW, Bortz CA, *et al.* Predictors of adverse discharge disposition in
36 adult spinal deformity and associated costs. *Spine J* 2018;**18**:1845–52.
37
38 136 Manriquez E, Mandelbaum A, Aguayo E, *et al.* Factors associated with high-cost
39 hospitalizations in elderly ovarian cancer patients. *Gynecol Oncol* 2020;**159**:767–72.
40
41 137 Rocque GB, Pisu M, Jackson BE, *et al.* Resource Use and Medicare Costs During Lay
42 Navigation for Geriatric Patients With Cancer. *JAMA Oncol* 2017;**3**:817–25.
43
44 138 Brixner D, Rubin DT, Mease P, *et al.* Patient support program increased medication
45 adherence with lower total health care costs despite increased drug spending. *Journal of*
46 *Managed Care and Specialty Pharmacy* 2019;**25**:770–9.
47
48 139 Alli VV, Zhang J, Telem DA. Impact of incisional hernia development following abdominal
49 operations on total healthcare cost. *Surg Endosc* 2018;**32**:2381–6.
50
51 140 Thakore RV, Greenberg SE, Shi H, *et al.* Surgical site infection in orthopedic trauma: A
52 case-control study evaluating risk factors and cost. *Journal of Clinical Orthopaedics and*
53 *Trauma* 2015;**6**:220–6.
54
55
56
57
58
59
60

- 1
2
3 141 Smith BD, Jiang J, Shih YC, *et al.* Cost and complications of local therapies for early-stage
4 breast cancer. *J Natl Cancer Inst* 2017;**109**. doi:10.1093/jnci/djw178
5
6 142 Klink AJ, Chmielowski B, Feinberg B, *et al.* Health care resource utilization and costs in
7 first-line treatments for patients with metastatic melanoma in the United States. *Journal of*
8 *Managed Care and Specialty Pharmacy* 2019;**25**:869–77.
9
10 143 Chotai S, Sivaganesan A, Parker SL, *et al.* Drivers of Variability in 90-Day Cost for
11 Elective Anterior Cervical Discectomy and Fusion for Cervical Degenerative Disease. *Clin*
12 *Neurosurg* 2018;**83**:898–904.
13
14 144 Ackerman RS, Hirschi M, Alford B, *et al.* Enhanced REVENUE after surgery? A cost-
15 standardized enhanced recovery pathway for mastectomy decreases length of stay. *World J*
16 *Surg* 2019;**43**:839–45.
17
18 145 Williams SB, Shan Y, Jazzar U, *et al.* Comparing Survival Outcomes and Costs Associated
19 with Radical Cystectomy and Trimodal Therapy for Older Adults with Muscle-Invasive
20 Bladder Cancer. *JAMA Surg* 2018;**153**:881–9.
21
22 146 Schilling PL, He J, Chen S, *et al.* Risk-Adjusted Cost Performance for 90-Day Total Hip
23 Arthroplasty Episodes: Comparing US Hospitals Nationwide Before CJR. *J Arthroplasty*
24 2020;**35**:3452–63.
25
26 147 Ackerman SJ, Knight T, Wahl PM, *et al.* Health care utilization and costs following
27 amplified versus non-amplified molecular probe testing for symptomatic patients with
28 suspected vulvovaginitis: A us commercial payer population. *Clinicoecon Outcomes Res*
29 2019;**11**:179–89.
30
31 148 Patel MI, Ramirez D, Agajanian R, *et al.* Lay health worker-led cancer symptom screening
32 intervention and the effect on patient-reported satisfaction, health status, health care use, and
33 total costs: Results from a tri-part collaboration. *J Oncol Pract* 2020;**16**:E19–28.
34
35 149 Stearns LJ, Narang S, Albright RE, *et al.* Assessment of Health Care Utilization and Cost of
36 Targeted Drug Delivery and Conventional Medical Management vs Conventional Medical
37 Management Alone for Patients With Cancer-Related Pain. *JAMA Netw Open*
38 2019;**2**:e191549.
39
40 150 Skill NJ, Butler J, O'Brien DC, *et al.* Financial Burden of Liver Transplant vs Resection for
41 Hepatocellular Carcinoma. *Transplant Proc* 2019;**51**:1907–12.
42
43 151 Karnuta JM, Navarro SM, Haeberle HS, *et al.* Predicting Inpatient Payments Prior to Lower
44 Extremity Arthroplasty Using Deep Learning: Which Model Architecture Is Best? *J*
45 *Arthroplasty* 2019;**34**:2235-2241.e1.
46
47 152 Ning MS, Palmer MB, Shah AK, *et al.* Three-Year Results of a Prospective Statewide
48 Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient
49 Access to Care. *JCO Oncol Pract* 2020;**16**:e966–76.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 153 Keller DS, Zhang J, Chand M. Opioid-free colorectal surgery: a method to improve patient
4 & financial outcomes in surgery. *Surg Endosc* 2019;**33**:1959–66.
5
6 154 Rocque GB, Williams CP, Kenzik KM, *et al.* Where are the opportunities for reducing
7 health care spending within alternative payment models? *J Oncol Pract* 2018;**14**:e375–83.
8
9 155 Sheetz KH, Kenney B, Dupree JM, *et al.* Targeting Value-Driven Quality Improvement for
10 Laparoscopic Cholecystectomy in Michigan. *Ann Surg* 2019;**269**:127–32.
11
12 156 Zolin SJ, Tastaldi L, Alkhatib H, *et al.* Open retromuscular versus laparoscopic ventral
13 hernia repair for medium-sized defects: where is the value? *Hernia* 2020;**24**:759–70.
14
15 157 Orhurhu V, Urits I, Olusunmade M, *et al.* Trends of Co-Morbid Depression in Hospitalized
16 Patients with Failed Back Surgery Syndrome: An Analysis of the Nationwide Inpatient
17 Sample. *Pain and Therapy* 2018;**7**:217–26.
18
19 158 Hollenbeck B, Hoffman MA, Tromanhauser SG. High-Volume Arthroplasty Centers
20 Demonstrate Higher Composite Quality Scores and Enhanced Value: Perspective on Higher-
21 Volume Hospitals Performing Arthroplasty from 2001 to 2011. *Journal of Bone and Joint*
22 *Surgery - American Volume* 2020;**102**:362–7.
23
24 159 Loftus TJ, Rosenthal MD, Croft CA, *et al.* Effect of time to operation on value of care in
25 acute care surgery. *World J Surg* 2018;**42**:2356–63.
26
27 160 Buell JF, Sigmon D, Ducoin C, *et al.* Initial Experience with Biologic Polymer Scaffold
28 (Poly-4-hydroxybuturate) in Complex Abdominal Wall Reconstruction. *Ann Surg*
29 2017;**266**:185–8.
30
31 161 Jain N, Phillips FM, Shimer AL, *et al.* Surgeon Reimbursement Relative to Hospital
32 Payments for Spinal Fusion: Trends From 10-year Medicare Analysis. *Spine* 2018;**43**:720–
33 31.
34
35 162 Stull JD, Bhat SB, Kane JM, *et al.* Economic Burden of Inpatient Admission of Ankle
36 Fractures. *Foot Ankle Int* 2017;**38**:997–1004.
37
38 163 Lewis RB, Hariri O, Elliott ME, *et al.* Financial Analysis of Closed Femur Fractures in 3- to
39 6-Year-Olds Treated with Immediate Spica Casting Versus Intramedullary Fixation. *Journal*
40 *of Pediatric Orthopaedics* 2019;**39**:E114–9.
41
42 164 Murphy WS, Cheng T, Lin B, *et al.* Higher Volume Surgeons Have Lower Medicare
43 Payments, Readmissions, and Mortality After THA. *Clin Orthop Relat Res* 2019;**477**:334–
44 41.
45
46 165 King AM, Danagoulian S, Lynch M, *et al.* The Effect of a Medical Toxicology Inpatient
47 Service in an Academic Tertiary Care Referral Center. *J Med Toxicol* 2019;**15**:12–21.
48
49 166 Click B, Lopez R, Arrigain S, *et al.* Shifting Cost-drivers of Health Care Expenditures in
50 Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2020;**26**:1268–75.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 167 Padilla JA, Gabor JA, Ryan SP, *et al.* Total Hip Arthroplasty for Femoral Neck Fracture:
4 The Economic Implications of Orthopedic Subspecialty Training. *J Arthroplasty*
5 2020;**35**:S101–6.
6
7 168 Pang J, Crawford K, Faraji F, *et al.* An Analysis of 1-Year Charges for Head and Neck
8 Cancer: Targets for Value-Based Interventions. *Otolaryngol Head Neck Surg*
9 2020;**163**:546–53.
10
11 169 Patel MI, Ramirez D, Agajanian R, *et al.* Association of a Lay Health Worker Intervention
12 With Symptom Burden, Survival, Health Care Use, and Total Costs Among Medicare
13 Enrollees With Cancer. *JAMA Netw Open* 2020;**3**:e201023.
14
15 170 Thaci B, McGirt MJ, Ammerman JM, *et al.* Reduction of direct costs in high-risk lumbar
16 discectomy patients during the 90-day post-operative period through annular closure.
17 *Clinicoecon Outcomes Res* 2019;**11**:191–7.
18
19 171 Gupta P, Rettiganti M. Relationship of Hospital Costs With Mortality in Pediatric Critical
20 Care: A Multi-Institutional Analysis. *Pediatr Crit Care Med* 2017;**18**:541–9.
21
22 172 Nelson AA, Pearce DJ, Fleischer AB, *et al.* Infliximab for inpatient psoriasis management -
23 is there a role? *J Dermatolog Treat* 2005;**16**:314–8.
24
25 173 Zhang S, Vora M, Harris AHS, *et al.* Cost-Minimization Analysis of Open and Endoscopic
26 Carpal Tunnel Release. *J Bone Joint Surg Am* 2016;**98**:1970–7.
27
28 174 Adenikinju A, Ranson R, Rettig SA, *et al.* Ability of a Risk Prediction Tool to Stratify
29 Quality and Cost for Older Patients With Operative Distal Radius Fractures. *Geriatr Orthop*
30 *Surg Rehabil* 2021;**12**:2151459321999634.
31
32 175 Baughman DJ, Waheed A, Khan MN, *et al.* Enhancing Value-Based Care With a Walk-in
33 Clinic: A Primary Care Provider Intervention to Decrease Low Acuity Emergency
34 Department Overutilization. *Cureus* 2021;**13**:e13284.
35
36 176 Berinstein JA, Cohen-Mekelburg SA, Greenberg GM, *et al.* A Care Coordination
37 Intervention Improves Symptoms But Not Charges in High-Risk Patients With
38 Inflammatory Bowel Disease. *Clinical Gastroenterology & Hepatology* Published Online
39 First: 28 August 2021. doi:10.1016/j.cgh.2021.08.034
40
41 177 Beschloss A, Dicindio C, Lombardi J, *et al.* Marked increase in Spinal Deformity Surgery
42 throughout the United States. *Spine* 2021;**46**:1402–8.
43
44 178 Jang DW, Lee HJ, Chen PG, *et al.* Geographic variations in healthcare utilization and
45 expenditure for chronic rhinosinusitis: A population-based approach. *Laryngoscope*
46 2021;**131**:2641–8.
47
48 179 Ko H, Brodke DS, Vanneman ME, *et al.* Is discretionary care associated with safety among
49 Medicare beneficiaries undergoing spine surgery? *J Bone Joint Surg Am* 2021;**Publish**
50 **Ahead of Print.** doi:10.2106/JBJS.21.00389
51
52
53
54
55
56
57
58
59
60

- 1
2
3 180 Malik AT, Khan SN, Voskuil RT, *et al.* What is the value of undergoing surgery for spinal
4 metastases at Dedicated Cancer Centers? *Clin Orthop Relat Res* 2021;**479**:1311–9.
5
6 181 Newman TV, Munshi KD, Neilson LM, *et al.* Health care utilization and costs associated
7 with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
8 *Journal of Managed Care & Specialty Pharmacy* 2021;**27**:435–43.
9
10 182 Tomicki S, Dieguez G, Latimer H, *et al.* Real-World Cost of Care for Commercially Insured
11 versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-
12 Recommended Therapies. *American Health & Drug Benefits* 2021;**14**:70–8.
13
14 183 Buell JF, Flaris AN, Raju S, *et al.* Long-Term Outcomes in Complex Abdominal Wall
15 Reconstruction Repaired With Absorbable Biologic Polymer Scaffold (Poly-4-
16 Hydroxybutyrate). *Annals of Surgery Open* 2021;**2**:e032.
17
18 184 King BC, Richardson T, Patel RM, *et al.* Prioritization framework for improving the value
19 of care for very low birth weight and very preterm infants. *J Perinatol* 2021;**41**:2463–73.
20
21 185 Skibicki H, Yayac M, Krueger CA, *et al.* Target price adjustment for hip fractures is not
22 sufficient in the Bundled Payments for Care Improvement initiative. *J Arthroplasty*
23 2021;**36**:47–53.
24
25 186 Clewley D, Iftikhar Y, Horn ME, *et al.* Do the number of visits and the cost of
26 musculoskeletal care improve outcomes? More may not be better. *J Orthop Sports Phys*
27 *Ther* 2020;**50**:642–8.
28
29 187 Walker B, Wilfong L, Frytak J, *et al.* Practice patterns among oncologists participating in
30 the oncology care model after three years. *J Cancer Policy* 2021;**29**:100294.
31
32 188 Krueger CA, Yayac M, Vannello C, *et al.* Are we at the bottom? BPCI programs now
33 disincentivize providers who maintain quality despite caring for increasingly complex
34 patients. *J Arthroplasty* 2021;**36**:13–8.
35
36 189 Horton BS, Marland JD, West HS, *et al.* Transition to telehealth physical therapy after hip
37 arthroscopy for femoroacetabular impingement: A pilot study with retrospective matched-
38 cohort analysis. *Orthop J Sports Med* 2021;**9**:2325967121997469.
39
40 190 Nguyen NH, Luo J, Ohno-Machado L, *et al.* Burden and outcomes of fragmentation of care
41 in hospitalized patients with inflammatory bowel diseases: A nationally representative
42 cohort. *Inflamm Bowel Dis* 2021;**27**:1026–34.
43
44 191 Gregory D, Scotti DJ, de Lissovoy G, *et al.* A value-based analysis of hemodynamic support
45 strategies for high-risk heart failure patients undergoing a percutaneous coronary
46 intervention. *Am Health Drug Benefits* 2013;**6**:88–99.
47
48 192 Schwartz DA, Shah AA, Zogg CK, *et al.* Operative delay to laparoscopic cholecystectomy:
49 Racking up the cost of health care. *J Trauma Acute Care Surg* 2015;**79**:15–21.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 193 Aguayo E, Sanaiha Y, Seo YJ, *et al.* Heparin-induced thrombocytopenia in cardiac surgery:
4 Incidence, costs, and duration of stay. *Surgery* 2018;**164**:1377–81.
5
6 194 Canizares MF, Feldman L, Miller PE, *et al.* Complications and Cost of Syndactyly
7 Reconstruction in the United States: Analysis of the Pediatric Health Information System.
8 *Hand* 2017;**12**:327–34.
9
10 195 Sanaiha Y, Mantha A, Ziaecian B, *et al.* Trends in Readmission and Costs After
11 Transcatheter Implantation Versus Surgical Aortic Valve Replacement in Patients With
12 Renal Dysfunction. *Am J Cardiol* 2019;**123**:1481–8.
13
14 196 Sanaiha Y, Kavianpour B, Downey P, *et al.* National Study of Index and Readmission
15 Mortality and Costs for Thoracic Endovascular Aortic Repair in Patients With Renal
16 Disease. *Ann Thorac Surg* 2020;**109**:458–64.
17
18 197 Labovitz JM, Kominski GF. Forecasting the value of podiatric medical care in newly
19 insured diabetic patients during implementation of the affordable care act in California. *J*
20 *Am Podiatr Med Assoc* 2016;**106**:163–71.
21
22 198 Johnson JT, Scholtens DM, Kuang A, *et al.* Does Value Vary by Center Surgical Volume
23 for Neonates With Truncus Arteriosus? A Multicenter Study. *Ann Thorac Surg* Published
24 Online First: 2021. doi:10.1016/j.athoracsur.2020.05.178
25
26 199 Saifi C, Cazzulino A, Park C, *et al.* National Trends for Primary and Revision Lumbar Disc
27 Arthroplasty Throughout the United States. *Global Spine Journal* 2018;**8**:172–7.
28
29 200 Boucek DM, Lal AK, Eckhauser AW, *et al.* Resource Utilization for Initial Hospitalization
30 in Pediatric Heart Transplantation in the United States. *Am J Cardiol* 2018;**121**:981–5.
31
32 201 Laratta JL, Reddy H, Lombardi JM, *et al.* Utilization of Interspinous Devices Throughout
33 the United States Over a Recent Decade: An Analysis of the Nationwide Inpatient Sample.
34 *Global Spine Journal* 2018;**8**:382–7.
35
36 202 Karnuta JM, Golubovsky JL, Haeberle HS, *et al.* Can a machine learning model accurately
37 predict patient resource utilization following lumbar spinal fusion? *Spine J* 2020;**20**:329–36.
38
39 203 Karnuta JM, Navarro SM, Haeberle HS, *et al.* Bundled Care for Hip Fractures: A Machine-
40 Learning Approach to an Untenable Patient-Specific Payment Model. *J Orthop Trauma*
41 2019;**33**:324–30.
42
43 204 Navarro SM, Ramkumar PN, Egger AC, *et al.* Evidence-Based Thresholds for the Volume-
44 Value Relationship in Adolescent Idiopathic Scoliosis: Outcomes and Economies of Scale.
45 *Spine Deformity* 2018;**6**:156–63.
46
47 205 Bateni SB, Gingrich AA, Hoch JS, *et al.* Defining Value for Pancreatic Surgery in Early-
48 Stage Pancreatic Cancer. *JAMA Surg* 2019;**154**. doi:10.1001/jamasurg.2019.3019
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 206 Xiao R, Miller JA, Zafirau WJ, *et al.* Impact of Home Health Care on Health Care Resource
4 Utilization Following Hospital Discharge: A Cohort Study. *Am J Med* 2018;**131**:395-
5 407.e35.
6
7 207 Gandjian M, Williamson C, Sanaiha Y, *et al.* Continued Relevance of Minimum Volume
8 Standards for Elective Esophagectomy: A National Perspective. *Ann Thorac Surg* Published
9 Online First: 23 August 2021. doi:10.1016/j.athoracsur.2021.07.061
10
11 208 Hadaya J, Sanaiha Y, Hernandez R, *et al.* Impact of hospital volume on resource use after
12 elective cardiac surgery: A contemporary analysis. *Surgery* 2021;**170**:682–8.
13
14 209 Seyidova N, Chen AD, del Valle D, *et al.* Nationwide cost variation for lower extremity flap
15 reconstruction. *Eur J Plast Surg* 2021;**44**:475–82.
16
17 210 Sanaiha Y, Downey P, Lyons R, *et al.* Trends in utilization, mortality, and resource use after
18 implantation of left ventricular assist devices in the United States. *J Thorac Cardiovasc Surg*
19 2021;**161**:2083-2091.e4.
20
21 211 Frankel WC, Navarro SM, Haeberle HS, *et al.* Optimizing the Volume–Value Relationship
22 in Laminectomy. *Spine* 2019;**44**:659–69.
23
24 212 Miller PE, Guha A, Khera R, *et al.* National Trends in Healthcare-Associated Infections for
25 Five Common Cardiovascular Conditions. *Am J Cardiol* 2019;**124**:1140–8.
26
27 213 Mukdad L, Mantha A, Aguayo E, *et al.* Readmission and resource utilization after
28 orthotopic heart transplant versus ventricular assist device in the National Readmissions
29 Database, 2010–2014. *Surgery* 2018;**164**:274–81.
30
31 214 Navarro SM, Wang EY, Haeberle HS, *et al.* Machine Learning and Primary Total Knee
32 Arthroplasty: Patient Forecasting for a Patient-Specific Payment Model. *J Arthroplasty*
33 2018;**33**:3617–23.
34
35 215 Iloabuchi C, Dwibedi N, LeMasters T, *et al.* Low-value care and excess out-of-pocket
36 expenditure among older adults with incident cancer – A machine learning approach.
37 *Journal of Cancer Policy* 2021;**30**:100312.
38
39 216 Siu VJ, Varkey T, Khan UN, *et al.* Lend Me a Hand: A Value-Based Care Case Study on
40 Pan Plexopathy of Unknown Origin. *Cureus* 2021;**13**.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Inclusions RQ1 (215) extracted data to be shared with Erasmus Data Repository (FigShare)

Authors	Year Pub	Title paper (see full reference in manuscript)	Geography (country) of study	Geography, state of country, if N/A country	study design (if incl. in RQ2)	unit of analysis	disease/topic labels provided by study (overlapping tags, can be multiple)	Medical Specialty (non overlapping labels)	Medical Specialty sub category, where applicable	Care path studied	Costs included	Costs perspective (all)	Primary Cost perspective	Secondary Cost perspective if applicable	Costing method used as described in study	Primary Costing method classification	Secondary Costing method classification, if applicable	Implementation of costing method (N/A if reimbursements or charges, unspecified if not discussed in study)	if reimbursement: actual measurement used for estimation	RQ2 included - discuss consequences or impact of cost information in study
Gálvez, A. C. M. Sánchez, F. J. Moreno, C. A. Pérez Fernández, A. J. García, R. B. López, M. C. Quintana, M. D. P.	2020	Value-based healthcare in ostomies	Andalusia	Andalusia		71 surgical ostomy patients	digestive, urology, surgical	Urology		partial care path (full surgical episode)	Direct and indirect	provider	provider		unspecified	Absorption costing - unspecified/generic		Paper only		no
McLaughlin, N. Upadhyaya, P. Bussey, F. Martin, N. A.	2014	Value-based neurosurgery: Measuring and reducing the cost of microvascular decompression surgery	US	US: California	single center, retrospective	44 neurosurgical patients	neurosurgical, microvascular decompression, trigeminal neuralgia (TN) or hemifacial spasm (HFS)	Surgical	Neurosurgery	partial care path (full surgical episode)	Direct and indirect	provider	provider		ABC	Absorption costing - ABC		implemented		yes see second sheet
Hennink, S. D. Hofland, N. Gopic, J. P. Van Der Kaa, C. De Koning, K. Nielsen, M. Tone, C.	2016	Value-based healthcare in Lynch syndrome	The Netherlands	The Netherlands		64 Lynch Syndrome patients	oncology, lynch syndrome, colorectal cancer	Oncology		full care path	Direct and indirect	provider	provider		unspecified	Absorption costing - unspecified/generic		unspecified		no
French, K. E. Guzman, A. B. Rubio, A. C. Frenzel, J. C. Feeley, T. W.	2016	Value based care and bundled payments: Anesthesia care costs for outpatient oncology surgery using time-driven activity-based costing	US	US: Virginia	single center, retrospective, multiple care paths	5,357 outpatient anesthesia cases across 11 procedure groups	oncology	Oncology		partial care path (full surgical episode)	Direct and indirect	provider	provider		TDABC	Absorption costing - TDABC		implemented		yes see second sheet
Tan, R. Y. C. Met-Domestici, M. Zhou, K. Guzman, A. B. Lim, S. T. Soo, K. C. Feeley, T. W.	2016	Using quality improvement methods and time-driven activity-based costing to improve value-based cancer care delivery at a Cancer Genetics clinic	Singapore	Singapore	single center, retrospective, process mapping, observation	251 Patients with high-risk features suggestive of hereditary cancer	oncology, genetics, Cancer genetics	Oncology		partial care path	Direct	provider	provider		TDABC	Direct costing		unspecified		no
Daniyants, N. MacKoul, P. Baxi, R. van der Does, L. Q. Haworth, L. R.	2019	Value-based assessment of hysterectomy approaches	US	US: Maryland	single center, retrospective	2689 patients, female, 18 or over	gynecology, vaginal hysterectomy, robot, robot-assisted	gynecology & obstetrics		partial care path (full surgical episode)	Direct and indirect	provider	provider		Microcosting supplemented with charges	Absorption costing - unspecified/generic		Paper only		yes see second sheet
Hernandez, A. Kaplan, R. S. Wikowski, M. L. Forrest Faison, C. Porter, M. E.	2019	Navy medicine introduces value-based health care	US	US: Florida	single center, retrospective, multiple care paths, pilot project	22877 patients total	pregnancy, osteoarthritis, diabetes, lower back pain, multiple	gynecology & obstetrics		full care path	Direct and indirect	provider	provider		TDABC	Absorption costing - TDABC		implemented		yes see second sheet
Parra, E. Arenas, M. D. Alonso, M. Martinez, M. F. Gamen, A. Aguaron, J. Quintana, M. D. P.	2017	Assessing value-based health care delivery for haemodialysis	Spain	Spain	multi center, retrospective	5 haemodialysis treatment centers, patients unspecified	haemodialysis, renal	Urology		partial care path	Direct and indirect	provider	provider		Microcosting	Absorption costing - unspecified/generic		Paper only		yes see second sheet
Brown, G. C. Brown, M. M. Brown, H. C. Kindermann, S. Sharma, S.	2007	A Value-Based Medicine Comparison of Interventions for Subfoveal Neovascular Macular Degeneration	US	US: Pennsylvania		233 patients with age-related macular degeneration	Ophthalmology, Neovascular, macular degeneration	ophthalmology		partial care path	Direct	payer	payer		none, reimbursements	Charges/Reimbursements-based		N/A	average medicare reimbursements	no
Medbery, R. L. Chadd, T. S. Sweaney, J. F. Knechtle, S. J. Kooby, D. A. Maribel, S. K. Lee, J. S.	2014	Laparoscopic vs open right hepatectomy: A value-based analysis	US	US: Georgia		105 patients total, elective laparoscopic liver resection surgery or open right hepatectomy	Surgical, Hepatectomy, Laparoscopic liver resections	Surgical	Liver	partial care path	Direct and indirect	provider	provider		unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic		implemented		no
Daniyants, N. MacKoul, P. van der Does, L. Haworth, L. Baxi, R.	2019	A value-based evaluation of minimally invasive hysterectomy approaches	US	US: Maryland	single center, retrospective	2689 patients, female, 18 or over	gynecology, vaginal hysterectomy, robot, robot-assisted	gynecology & obstetrics		partial care path (full surgical episode)	Direct and indirect	provider	provider		Microcosting	Absorption costing - unspecified/generic		Paper only		yes see second sheet
Gabriel, L. Casey, J. Gee, M. Palmer, C. Sinha, J. Moxham, J. Quintana, M. D. P. Van Deen, W. K.	2019	Value-based healthcare analysis of joint replacement surgery for patients with primary hip osteoarthritis	UK	UK: London		50 patients primary hip osteoarthritis	orthopedics, joint replacement, total hip osteoarthritis	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	provider	provider		Patient Level Information Costing System methodology (PLICS)	Absorption costing - unspecified/generic		implemented		no
Spiro, A. Burak Ozbay, A. Skop, M. Centeno, A. Duran, N. E. Quintana, M. D. P.	2017	The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: A pilot study	US	US: California		60 patients with inflammatory bowel disease	IBS, bowel, Inflammatory bowel disease	Internal Medicine		full care path	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements t-based		N/A	Medicare reimbursements based on DRG/HCPCS codes	no

1	Isaacson, D. Ahmad, T. Mazzer, L. Tjau, D. T. Taguchi, K. Usawachintachit, M.							single center, direct observation, process mapping	10 Uteroscopes	Urology, Utereroscopy	Urology	partial care path	Direct and indirect	provider	provider		TDABC	Absorption costing - TDABC	Paper only	yes see second sheet		
2	Zatonskas, K. Janov, M. V. Zhukova, O. V. Yudina, Y. S. Avdonina, N. G. Emelyanov, I. V. Kurapnev, D. I. Zastouev, A. E.								240 hypertensive patients	Blood pressure, hypertension, Blood pressure telemonitoring and remote counselling (BPTM)	Cardiology	partial care path	Direct and indirect	provider	provider		unspecified	Absorption costing - unspecified/generic	unspecified	no		
3	Annabathula, R. Dugan, A. Bhalla, V. Davis, G. A. Smyth, S. S. Gupta, V. A.								634 patients, 18 or over, acute Pulmonary Embolism	Cardiology, pulmonary embolism	Cardiology	unspecified	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements-based	N/A	total reimbursements no		
4	Coretti, G. Marinari, G. M. Vanni, E. Ferrari, C.								2122 patients, morbidly obese, bariatric surgery	Obesity, surgical, bariatric surgery, Morbid Obesity	Surgical			provider	provider		unspecified	Absorption costing - unspecified/generic	Paper only	no		
5	Konda, S. R. Lott, A. Egol, K. A.								361 operative hip fracture patients	Geriatrics, trauma, hip fracture	Surgical	Orthopedic fracture	partial care path	Direct and indirect	provider	provider		unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	no	
6	Emis, R. D. Parikh, A. B. Sanderson, M. Liu, M. Isola, L.								210 patients, 377 episodes of care	Oncology, Hematology, prostate cancer	Oncology	full care path	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements no		
7	Denneny, J. C. Cyr, D. D. Witsell, D. L. Breerton, J. Schulz, K.								7499183 patients, 18-64, acute rhinosinitis	Rhinosinitis, Typical chronic rhinosinitis	Surgical	ENT	partial care path	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements-based	N/A	claims no	
8	Peele, P. Keyser, D. Lovelace, J. Moss, D.								262 child patients, under 21.	Pediatrics, complex conditions	Pediatrics	Pediatric other	partial care path	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements no	
9	Brown, M. M. Brown, G. C. Brown, H. C. Pect, J.								716 patients, classic or neovascular macular degeneration	Neovascular, macular degeneration, Subfoveal Neovascular Macular Degeneration	ophthalmology		partial care path	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements no	
10	Burnhope, E. Waring, M. Guilider, A. Malhotra, B. Cardoso, J. M. Razavi, R. Ganesh, S. S. Khuallar, O. V.								138 patients undergoing Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization	Cardiology, heart failure	Surgical	Cardiac/Thoracic	partial care path	Direct and indirect	provider	provider		unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	yes see second sheet	
11	Jiang, R. Furce, S. D. Pickens, A. Sanchetti, M. S. Ward, K.								942 patients esophagectomy 967 patients receiving primary percutaneous coronary intervention between 2009 and 2011	Oncology, esophageal cancer	Oncology		full care path	Direct and indirect	payer	payer		none, reimbursements	Charges/Reimbursements-based	N/A	Medicare costs, reimbursements no	
12	Ehinger, J. E. Strauss, C. E. Garberich, R. R. Bradley, S. M. Rush, P. Chavez, J. J. Bodnar, A. K. Bodar, Y. J. L.								Value-based ST-segment-elevation myocardial infarction care using risk-guided triage and early discharge	Cardiology, heart failure, myocardial infarction	Surgical	Cardiac/Thoracic	full care path (surgical episode)	Direct	provider	provider		unspecified, Hospital accounting data not otherwise specified	Unspecified	implemented	no	
13	Srinivasan, A. K. Shah, A. S. Kawal, T. Shukla, A. R.								single center, retrospective, direct observation	25 robot assisted laparoscopic pyeloplasties	Pediatrics, urology, robotics, robot	Pediatrics	Pediatric surgical	full care path (surgical episode)	Direct and indirect	provider	provider		TDABC	Absorption costing - TDABC	Paper only	yes see second sheet
14	Verberne, W. R. Dijkers, J. Kelder, J. C. Geerts, A. B. M. Jellema, W. T. Vincent, H. H. Van-Dalme, J. J. M.								366 patients aged ≥70 years with advanced chronic kidney disease	Nephrology, kidney, dialysis, chronic	Nephrology		full care path	Direct and indirect	provider	provider		unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	no	

1	Gregory, D. Scotti, D. J. de Lissovoy, G. Palacios, I. Dixon, S. Main, B. Zakari, W.	A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention	2013	US	US; various states	427 patients enrolled in trial, mean age 68, 80.6% male	Cardiology, heart failure	Surgical	Cardiac/Thoracic	partial care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursement-based proxy	N/A	none, charges, cost to charges	no	
2	Ravikumar, T. S. Sharma, C. Marini, C. Steele, G. D. Ritter, G. Barrera, R. Kiss, M.	A validated value-based model to improve hospital-wide perioperative outcomes: Adaptability to combined medical/surgical inpatient cohorts	2010	US	US; New York	>100,000 hospital admissions	Surgical	Surgical	other	partial care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	Paper only		no	
3	Ning, M. S. Venkatesan, A. M. Stafford, R. J. Bui, T. P. Carlson, R. Baillard, N. S. Mason, S.	Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis	2020	US	US; Texas	single center, retrospective, direct observation, process mapping	10 female patients 358 resected patients	Oncology, Gynecology, gynecologic pelvic tumor	Oncology	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet	
4	Sun, L. L. Cao, D. Y. Yang, J. X. Bian, M. L. Wei, L. H. Shen, K.	Value-based medicine analysis on loop electrosurgical excision procedure and CO2 laser vaporization for the treatment of cervical intraepithelial neoplasia 2	2012	China	China	18-65, colposcopic-histopathologically confirmed CIN2, intact uterus, no past history of cervical neoplasia, and had a	Obstetrics, Gynecology, cervical neoplasia	gynecology & obstetrics		partial care path	unspecified	provider	provider	unspecified	Unspecified	unspecified		no	
5	Fortmann, A. L. Walker, C. Barger, K. Robacker, M. Morrisey, R. Ortwine, K. Lawrence, J.	Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care	2020	US	US; California	236 treated patients, 239 usual care patients. All diagnosed with type 1 or 2 diabetes.	Diabetes	Internal Medicine		partial care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	implemented		no	
6	Ramirez, M. M. Brennan, G. P.	Using the value-based care paradigm to compare physical therapy access to care models in cervical spine radiculopathy: a case report	2020	US	US; Florida	case study; 39 yo female	Physiotherapy	Neurology		partial care path	Direct and indirect	payer, patient	payer	patient	none, reimbursements	Charges/Reimbursement-based patient OoO	N/A	cost to patient, reimbursement	no
7	Ryan, S. P. Plate, J. F. Black, C. S. Howell, C. B. Jiranek, W. A. Bolognesi, M. P. Scotti, D. J. Plate, J. F.	Value-Based Care Has Not Resulted in Biased Patient Selection: Analysis of a Single Center's Experience in the Care for Joint Replacement Bundle	2019	US	US; North Carolina	1248 total knee arthroplasty patients,	orthopedics, joint replacement, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	full care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	implemented		no	
8	Ryan, S. P. Black, C. S. Howell, C. B. Jiranek, W. A. Bolognesi, M. P. Scotti, D. J. Abbott, M. M. Meara, J. G.	No Changes in Patient Selection and Value-Based Metrics for Total Hip Arthroplasty After Comprehensive Care for Joint Replacement Bundle Implementation at a Single Center	2019	US	US; North Carolina	751 total hip arthroplasty patients,	orthopedics, joint replacement, total hip arthroplasty	Surgical	Orthopedic, arthroplasty	full care path	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	implemented		no	
9	Regan, D. K. Manoli, A. Hutzler, L. Konda, S. R. Egol, K. A.	A microcosting approach for isolated, unilateral cleft lip care in the first year of life	2011	US	US; Massachusetts	single center, retrospective	12 children, cleft lip repair	Pediatrics, cleft palate, plastic surgery	Pediatrics	Pediatric Plastic surgery	partial care path (full surgical episode)	Direct and indirect	provider	provider	Microcosting	Absorption costing - ABC	Paper only	yes see second sheet	
10	Regan, D. K. Manoli, A. Hutzler, L. Konda, S. R. Egol, K. A.	Impact of Diabetes Mellitus on Surgical Quality Measures After Ankle Fracture Surgery: Implications for "Value-Based" Compensation and "Pay for Performance"	2015	US	US; New York	58,748 patients, 7501 with Diabetes Mellitus	Diabetes	Internal Medicine		unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursement-based	N/A	mean total hospital charges	no	
11	Yu, Y. R. Abbas, P. I. Smith, C. M. Carberry, K. E. Ren, H. Patel, B. Swanson, J. G.	Time-driven activity-based costing: A dynamic value assessment model in pediatric appendicitis	2017	US	US; Texas	single center, retrospective, direct observation, process mapping	207 patients total, 6 phases of care	Pediatrics, appendicitis, simple appendicitis	Pediatrics	Pediatric appendicitis	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	
12	Rice-Townsend, S. Barnes, J. N. Hall, M. Baxter, J. L. Rangel, S. J.	Variation in practice and resource utilization associated with the diagnosis and management of appendicitis at freestanding children's hospitals: Implications for value-based comparative analysis	2014	US	US; Massachusetts	13,328 patients, 34 children's hospitals, 25 states in US, acute appendicitis, age 3-18	Pediatrics, appendicitis	Pediatrics	Pediatric appendicitis	unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursement-based	N/A	charges transformed with cost-to-charge ratio	no	
13	Ahluwalia, R. Cook, J. Raheman, F. Karuppiyah, K. Colegate-Stone, T. Tavakolizadeh, A. Kasheba, M.	Improving the efficiency of ankle fracture care through home care and day-surgery units: Delivering safe surgery on a value-based healthcare model	2020	UK	UK; London	single center, prospective, process mapping	53 trauma patients	trauma, orthopedics, surgical, ankle fracture	Surgical	Orthopedic fracture	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	
14	Bisto, J. Chahal, R. Riedel, B.	Time-driven activity-based costing to model the utility of parallel induction redesign in high-turnover operating lists	2019	Australia	Australia	single center, prospective, process mapping	19 all-day surgery lists, patients unspecified	melanoma, oncology	Oncology	partial care path (partial surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet		

1	Kadakia, R. J., Ahearn, B.M., Tenenbaum, S., Bariteau, J.T.	Costs Associated With Geriatric Ankle Fractures, Operative Versus Nonoperative Management	2017	US	US, Georgia	19648 ankle fracture patients	trauma, orthopedics, geriatrics, ankle fracture	Surgical	Orthopedic fracture	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	medicare reimbursements	no		
2	Barkley, R. S., Sosabower, M.J., Wang, J., Blau, S., Page, R. D.	Reducing Cancer Costs Through Symptom Management and Triage Pathways	2019	US	US, Florida	10417 ER Events, 1879 unique patients	Emergency care, Acute care, Oncology	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	medicare claims	no		
3	McLaughlin, N., Martin, N. A., Upadhyaya, P., Bari, A. A., Buxey, F., Wang, M. B., Hersh, E. H., Yaeger, K. A., Neifert, S. N., Kim, J., Dangayach, N. S., Weiss, N.	Assessing the cost of contemporary pituitary care	2014	US	US, California	single center, retrospective	27 neurosurgical patients	Neurosurgical, pituitary adenoma	Surgical	Neurosurgery	partial care path (full surgical episode)	Direct and indirect	provider	provider	ABC	Absorption costing - ABC	implemented	yes see second sheet		
4	Meara, J. G., Hughes, C. D., Sanchez, K., Catalozzo, L., Clark, R., Kummer, A. W.	Optimal Outcomes Reporting (OOR): A New Value-Based Metric for Outcome Reporting Following Cleft Palate Repair	2020	US	US, Massachusetts	Retrospective, single-center cohort analysis	94 patients were identified who underwent primary cleft palate repair by the same surgeon	Cleft palate, Palatoplasty, plastic surgery	Surgical	Plastic surgery	full care path	Direct and indirect	provider	provider	Relative Value Units	Absorption costing - unspecified/generic	Paper only	no		
5	Jakovljevic, M., Zagic, A., Rankovic, A., Dugovic, A.	Radiation therapy remains the key cost driver of oncology inpatient treatment	2015	Serbia	Serbia	2544 complex oncology patients		Oncology	Oncology	partial care path	Direct	provider	provider	Microcosting direct costs only	Direct costing	unspecified	no			
6	Sudan, R. S., He, W., Sun, C. C., Zhao, H., Rauh-Haim, J. A., Fleming, N. D., Lenzini, L., Sawczyn, G., Kim, S., Aminsharif, A., Kaouk, J.	Total and out-of-pocket costs of different primary management strategies in ovarian cancer	2019	US	US, Texas	12761 patients	Gynecology, oncology, ovarian cancer	gynecology & obstetrics		unspecified	Direct and indirect	Payer, patient	payer	patient	none, reimbursements	Charges/Reimbursements-based	Charges/Reimbursement-based patient OoO	N/A	charges	no
7	Hemmila, M. R., Cain-Nielsen, A. H., Wahl, W. L., Vander Kolk, W. E., Jakubus, J. L., Mikhail, J. N., AlAbdour, A., Goktepe, M. E., Kilic, G. S., Borahay, M. A.	Regional collaborative quality improvement for trauma reduces complications and costs	2014	US	US, Texas	72084 episodes of acute trauma care	Acute care	emergency care & acute care		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	price-standardized payments, claims, DRG prices	no		
8	Naghavi, A. O., Gonzalez, R. J., Scott, J. G., Kim, Y., Aboodeh, Y. A., Strom, T. J., Puvanesarajah, V., Kirby, D. J., Jain, A., Werner, B. C., Hassanzadeh, H.	Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma	2017	US	US, Florida	22 soft-tissue sarcoma patients	Oncology, soft-tissue sarcoma	Oncology		full care path	unspecified	payer	payer	none, charges	Charges/Reimbursements-based	N/A	charges	no		
9	Siu, A., Patel, J., Prentice, H. A., Cappuzzo, J. M., Hashemi, H., Mukherjee, D.	Cost Variation of Anterior Cervical Fusions in Elderly Medicare Beneficiaries	2017	US	US, unspecified	21,853 patients	orthopedics, geriatrics, elective anterior cervical fusions	Surgical	Orthopedic fracture	unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no		
10	Kirsch, D. B., Yang, H., Maslow, A. L., Stolzenbach, M., McCall, A.	A Cost Analysis of Regional Versus General Anesthesia for Carotid Endarterectomy	2017	US	US, Virginia	346 patients	Neurosurgery, anesthesia, carotid endarterectomy	Surgical	Neurosurgery	unspecified	direct	provider	provider	unspecified	Direct costing	implemented	no			
11		Association of Positive Airway Pressure Use With Acute Care Utilization and Costs	2019	US	US, North Carolina	1098 patients	Sleep medicine, sleep apnea, Obstructive Sleep Apnea	Internal Medicine		partial care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented	no			

1	Passias, P. G. Poorman, G. W. Bortz, C. A. Qureshi, R. Diebo, B. G. Paul, J. C. Lyon, S. D.	2018	US	US, New York	2408 patients	orthopedic, surgical	Surgical	Spine	partial care path	unspecified	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no
2	Monroe, G. R. Frederix, G. W. Savelberg, S. M. C. De Vries, T. I. Duran, K. J. Van Der Smagt, J. J. Lambert, B.	2016	The Netherlands	The Netherlands	17 patients	Genetics, Pediatrics, Intellectual disability	Pediatrics	Pediatric other	full care path	Direct	provider	provider	bottom-up clinical costing approach	Direct costing	implemented		no
3	Manriquez, E. Mandelbaum, A. Aguayo, E. Zakbour, M. Karlan, B. Benharash, P. Cobian, J. G.	2020	US	US, Virginia	21853 patients	Geriatrics, oncology, ovarian cancer, anterior cervical discectomy and fusion, anterior cervical fusion, cervical spine, cervical spondylosis	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursement	no
4	Wise, K. Blaschke, B. L. Parikh, H. R. Gorman, T. Casnovsky, I. McMillan, L. J. Einhorn, L.	2020	US	US, Minnesota	single center, retrospective 287 patients	orthopedics, geriatrics, hip fracture, surgical	Surgical	Orthopedic fracture	partial care path (full surgical episode)	Direct and indirect	provider	provider	ABC	Absorption costing - ABC	implemented		yes see second sheet
5	Rocque, G. B. Williams, C. P. Jackson, B. E. Ingram, S. A. Halliwole, K. I. Pisu, M. Schwartz, D. A. Shah, A. A. Zogg, C. K. Nicholas, L. H. Velopoulos, C. G. Efron, D. T. Schwartz, E. D.	2018	US	US, Alabama	988 patients	Geriatrics, oncology, De Novo Metastatic Breast Cancer	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursement	no
6	Operative delay to laparoscopic cholecystectomy: Racking up the cost of health care	2015	US	US, Massachusetts	191032 patient records	Surgical, acute care, acute cholecystitis, laparoscopic cholecystectomy	Surgical	Gallbladder	unspecified	Direct and indirect	provider (proxy)	payer	none; charges transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio	no
7	Brixner, D. Rubin, D. T. Mease, P. Mittal, M. Liu, H. Davis, M. Cassendi, A.	2019	US	US, various states	1134 patients	Multiple	multiple		unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
8	Aguayo, E. Santha, Y. Seo, Y. J. Mardock, A. Bailey, K. Dobaria, V. Kishore, S. Cronin, K. J. Mair, S. D.	2018	US	US, California	13943 patients	Cardiology, surgical, thrombocytopenia, Heparin-induced thrombocytopenia	Surgical	Cardiac/Thoracic	unspecified	Direct and indirect	payer	payer	none; charges transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio	no
9	Hawk, G. S. Thompson, K. L. Hettrich, C. M. Jacobs, C. A.	2020	US	US, Kentucky	170329 patients	orthopedic, surgical, depression, Rotator Cuff Repair	Surgical	Orthopedic rotator cuff repair	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
10	Alli, V. V. Zhang, J. Telem, D. A.	2018	US	US, Texas	14290 patients	Surgical, hernia, Incisional hernia	Surgical	Abdominal	full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
11	Robles, A. J. Komblioth, L. Z. Hendrickson, C. M. Howard, B. M. Conroy, A. S. Moazed, F. Lafont, C. E.	2018	US	US, California	1552 patients	Acute care, trauma care	emergency care & acute care		unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
12	van Dijk, J. T. J. M. van Essen, T. A. Dijkman, M. D. Mostert, C. Q. B. Polinder, S. Peul, W. C. Lambert, C. W. Thakore, R. V. Greenberg, S. E.	2019	The Netherlands	The Netherlands	108 patients	Acute care, brain injury, acute subdural hematoma, trauma care	emergency care & acute care		partial care path	Direct and indirect	provider	provider	Absorption costing - reference pricing	unspecified/generic	Paper only		no
13	Shi, H. Fox, A. M. Francois, E. L. Prabek, M. A. Khanlou, S. K. Smith, B. D. Jiang, J. Shih, Y. C. Giordano, S. H. Huo, J. Jaggi, R. Monosh, A. G.	2015	US	US, Tennessee	78 patients	orthopedic, surgical	Surgical	Orthopedic	unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no
14	Cost and complications of local therapies for early-stage breast cancer	2017	US	US, Texas	105 211 female patients	Oncology, breast cancer	Oncology		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no

1	Lentz, T. A. Rhon, D. I. George, S. Z.	Predicting Opioid Use, Increased Health Care Utilization and High Costs for Musculoskeletal Pain: What Factors Mediate Pain Intensity and Disability?	2020	US	US, Washington	283 patients	Pain, Musculoskeletal Pain	Pain medicine	partial care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	unspecified	no	
2	Kaul, S. Korgenski, E. K. Ying, J. Ng, C. F. Smits-Szemmann, R. R. Nelson, R. E. Arias-Solis, S. Silva-Velazco, J.	A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia	2016	US	US, Utah	single center, retrospective 505 patients	Oncology, leukemia, acute lymphoblastic leukemia	Pediatrics	Pediatric Oncology	partial care path	Direct and indirect	provider	provider	ABC	Absorption costing - ABC	implemented	no
3	Dietz, D. W. Stocchi, L. Costedio, M. Gorgan, E. Kalady, M. F. Kassler, J. Cunhares, M. F. Feldman, L. Miller, P. E. Waters, P. M. Bae, D. S.	Considering Value in Rectal Cancer Surgery: An Analysis of Costs and Outcomes Based on the Open, Laparoscopic, and Robotic Approach for Proctectomy	2017	US	US, Ohio	488 patients	Oncology, rectal cancer	Oncology	partial care path (surgical episode)	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	unspecified	no	
4	Vuong, B. Dehal, A. Uppal, A. Stern, S. L. Mejia, J. Weerasinghe, R. Sanaia, Y. Mantha, A. Zaician, B. Juo, Y. Y. Shemin, R. J. Benharash, P.	Complications and Cost of Syndactyly Reconstruction in the United States: Analysis of the Pediatric Health Information System	2017	US	US, Massachusetts	38 hospitals, 2047 procedures	Pediatrics, orthopedic, surgical, Syndactyly Reconstruction	Pediatrics	Pediatric surgical	partial care path	Direct and indirect	provider (proxy)	payer	none, charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio no
5	Chatfield, S. C. Volpicelli, F. M. Adler, N. M. Kim, K. L. Jones, S. A. Francois, F. Chawla, S. S. Whitson, A. J. Schiffman, C. J. Matsen, F. A. Hsu, J. E.	What Are the Most Significant Cost and Value Drivers for Pancreatic Resection in an Integrated Healthcare System?	2018	US	US, California	796 patients	Surgical, Pancreas, Pancreatic Resection	Surgical	Endocrine	partial care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	unspecified	no
6	Charfield, S. C. Volpicelli, F. M. Adler, N. M. Kim, K. L. Jones, S. A. Francois, F. Chawla, S. S. Whitson, A. J. Schiffman, C. J. Matsen, F. A. Hsu, J. E.	Trends in Readmission and Costs After Transcatheter Implantation Versus Surgical Aortic Valve Replacement in Patients With Renal Dysfunction	2020	US	US, LA	350,609 isolated aortic valve replacements	Cardiology, Renal, Aortic Repair, Thoracic Endovascular Aortic Repair	Surgical	Cardiac/Thoracic	partial care path	Direct and indirect	provider (proxy)	payer	none, charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio no
7	Chatfield, S. C. Volpicelli, F. M. Adler, N. M. Kim, K. L. Jones, S. A. Francois, F. Chawla, S. S. Whitson, A. J. Schiffman, C. J. Matsen, F. A. Hsu, J. E.	Bending the cost curve: time series analysis of a value transformation programme at an academic medical centre	2019	US	US, New York	single center, retrospective 74 projects, 160434 patients	Multiple	multiple	partial care path	Direct	provider	provider	ABC	Direct costing	implemented	yes see second sheet	
8	Klink, A. J. Chmielowski, B. Feinberg, B. Ahsan, S. Nero, D. Liu, F. X.	Drivers of lower inpatient hospital costs and greater improvements in health-related quality of life for patients undergoing total shoulder and ream-and-run arthroplasty	2020	US	US, Washington	433 patients	orthopedics, athroplasty, total shoulder and ream-and-run arthroplasty	Surgical	Orthopedic, arthroplasty	unspecified	Direct and indirect	provider	provider	unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented	no
9	Klink, A. J. Chmielowski, B. Feinberg, B. Ahsan, S. Nero, D. Liu, F. X.	Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States	2019	US	US, various states	1599 patients	Oncology, melanoma	Oncology	unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	claims no	
10	Chotali, S. Sivaganesan, A. Parker, S. L. Sielatycki, J. A. McGirt, M. J. Devlin, C. J.	Drivers of Variability in 90-Day Cost for Elective Anterior Cervical Discectomy and Fusion for Cervical Degenerative Disease	2018	US	US, Tennessee	445 patients	Spine, cervical degenerative disease	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements no
11	Sanaia, Y. Kaviampour, B. Downey, P. Morchi, R. Shemin, R. J. Benharash, P.	National Study of Index and Readmission Mortality and Costs for Thoracic Endovascular Aortic Repair in Patients With Renal Disease	2020	US	US, California	121046 patients	Cardiology, Surgical, Aortic repair, Renal Disease	Surgical	Cardiac/Thoracic	unspecified	Direct and indirect	provider (proxy)	payer	none, charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio no
12	Jain, N. Brock, J. L. Phillips, F. M. Weaver, T. Khan, S. N.	Chronic preoperative opioid use is a risk factor for increased complications, resource use, and costs after cervical fusion	2018	US	US, various states	29101 patients	Spine, cervical degenerative disease	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges no
13	Featherall, J. Brigati, D. P. Atney, A. N. Fatur, M. Bokar, D. V. Murray, T. G. Mullins, R. M. Ackerman, R. S. Hirschi, M. Alford, B. Evans, T. Kiluk, J. V. Patel, S. Y.	Effects of a Total Knee Arthroplasty Care Pathway on Cost, Quality, and Patient Experience: Toward Measuring the Triple Aim	2019	US	US, Ohio	6760 surgeries	orthopedics, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	full care path (surgical episode)	Direct	provider	provider	Relative Value Unit costing	Direct costing	implemented	yes see second sheet
14	Featherall, J. Brigati, D. P. Atney, A. N. Fatur, M. Bokar, D. V. Murray, T. G. Mullins, R. M. Ackerman, R. S. Hirschi, M. Alford, B. Evans, T. Kiluk, J. V. Patel, S. Y.	Enhanced REVENUE After Surgery? A Cost-Standardized Enhanced Recovery Pathway for Mastectomy Decreases Length of Stay	2019	US	US, unspecified	103 patients	Oncology, mastectomy	Oncology	unspecified	Direct and indirect	payer	payer	none, charges	Charges/Reimbursements-based	N/A	charges no	

Williams, S. B. Shan, Y. Jazzar, U. Mehra, H. B. Baillargoon, J. G. Huo, J. Somasundara, A. J. Schilling, P. L. He, J. Chen, S. Placzek, H. Bini, S. A.	2018	US	US; various states	3200 patients	Oncology, urology, surgical, bladder cancer	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges	no	
Lott, A. Haglin, J. Saleh, H. Hall, J. Egol, K. A. Konda, S. R.	2018	US	US; various states	1486 patients	Acute care, geriatrics, Emergency care	emergency care & acute care		partial care path	Direct	provider	provider	unspecified; Hospital accounting data not otherwise specified	Direct costing	implemented		no	
Ackerman, S. J. Knight, T. Wahl, P. M. Cartwright, C. P.	2019	US	US; various states	313145 patients	Gynecology, obstetrics, vulvovaginitis	gynecology & obstetrics		unspecified	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges	no	
Peard, L. Goodwin, J. Hensley, P. Dugan, A. Bylund, J. Harris, A. M.	2019	US	US; Kentucky	275 patients	Surgical, robot, Robot-Assisted Laparoscopic Radical Prostatectomy	Surgical	Prostatectomy	partial care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified generic	implemented		no	
Patel, M. I. Ramirez, D. Agajanian, R. Agajanian, H. Bhattacharya, J. Bundorf, K. M.	2020	US	US; California	425 enrollees	Oncology	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges	no	
Harris, A. M. Hensley, P. Goodwin, J. Dugan, A. Peard, L. Bell, J. R. Stearns, L. J. Narang, S. Albright, R. E. Hammond, K. Xia, Y. Richter, H. B. McCreary, D. L.	2019	US	US; Kentucky	215 patients	Urology, surgical, Nephrectomy	Surgical	kidney	partial care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified generic	implemented		no	
Dugarte, A. J. Vang, S. Pflowman, B. Williams, B. R. Parikh, H. R.	2019	US	US; Minnesota	67 patients	orthopedics	Surgical	Orthopedic fracture	partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet	
Yamasaki, A. Callans, K. M. Shah, M. Kaplan, R. S. Hartnick, C.	2020	US	US; Massachusetts	10 patients	Neonatal, pediatrics, tracheostomy, surgical	Pediatrics	Pediatric Neonatal	partial care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet	
Navarro, S. M. Wang, E. Y. Haeblerle, H. S. Mont, M. A. Krebs, V. E. Patterson, B. M. Skell, N. J. Butler, J. O'Brien, D. C. Kays, J. K. Kubal, C. Liangpunskul, S.	2018	US	US; New York	141446 patients	orthopedics, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path (surgical episode)	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
Robinson, Jamie R. Avritscher, Elenir B. C. Gay, James C. Willis, Zachary I. Putnam, Luke R. Anglemeyer, Andrew Labovitz, J. M. Kominiski, G. F.	2019	US	US; Indiana	44 patients	Oncology, renal	Oncology		partial care path	Direct and indirect	provider (proxy)	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
Gay, James C. Willis, Zachary I. Putnam, Luke R. Anglemeyer, Andrew Labovitz, J. M. Kominiski, G. F.	2017	US	US; Tennessee	313 patients	Appendicitis, Pediatrics	Pediatrics	Pediatric appendicitis	partial care path (surgical episode)	Direct and indirect	provider, payer	provider, payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	Absorption costing - unspecified generic	N/A	charges	no
	2016	US	US; California	unspecified	Diabetes	Internal Medicine		unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	

Johnson, J. T. Scholtens, D. M. Kuang, A. Feng, X. Y. Elaysh, O. M. Post, L. A. Marano, D. S. Kamata, J. M. Navarro, S. M. Haeberle, H. S. Helm, J. M. Kamath, A. F. Schaffler, J. L. Krauss, A. T. Saifi, C. Cazzulino, A. Park, C. Laratta, J. Louie, P. K. Shillingford, J. N. Lehman, R. Ning, M. S. Palmer, M. B. Shah, A. K. Chambers, L. C. Garlock, L. B. Melson, B. B. Krauss, A. T. Mukdad, L. Mantha, A. Aguiayo, E. Samaha, Y. Jao, Y. Y. Zaicain, B. Frankel, W. C. Navarro, S. M. Haeberle, H. S. Ramanathan, D. Ramkumar, P. N.	Does value vary by center surgical volume for neonates with truncus arteriosus? A multicenter study	2020	US	US; various states	1024 neonates	Neonatal, pediatrics, surgical, cardiology, thoracic surgery	Pediatrics	Pediatric Neonatal	full care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
Predicting Inpatient Payments Prior to Lower Extremity Arthroplasty Using Deep Learning: Which Model Architecture Is Best?	2019	US	US; New York	295605 patients	orthopedics, total hip arthroplasty, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	payment, cost to payor	no	
National Trends for Primary and Revision Lumbar Disc Arthroplasty Throughout the United States	2018	US	US; various states	12957 patients	Arthroplasty	Surgical	Orthopedic, arthroplasty	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
Three-year results of a prospective statewide insurance coverage pilot for proton therapy: Stakeholder collaboration improves patient access to care	2020	US	US; Texas	32 patients	Oncology	Oncology		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
Readmission and resource utilization after orthopedic heart transplant versus ventricular assist device in the National Readmissions Database, 2010-2014	2018	US	US; California	12111 patients	Thoracic surgery, Cardiology, heart failure, heart transplant, VADs	Surgical	Cardiac/Thoracic	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
Optimizing the Volume-Value Relationship in Laminectomy: An Evidence-Based Analysis of Outcomes and Economics of Scale	2019	US	US; New York	67758 patients	orthopedic, laminectomy, surgical	Surgical	Spine	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
Resource Utilization for Initial Hospitalization in Pediatric Heart Transplantation in the United States	2018	US	US; Pennsylvania	1629 patients	Pediatrics, cardiology	Pediatrics	Pediatric surgical	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
Opioid-free colorectal surgery: a method to improve patient & financial outcomes in surgery	2019	US	US; various states	50098 cases	Surgical, Laparoscopic colorectal surgery	Surgical	Colon/Rectal	unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
Creating a Value Dashboard for orthopedic Surgical Procedures	2020	Lebanon	Lebanon	6 surgeons' data	Orthopedics, total knee arthroplasty, total hip arthroplasty	Surgical	Orthopedic, arthroplasty	unspecified	Direct	provider	provider	unspecified, Hospital accounting data not otherwise specified	Direct costing	implemented		no	
National Trends in Healthcare-Associated Infections for Five Common Cardiovascular Conditions	2019	US	US; various states	1788982 hospitalizations	Cardiology, cardiovascular	Cardiology		unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
The coming hip and femur fracture bundle: A new inpatient risk stratification tool for care providers	2018	US	US; New York	173 patients	Orthopedics, Geriatrics, total hip arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path	Direct	provider	provider	unspecified, Hospital accounting data not otherwise specified	Direct costing	implemented		no	
A Surgeon Scorecard Is Associated with Improved Value in Elective Primary Hip and Knee Arthroplasty	2019	US	US; Texas	470 patients	Surgical, total hip arthroplasty, knee arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path	Direct and indirect	provider	provider	unspecified, Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	implemented		no	
Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?	2017	US	US; Alabama	3427 patients from 12 cancer centers	Oncology	Oncology		partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no	
Utilization of Interspinous Devices Throughout the United States Over a Recent Decade: An Analysis of the Nationwide Inpatient Sample	2018	US	US; various states	14225 patients	Surgical, spine	Surgical	Spine	partial care path (surgical episode)	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
Can a machine learning model accurately predict patient resource utilization following lumbar spinal fusion?	2020	US	US; various states	38070 patients	Spine, lumbar spinal fusion	Surgical	Spine	unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	

1	Karmuta, J. M. Navarro, S. M. Hachberle, H. S. Billow, D. G. Krebs, V. E. Rankumar, P. N.	Bundled Care for Hip Fractures: A Machine-Learning Approach to an Untenable Patient-Specific Payment Model	2019	US	US, New York	9856 patients	orthopedics, hip fracture, trauma	Surgical	Orthopedic fracture	partial care path	Direct and indirect	provider (proxy)	payer	none; estimation, cost-to-charge ratio, SPARCS data	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
2	Cicemins, M. Vollstsky, S. McCann, G. Mancini, M. Sanzari, L. Yannopoulos, A.	Considering healthcare value and associated risk factors with postoperative urinary retention after elective laminectomy	2020	US	US, Connecticut	433 patients	surgical, elective laminectomy	Surgical	Spine	partial care path	Direct	provider	provider	direct costs	Direct costing	unspecified		no
3	Navarro, S. M. Rankumar, P. N. Egger, A. C. Goodwin, R. C.	Evidence-Based Thresholds for the Volume-Value Relationship in Adolescent Idiopathic Scoliosis: Outcomes and Economics of Scale	2018	US	US, New York	3224 patients	Orthopedic, Pediatrics, Adolescent Idiopathic Scoliosis	Pediatrics	Pediatric other	partial care path	Direct and indirect	provider (proxy)	payer	none; estimation, cost-to-charge ratio, SPARCS data	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
4	Batoni, S. B. Gingrich, A. A. Hoch, J. S. Canter, R. J. Bold, R. J.	Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer	2019	US	US, California	2786 patients, 157 hospitals	Oncology, pancreatic cancer	Oncology		unspecified	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
5	Xiao, R. Miller, J. A. Zafra, W. J. Goretski, E. Z. Young, J. B.	Impact of Home Health Care on Health Care Resource Utilization Following Hospital Discharge: A Cohort Study	2018	US	US, unspecified	6363 patients	Multiple	multiple		partial care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursements-based proxy	N/A	charges, transformed with cost-to-charge ratio	no
6	Ramshaw, B. Forman, B. R. Moore, K. Heidel, E. Fabian, M. Mancini, G.	Real-World Clinical Quality Improvement for Complex Abdominal Wall Reconstruction	2017	US	US, Texas	102 patients	Surgical, complex abdominal wall reconstruction	Surgical	Abdominal	full care path (surgical episode)	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented		no
7	Heinzelman, M. Schumann, S. O. Riley, J. Zhang, J. Marsden, J. E. Mauldin, P. D.	Identification of High Utilization Inpatients on Internal Medicine Services	2016	US	US, unspecified	7571 patients	Internal medicine	Internal Medicine		unspecified	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented		no
8	Sheets, K. H. Kenney, B. Dupree, J. M. Campbell, D. A. Englesbe, M. J.	Targeting Value-Driven Quality Improvement for Laparoscopic Cholecystectomy in Michigan	2019	US	US, Michigan	19213 patients	Surgical, Laparoscopic Cholecystectomy	Surgical	Gallbladder	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no
9	Zolin, S. J. Tastaldi, L. Alkhatib, H. Lampert, E. J. Brown, K. Fafaj, A.	Open retromuscular versus laparoscopic ventral hernia repair for medium-sized defects: where is the value?	2020	US	US, various states	All medicare shoulder surgeries 2002-2018	orthopedics, Surgical, Shoulder surgery	Surgical	Abdominal	partial care path	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no
10	Ahluwalia, R. Vainieri, E. Tam, J. Sait, S. Sinha, A. Mani, C. A.	Surgical Diabetic Foot Debridement: Improving Training and Practice Utilizing the Traffic Light Principle	2019	UK	UK, London	single center, retrospective, direct observation, pre and post comparison 53 patients	Surgical, diabetic foot infection, diabetes	Surgical	Diabetes	partial care path (full surgical episode)	Direct and indirect	payer	payer	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet
11	Ramly, E. P. Laurentzakis, A. Bolsen, J. D. Mavros, M. Chang, Y. Lee, J.	The financial impact of intraoperative adverse events in abdominal surgery	2015	US	US, Massachusetts	9111 patients	surgical, abdominal surgery	Surgical	Abdominal	unspecified	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	implemented		no
12	Orbanu, V. Urits, I. Olusunmade, M. Owais, K. Jones, M. Galasso, A.	Trends of Co-Morbid Depression in Hospitalized Patients with Failed Back Surgery Syndrome: An Analysis of the Nationwide Inpatient Sample	2018	US	US, unspecified	115976 patients	Surgical, depression, psychiatry	Pain medicine		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A		no
13	Hollenbeck, B. Hoffman, M. A. Trombanhauser, S. G.	High-Volume Arthroplasty Centers Demonstrate Higher Composite Quality Scores and Enhanced Value: Perspective on Higher-Volume Hospitals Performing Arthroplasty from 2001 to 2011	2020	US	US, various states	1651354 total hip or total knee arthroplasties	orthopedics, surgical, total hip arthroplasty, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	unspecified	Direct and indirect	provider (proxy)	payer	none; charges	Charges/Reimbursements-based	N/A	charges per quartile, discuss how it should be costs in discussion	no
14	Loftus, T. J. Rosenthal, M. D. Croft, C. A. Stephen Smith, R. Efron, P. A. Moore, F. A. Maha, A. M.	Effect of Time to Operation on Value of Care in Acute Care Surgery	2018	US	US, Florida	800 patients	Acute care, appendicitis, surgical, laparotomy for intra-abdominal sepsis with temporary abdominal closure	Surgical	Appendicitis	full care path (surgical episode)	unspecified	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	charges, discuss shortcoming in discussion	no

1	Buell, J. F. Sigmon, D. Dacon, C. Shapiro, M. Teja, N. Wynter, E. Jain, N. Phillips, F. M. Shimer, A. L. Khan, S. N.	2017	US	US, Louisiana	73 patients	Surgical, complex abdominal wall reconstruction	Surgical	Abdominal	full care path (surgical episode)	unspecified	payer	payer	none, charges	Charges/Reimbursements-based	N/A	no
2																
3																
4																
5																
6																
7																
8	Stull, J. D. Bhat, S. B. Kane, J. M. Raikan, S. M.	2017	US	US, unspecified	76 cases/patients, and 48044 retrospective patient files	orthopedics, Surgical, ankle fractures	Surgical	Orthopedic fracture	unspecified	unspecified	payer	payer	none, reimbursements	Charges/Reimbursements-based	N/A	reimbursement no
9																
10																
11																
12																
13																
14																
15																
16																
17																
18																
19																
20																
21																
22																
23																
24																
25																
26																
27																
28																
29																
30																
31																
32																
33																
34																
35																
36																
37																
38																
39																
40																
41																
42																
43																
44																
45																
46																

Kaplan, A. L., Agarwal, N., Setlur, N. P., Tian, H. J., Niedzwiecki, D., McLaughlin, N., Pong, J., Crawford, K., Faraji, R., Ramsay, C., Kemp, A., Califano, J. A.	2015	US	US, California	Measuring the cost of care in benign prostatic hyperplasia using time driven activity-based costing (TDABC)	single center, retrospective, direct observation	one care pathway, 5 surgical options	Urology, benign prostatic hyperplasia	Urology	partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified	yes see second sheet	
Lobatto, D. J., van den Hout, W. B., de Vries, F. F., Schutte, P. J., Patel, M. I., Ramirez, D., Agajanian, R., Agajanian, H., Coker, T.	2020	US	US; various states	An Analysis of 1-Year Charges for Head and Neck Cancer: Targets for Value-Based Interventions		196 consecutive patients	Oncology, head and neck cancer	Oncology	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement-based	N/A	charges no	
Lobatto, D. J., van den Hout, W. B., de Vries, F. F., Schutte, P. J., Patel, M. I., Ramirez, D., Agajanian, R., Agajanian, H., Coker, T.	2020	The Netherlands	The Netherlands	Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery	prospective, observational study, process mapping	155 patients	Endocrinology, surgical, pituitary	endocrinology	partial care path (full surgical episode)	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	Paper only	no	
Jalilian, H., Doshmangir, L., Ajami, S., Mir, H., Siraneh, Y., Hasanpoor, E.	2019	Iran	Iran	Economic burden of gastric cancer in the first six months after diagnosis		118 patients	Oncology, bowel, gastric cancer	Oncology	unspecified	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	Paper only	no	
Lobatto, D. J., van den Hout, W. B., Najafabadi, A. H. Z., Steffens, A. N. V., Andela, C. D., Pereira, A. M., Gray, C. F., Prieto, H. A., Deen, J. T., Parvataneni, H. K.	2019	The Netherlands	The Netherlands	Healthcare utilization and costs among patients with non-functioning pituitary adenomas		167 patients	Endocrinology, Pituitary adenoma	endocrinology	partial care path	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	N/A	no	
Kurt, P., Saban, M., Cankaya, F., Annac, M. C.	2019	US	US, Florida	Bundled Payment "Creep": Institutional Redesign for Primary Arthroplasty Positively Affects Revision Arthroplasty		168 patients	orthopedics, total joint arthroplasty	Surgical	Orthopedic, arthroplasty	full care path (surgical episode)	Direct and indirect	payer, provider	provider	none; charges	Charges/Reimbursement-based	Direct costing N/A	no
Thaci, B., McGirt, M. J., Ammerman, J. M., Thome, C., Kim, K. D., Ament, J. D.	2019	Turkey	Turkey	Time-Driven Activity-Based Costing in the Ophthalmology Department of State Hospital: A Case Study	single center, retrospective, case study	case study; 5 surgical procedures in one department	Ophthalmology	ophthalmology	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	
Karns, M. R., Jones, D. L., Todd, D. C., Maak, T. G., Aoki, S. K., Barks, R. T., Robinson, J. R., Carter, N. H., Gibson, C., Brinkman, A. S., Van Arendonk, K., Speck, K. E., Gupta, P., Rettiganti, M.	2018	US	US, California	Reduction of direct costs in high-risk lumbar discectomy patients during the 90-day post-operative period through amular closure	randomized controlled trial	272 patients	Surgical, high-risk lumbar discectomy	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement-based	N/A	no
Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mishkin, A.	2018	US	US, Utah	Patient- and Procedure-Specific Variables Driving Total Direct Costs of Outpatient Anterior Cruciate Ligament Reconstruction	Retrospective cohort, single center, economic and decision analysis	434 patients	orthopedic, surgical, Anterior Cruciate Ligament Reconstruction, sports medicine	Surgical	Orthopedic	partial care path (full surgical episode)	Direct	provider	provider	VDO tool, total direct costs	Direct costing	implemented	yes see second sheet
Robinson, J. R., Carter, N. H., Gibson, C., Brinkman, A. S., Van Arendonk, K., Speck, K. E., Gupta, P., Rettiganti, M.	2018	US	US, Tennessee	Improving the value of care for appendectomy through an individual surgeon-specific approach	prospective observational study	216 patients	Appendicitis, surgical	Surgical	Appendicitis	partial care path (full surgical episode)	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	N/A	yes see second sheet
Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mishkin, A.	2017	US	US; various states	Relationship of Hospital Costs With Mortality in Pediatric Critical Care: A Multi-Institutional Analysis	single center, pre and post intervention	917,663 patients, 47 hospitals	Acute care, pediatrics	pediatrics	Pediatric acute care	partial care path	unspecified	payer	payer	unspecified	Charges/Reimbursement-based	N/A	charges no
Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mishkin, A.	2016	US	US, California	Time-driven activity-based costing of low-dose-rate and high-dose-rate brachytherapy for low-risk prostate cancer	single center, retrospective, process mapping, direct observation	2 treatment options	Oncology, prostate cancer, brachytherapy	Oncology	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	
Ilg, A. M., Laviana, A. A., Kamrava, M., Veruttipong, D., Steinberg, M., Park, S. J., McLaughlin, N., Burke, M. A., Setlur, N. P., Niedzwiecki, D. R., Kaplan, A. L., Saigal, C., Mishkin, A.	2014	US	US, California	Time-driven activity-based costing: a driver for provider engagement in costing activities and redesign initiatives	single center, process mapping	2 pilots	Urology, neurosurgery	Surgical	Neurosurgery	partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	implemented	no

1	Keating, C. L., Dixon, J. B., Moodie, M. L., Pieters, A., Playfair, J., O'Brien, P. E.	2009	Australia	Australia	randomized controlled trial	40 patients, 23 surgical, 7 medical	Surgical, Diabetes	Internal Medicine	unspecified	Direct	provider	provider	direct costs	Direct costing	Paper only	no		
2	Nelson, A. A., Pearce, D. J., Fleischer, A. B., Balkrishnan, R., Feldman, S. R.	2005	US	US; Ohio	208 inpatient admissions		Psoriasis, Dermatology	Dermatology		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements t-based	N/A	charges	no
3	Yanik, John M., Bedard, Nicholas A., Hanley, Jessica M., Otero, Jesse E., Callaghan, John J., Marsh, John L.	2018	US	US; Iowa	78 patients		orthopedics, total hip arthroplasty, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	unspecified		no
4	Zhang, Steven, Vora, Molly, Harris, Alex H. S., Baker, Laurence, Curtin, Catherine, Kamal, Robin N.	2016	US	US; California	16 million patient records		Carpal Tunnel Release	Surgical	Carpal Tunnel Release	full care path (surgical episode)	Direct and indirect	payer	payer	none, reimbursements	Charges/Reimbursements t-based	N/A	reimbursements	no
5	A. Adenkinju, R. Ranson, S. A. Rettig, K. A. Egol and S. R. Konda	2021	US	US; New York			Orthopedic, Geriatric, Operative Distal Radius Fractures	Surgical	Orthopedic fracture	unspecified	Direct and indirect	payer	payer	unspecified; Hospital accounting data not otherwise specified	Charges/Reimbursements t-based	N/A	index admission cost, per category	no
6	A. Albrahim, Y. Abdulsalam, S. Al Mutawa, H. Behbehani, D. Alhuwail and S. Al Jenaei	2021	Kuwait	Kuwait	single center, observation, interviews	one pharmacy	Diabetes, pharmacy	Internal Medicine		partial care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		yes see second sheet
7	D. J. Baughman, A. Waheed, M. N. Khan and J. M. Nicholson	2021	US	US; Pennsylvania			Emergency care	emergency care & acute care		unspecified	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements t-based	N/A	average charges	no
8	J. A. Berinstein, S. A. Cohen-Mekelburg, G. M. Greenberg, D. Wray, S. K. Berry, S. D. Saini, A. M. Fendrick, M. A. Adams, A. K. Wajjee and D. D. Hwang	2021	US	US; Michigan			IBS/IBD inflammatory bowel disease	Internal Medicine		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements t-based	N/A	charges	no
9	A. Beschloss, C. Dicindio, J. Lombardi, A. Varthi, A. Ozurk, R. Lehman, L. Lenke and C. Saifi	2021	US	US; various states			Orthopedic, Spinal Deformity Surgery	Surgical	Spine	full care path	Direct and indirect	provider	provider	none; charges	Charges/Reimbursements t-based	N/A	unspecified	no
10	H. Baeno, J. L. Bernal, V. Jimenez-Jimenez, F. J. Martin-Sanchez, X. Rosello, G. Moreno, C. Goni, V. Gil, P. Llorens, N. Naranjo, J. Lopez, D. Hernandez, R. A. Burnett Iii, J. Yang, P. M. Courtney, E. B. Terhune, C. P. Hamon and C. J. Della Valle	2021	Spain	Spain	Retrospective, multi-center	30 day period of heart failure patients	heart failure, cardiovascular	Cardiology		partial care path	Direct and indirect	provider	provider	DRG costs	Absorption costing - unspecified/generic	implemented		yes see second sheet
11	M. Casey, D. Perera, J. Enticott, H. Vo, S. Cubra, A. Gravell, M. Waerea and G. Habib	2021	US	US; various states			Total knee arthroplasty, orthopedic	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	provider	provider	none; reimbursements	Charges/Reimbursements t-based	N/A	reimbursement	no
12	K. A. Chovancec, C. Arsene, A. Beck and B. Liddel	2022	Australia	Australia			Emergency care	emergency care & acute care		partial care path	Direct and indirect	provider	provider	unspecified; Hospital accounting data not otherwise specified	Absorption costing - unspecified/generic	N/A		yes see second sheet
13	R. V. Cohen, A. M. Nishikawa, R. A. Ribeiro, F. M. Oliveira, P. C. Andrade, S. M. Junqueira and B. Toldo	2021	US	US; various states			Various, post-acute	emergency care & acute care		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements t-based	N/A	charges	no
14	R. V. Cohen, A. M. Nishikawa, R. A. Ribeiro, F. M. Oliveira, P. C. Andrade, S. M. Junqueira and B. Toldo	2021	Brazil	Brazil			Obesity, surgical, bariatric surgery	Surgical	Bariatric	full care path	Direct and indirect	provider	provider	reference pricing	Absorption costing - unspecified/generic	N/A		yes see second sheet

1	A. P. B. da Silva Etges, L. N. Cruz, R. Schlatter, J. Neyeloff, R. B. Cardoso, L. Koptilke, A. A. Nunes, J. A. Neto, J. L. Nogueira, R. M. de Aguiar, J. S. D. Tobias, J. M. Dziemianowicz, J. Burneister and M. Dominello	2022	Brazil	Brazil	multi center, retrospective, process mapping, 5 hospitals	5 hospitals, 90 patients	Interventional Coronary Procedures	Cardiology	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified	yes see second sheet	
2																	
3																	
4																	
5																	
6																	
7																	
8	C. Fang, A. Hagar, M. Gordon, C. T. Talamo, D. A. Mattingly and E. L. Smith	2021	US	US; Michigan	single center, retrospective, patient comparison	889 surgeries	Geriatrics, Orthopedic, Primary Total Joint Arthroplasty	Surgical	Orthopedic fracture	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet
9																	
10																	
11																	
12																	
13																	
14																	
15																	
16																	
17																	
18																	
19																	
20																	
21																	
22																	
23																	
24																	
25																	
26																	
27																	
28																	
29																	
30																	
31																	
32																	
33																	
34																	
35																	
36																	
37																	
38																	
39																	
40																	
41																	
42																	
43																	
44																	
45																	
46																	

1	H. Ko, D. S. Brodtk, M. E. Vanneman, A. J. Schoenfeld and B. I. Martin	Is Discretionary Care Associated with Safety Among Medicare Beneficiaries Undergoing Spine Surgery?	2021	US	US; various		spine surgery, surgical	Surgical	Spine	partial care path	Direct and indirect	payer	payer	none; reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no	
2	S. R. Konda, J. R. Johnson, N. Dethia, E. A. Kelly and K. A. Egol	Can We Stratify Quality and Cost for Older Patients With Proximal and Midshaft Humerus Fractures?	2021	US	US; various		Humerus Fractures, geriatrics, orthopedic	Surgical	Orthopedic fracture	unspecified	Direct	provider	provider	direct variable costs as an estimation of total costs	Direct costing	N/A		no	
3	A. T. Malik, S. N. Khan, R. T. Voskuil, J. H. Alexander, J. P. Drain and T. J. Scharschmidt	What Is the Value of Undergoing Surgery for Spinal Metastases at Dedicated Cancer Centers?	2021	US	US; various		Orthopedic, Surgical, spine surgery	Oncology		partial care path	Direct and indirect	payer	payer	none; reimbursements	Charges/Reimbursements-based	N/A	reimbursements	no	
4	T. R. McClintock, D. F. Friedlander, A. Y. Feng, M. A. Shah, D. J. Pallin, S. L. Chang, A. M. Bader, T. W. Feeley, R. S. Kaplan and G. E. Latt	Determining Variable Costs in the Acute Urolithiasis Cycle of Care Through Time-Driven Activity-Based Costing	2021	US	US; Boston	multi center, retrospective, process mapping, unspecified number of patients, acute stone episodes	Acute Urolithiasis	emergency care & acute care		full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		yes see second sheet	
5	R. Negrini, R. D. da Silva Ferreira and D. Z. Guimaraes	Value-based care in obstetrics: comparison between vaginal birth and caesarean section	2021	Brazil	Brazil	single center, retrospective, process mapping	9345 deliveries	Obstetrics, birth, vaginal birth, caesarean birth	gynecology & obstetrics		full care path	Direct and indirect	provider	provider	direct and indirect costs	Absorption costing - unspecified/generic	Paper only		yes see second sheet
6	T. V. Newman, K. D. Munshi, L. M. Neilson, C. B. Good, E. C. S. Swart, Y. Huang, R. Henderson and N. Parekh	Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2: an observational cohort study	2021	US	US; various		Diabetes	Internal Medicine		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
7	N. Panda, L. Shagabayeveva, C. E. Comrie, N. Phan, P. Moonssamy, C. F. Jeffrey Yang, F. G. Fernandez and C. R. S. K. Pasquali, D. Thibault, M. Hall, K. Chiswell, J. C. Romano, J. W. Gaynor, D. M. Shahian, M. L. Jacobs, M. G. Gales, S. M. Pappas, R. K. Sethi, R. P. Pumpian, C. E. Drolet and P. K. Louie	Drivers of Cost Associated With Minimally Invasive Esophagectomy	2022	US	US; Boston		esophagectomy, surgical, thoracic surgery	Surgical	Cardiac/Thoracic	full care path	Direct	provider	provider	direct costs	Direct costing	N/A		no	
8	S. K. Pasquali, D. Thibault, M. Hall, K. Chiswell, J. C. Romano, J. W. Gaynor, D. M. Shahian, M. L. Jacobs, M. G. Gales, S. M. Pappas, R. K. Sethi, R. P. Pumpian, C. E. Drolet and P. K. Louie	Evolving Cost-Quality Relationship in Pediatric Heart Surgery	2021	US	US; Boston	Retrospective, multi-center	45315 patients, 32 hospitals	pediatrics, surgical, pediatric heart surgery	Pediatrics	Pediatric surgical	full care path	direct and indirect	provider	provider	CHD-method standardized costs	Absorption costing - unspecified/generic	Paper only		no
9	N. G. Thaker, D. Boyce-Fappiano, M. S. Ning, D. Pasalic, A. Guzman, G. Smith, E. B. Holliday, J. Incalcaterra, A. S. Gaudin, S. P. S. Tomicki, G. Dieguez, H. Latimer, P. Cockrum and G. Kim	Utilizing Lean Methodology and Time-Driven Activity-Based Costing Together: An Observational Pilot Study of Hip Replacement Surgery Utilizing a New Method to Study Value-Based Health Care	2021	US	US; Washington	single center, retrospective, surgeon comparison	346 patients	surgical, orthopedic, hip replacement surgery, anterior hip arthroplasty	Surgical	Orthopedic, arthroplasty	full care path (surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only		yes see second sheet
10	W. Wang, E. Li, K. Campbell, A. McBride and S. D'Amato	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer	2021	US	US; Texas	single center, process mapping, matched sample	50 patients (matched pairs)	oncology, radiation oncology	Oncology		partial care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	implemented		yes see second sheet
11	S. Tomicki, G. Dieguez, H. Latimer, P. Cockrum and G. Kim	Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies	2021	US	US; various		oncology, metastatic pancreatic cancer	Oncology		full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursements-based	N/A	charges	no	
12	K. L. Wise, H. R. Parikh, B. Okelana, A. J. Only, M. Reams, A. Harrison, J. Braman, E. Craig and B. P. Cunningham	Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework	2021	US	US; New Jersey		oncology, Nonmyeloid Cancer	Oncology		partial care path	Direct	provider	provider	direct costs	Direct costing	N/A		no	
13	C. Iloabachi, N. Dwibedi, T. LeMasters, C. Shen, A. Ladani and U. Sambamoorthi	Measurement of value in rotator cuff repair: patient-level value analysis for the 1-year episode of care	2022	US	US; Minnesota	single center, retrospective, process mapping	396 patients	orthopedic, surgical, rotator cuff repair	Surgical	Orthopedic rotator cuff repair	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		yes see second sheet
14	C. Iloabachi, N. Dwibedi, T. LeMasters, C. Shen, A. Ladani and U. Sambamoorthi	Low-value care and excess out-of-pocket expenditure among older adults with incident cancer – A machine learning approach	2021	US	US; various		oncology, incident cancer	Oncology		full care path	Direct	patient	patient	total out of pocket expenditures (SEER data)	Charges/Reimbursements-based patient OoO	N/A		no	

N. Seyidova, A. D. Chen, D. del Valle, D. Chi, R. P. Cauley, B. T. Lee and S. J. Lin	Nationwide cost variation for lower extremity flap reconstruction	2021	US	US; various		lower extremity flap reconstruction, surgical, plastic surgery	Surgical	Plastic surgery	full care path	Direct and indirect	provider (proxy)	payer	none; charges, transformed with cost-to-charge ratio	Charges/Reimbursement t-based proxy	N/A	charges, transformed with cost-to-charge ratio	no	
A. Jacir, D. Mendoza, E. Dean and H. Gritlow	The cost of care during times of COVID: Case study of TDABC and minimum utilization cost analysis in a medicare advantage population	2021	US	US; Florida	single center, process mapping, case study	case study, telehealth visits	Covid	Infectious disease	full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	unspecified		no	
D. Fürstenau, H. Hancke, C. Spies, T. Walz, K. Schewina, M. Hüft, R. Müggeli and F. Balzer	Tackling the frailty burden with an integrative value-based approach: results from a mixed-methods study	2021	Germany	Germany			surgical, perioperative process	Surgical	other	partial care path	unspecified	provider	provider	bottom-up clinical costing approach	Unspecified	N/A	no	
J. F. Buehl, A. N. Flaris, S. Raju, A. Haach, M. Darden and G. G. Parker	Long-Term Outcomes in Complex Abdominal Wall Reconstruction Repaired with Absorbable Biologic Polymer Scaffold (Poly-4-Hydroxybutyrate)	2021	US	US; North Carolina			Surgical, abdominal wall reconstruction, reherniation, complex abdominal wall hernia	Surgical	Abdominal	partial care path	Direct	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	no	
V. J. Siu, T. Varkey, U. N. Khan, J. B. Ding and S. Gandhi	Lend Me a Hand: A Value-Based Care Case Study on Pan Plexopathy of Unknown Origin	2021	US	US; Texas			pan plexopathy, neurology, brachial plexus injury	Neurology		unspecified	Direct	patient	patient	out of pocket costs to patient	Charges/Reimbursement t-based patient O&O	N/A	no	
J. B. Kuleja, M. A. Seif, M. W. Mery, J. R. Incalcaterra, A. M. Kamat, C. P. Dinney, J. B. Shah, T. W. Feeley and N. Navai	Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers	2021	US	US; Texas	single center, retrospective, process mapping	100 patients	open radical cystectomy, urology, oncology, bladder cancer	Oncology		full care path	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	Paper only	yes see second sheet	
King, B. C. Richardson, T. Patel, R. M. Lee, H. C. Bamat, N. A. Hall, M. Schabas, L. L. L. Fernando-Campan, A. Gust, A. Hsueh, A. Tran-Duy, M. Kirk, P. Brooks and J. Knight	Prioritization framework for improving the value of care for very low birth weight and very preterm infants	2021	US	US; Texas	Retrospective cohort, multi center	26098 preterm or low birth weight infants	Preterm infants, neonatal, perinatology, pediatrics	Pediatrics	Pediatric Neonatal	partial care path	Direct and indirect	payer	payer	charges standardized across hospitals	Charges/Reimbursement t-based	N/A	charges	no
H. Skibicki, M. Yayac, C. A. Krueger and P. M. Courtney	Target Price Adjustment for Hip Fractures Is Not Sufficient in the Bundled Payments for Care Improvement Initiative	2021	Australia	Australia	single center, retrospective, mixed methods observational study	93 056 cases	emergency care, hospital acquired complications	emergency care & acute care		partial care path	Direct and indirect	provider	provider	bottom-up clinical costing approach	Absorption costing - unspecified/generic	unspecified		yes see second sheet
D. Clewley, V. Iftikhar, M. E. Horn and D. I. Rhon	Do the Number of Visits and the Cost of Musculoskeletal Care Improve Outcomes? More May Not Be Better	2020	US	US; Pennsylvania			arthroplasty, hip fractures, orthopedics	Surgical	Orthopedic, arthroplasty	full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	charges (EOC costs)	no
B. Walker, L. Wilfong, J. Frytak and N. Robert	Practice patterns among oncologists participating in the oncology care model after three years	2021	US	US; Louisiana	Retrospective, clinical trial	98 patients	Subacromial pain syndrome	Pain medicine		partial care path	Direct and indirect	payer	payer	none; reimbursements	Charges/Reimbursement t-based	N/A	reimbursements	no
C. A. Krueger, M. Yayac, C. Vannello, J. Wilsman, M. S. Austin and P. M. Courtney	Are We at the Bottom? BPCI Programs Now Disincentivize Providers Who Maintain Quality Despite Caring for Increasingly Complex Patients	2021	US	US; Pennsylvania			oncology, cancer	Oncology		full care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	charges	no
B. S. Horton, J. D. Marland, H. S. West and J. D. Wylie	Transition to Telehealth Physical Therapy After Hip Arthroscopy for Femoroacetabular Impingement: A Pilot Study With Retrospective Matched-Cohort Analysis	2021	US	US; Utah	Pilot		orthopedic, total hip arthroplasty, total knee arthroplasty	Surgical	Orthopedic, arthroplasty	partial care path	Direct and indirect	payer	payer	none; reimbursement	Charges/Reimbursement t-based	N/A	reimbursement	no
N. H. Nguyen, J. Luo, L. Ohno-Machado, W. J. Sandborn and S. Singh	Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort	2021	US	US; California			orthopedics, hip arthroscopy, physical therapy	Orthopedic		partial care path	Direct and indirect	payer	payer	none; charges	Charges/Reimbursement t-based	N/A	charges	no
							Gastroenterology, Inflammatory Bowel Diseases	Internal Medicine		full care path	Direct and indirect	provider (proxy)	payer	none; charges HCUP data	Charges/Reimbursement t-based	N/A	charges	no

1	Y. Sanaia, P. Downey, R. Lyons, A. Nsaif, R. J. Shemin and P. Benharash	Trends in utilization, mortality, and resource use after implantation of left ventricular assist devices in the United States	2021	US	US; various		cardiovascular, left ventricular assist devices	Surgical	Cardiac/Thoracic	full care path	Direct and indirect	provider (proxy)	payer	none; reimbursements, cost-charge-ratio, NIS data	Charges/Reimbursements-based proxy	N/A	charges transformed with cost-to-charge ratio	no
2	Khanjow, A. N. Wood, L. N. Xie, R. Theiss, L. M. Hollis, R. H. Hardiman, K. M. Gonzalez, D. J.	The impact of an enhanced recovery program (ERP) on the costs of colorectal surgery	2021	US	US; Alabama	single center, retrospective	616 surgical cases	surgical, colorectal surgery	Surgical	Colon/Rectal	partial care path (full surgical episode)	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	Paper only	yes see second sheet
3	Jacobs, K. Dewilde, T. Vandoren, C. Cardoen, B. Vansteenkiste, N. Scheys, L. Roelofs, F. Matar, D.	Variability in Hospital Costs of Adult Spinal Deformity Care	2020	The Netherlands	The Netherlands	single center, retrospective	139 patients	Surgical, spine, Adult Spinal Deformity	Surgical	Spine	full care path	Direct	provider	provider	ABC (excluding overheads)	Absorption costing - ABC	Paper only	yes see second sheet
4	Di Filippo, A. Invento, A. Radice, D. Bucuta, M. Bignardi, V. Mazzanti, E. Weir, T. B.	Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology	2021	Italy	Italy	single center, retrospective, clinical trial, compare pre and post	3912 patients	oncology, breast cancer, cancer, sentinel lymph node biopsy	Oncology		partial care path (full surgical episode)	Direct and indirect	provider	provider	TDABC	Absorption costing - TDABC	implemented	yes see second sheet
5	Usmani, M. F. Camacho, J. Sokolow, M. Bruckner, J. Jazini, E. Lorenzini, L. T.	Effect of Surgical Setting on Cost and Hospital Reported Outcomes for Single-Level Anterior Cervical Discectomy and Fusion	2021	US	US; Maryland	multi center, retrospective	301 patients	Spine, surgical, Anterior Cervical Discectomy and Fusion	Surgical	Spine	full care path	Direct and indirect	provider	provider	unspecified	Absorption costing - unspecified/generic	Paper only	no

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



PRISMA 2020 for Abstracts Checklist

Section and Topic	Item #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	yes
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	yes
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	yes
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	yes
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	no
Synthesis of results	6	Specify the methods used to present and synthesise results.	yes
RESULTS			
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	yes
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	yes
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	yes
Interpretation	10	Provide a general interpretation of the results and important implications.	yes
OTHER			
Funding	11	Specify the primary source of funding for the review.	yes
Registration	12	Provide the register name and registration number.	N/A

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <http://www.prisma-statement.org/>



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	pg 0
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	pg1-3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	pg 3
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	pg 4 and supplement
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pg 4 and supplement
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplement
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	pg 6
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	pg 6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	pg 4, supplement
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	pg 4, supplement
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	pg 4, supplement
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	pg 4
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	pg 8
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	N/A
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	pg 8
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	pg 4
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	N/A
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	N/A
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	N/A, discussed pg 23
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	N/A



PRISMA 2020 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	pg 5,6, 7
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	pg 5 (flowchart)
Study characteristics	17	Cite each included study and present its characteristics.	pg 7-14, and supplement
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	N/A
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	N/A
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	N/A
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	N/A
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	pg 7-9
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	N/A
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	N/A
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	N/A
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	pg 18-21
	23b	Discuss any limitations of the evidence included in the review.	pg 21
	23c	Discuss any limitations of the review processes used.	pg 21, 4
	23d	Discuss implications of the results for practice, policy, and future research.	pg 18-21
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	pg 4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	supplement
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Funding statement
Competing interests	26	Declare any competing interests of review authors.	Author statement
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Data availability statement

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>
For more information, visit: <http://www.prisma-statement.org/>